US20230357259A1 - Bioactive conjugate, preparation method therefor and use thereof - Google Patents

Bioactive conjugate, preparation method therefor and use thereof Download PDF

Info

Publication number
US20230357259A1
US20230357259A1 US18/155,650 US202318155650A US2023357259A1 US 20230357259 A1 US20230357259 A1 US 20230357259A1 US 202318155650 A US202318155650 A US 202318155650A US 2023357259 A1 US2023357259 A1 US 2023357259A1
Authority
US
United States
Prior art keywords
compound
membered
alkyl
antibody
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/155,650
Inventor
Jiaqiang Cai
Shuai SONG
Tongtong Xue
Liang Xiao
Hanwen DENG
Qiang Tian
Jing Wang
Dengnian LIU
Liping Liu
Haimin Yu
Zhouning YANG
Xu Cao
Guoqing Zhong
Lichun Wang
Jingyi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority to US18/155,650 priority Critical patent/US20230357259A1/en
Assigned to SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. reassignment SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAI, JIAQIANG, CAO, XU, DENG, Hanwen, LIU, Dengnian, LIU, LIPING, SONG, Shuai, TIAN, QIANG, WANG, JING, WANG, JINGYI, WANG, Lichun, XIAO, LIANG, XUE, Tongtong, YANG, Zhouning, YU, Haimin, ZHONG, Guoqing
Publication of US20230357259A1 publication Critical patent/US20230357259A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the disclosure belongs to the technical field of medical technology, and relates to a bioactive molecule conjugate, preparation method thereof, and use in the prevention and/or treatment of a disease associated with an abnormal cell activity, including but not limited to the use in the prevention and/or treatment of a neoplastic disease.
  • Chemotherapy was once a standard therapy for cancer, but bioactive molecules having high killing effect can mistakenly kill normal cells, resulting in serious side effects.
  • Targeted therapy has become a hot research topic in the field of oncology due to the targetability and anti-tumor activity.
  • bio-macromolecular drugs e.g., therapeutic antibodies or antibody fragments
  • targeted small molecule ligands e.g., targeted small molecule ligands.
  • bio-macromolecular drugs e.g., therapeutic antibodies or antibody fragments
  • bio-macromolecular drugs have limited curative effects on solid tumors; in addition, bioactive molecules often lack targetability and accidentally injure normal cells and cause serious toxic and side effects, despite of their high killing effect on cancer cells.
  • ADCs antibody-drug conjugates
  • the ADC combine the targeting effect of antibodies and the activity of bioactive molecules making it a “biological missile”.
  • the ADC is guided by antibodies to bind to target cells, and then is internalized by cells to release drugs thereby treating relevant diseases. Due to the specificity and targetability to tumor cell related targets, the application values of antibodies not only are reflected in the treatment, but also become an ideal carrier for drug targeted delivery, and reduce side effects of drugs.
  • Small molecule drug conjugates are designed on the basis of same principle as antibody-drug conjugates (ADCs); that is, coupling bioactive molecules with some small molecule ligands which can selectively bind to receptors on the surfaces of tumor cells through chemical processes, thereby improving the targetability of effector molecules (bioactive molecules) to tumor cells.
  • ADCs antibody-drug conjugates
  • the difference between the SMDCs and the ADCs is that the SMDCs use small molecule ligands instead of antibodies, and there is not yet SMDC available on the market.
  • An ADC generally consists of an antibody, a bioactive molecule and a linker.
  • the bioactive molecule is covalently coupled to the antibody via the linker; the antibody (e.g., monoclonal antibodies) can specifically recognize a specific target on the surface of a tumor cell, thus guiding the ADC to reach the surface of cancer cell and enabling the ADC to enter the cancer cell through endocytosis effect; then the bioactive molecule is released in the cancer cell to achieve the effect of specifically killing the cancer cell without damaging normal tissue cells.
  • the antibody e.g., monoclonal antibodies
  • Lysine is the most common linking site in antibodies, and ⁇ -amino groups thereof can react with activated carboxyl groups of linkers to form amide bonds.
  • Techniques for site-specific coupling are currently available, that is, carboxyl groups of linkers are activated, and then form amide bonds with specific lysine ⁇ -amino groups in antibodies to complete the coupling.
  • amide bonds are prone to hydrolysis under the action of enzymes enzymes in vivo, as a result, bioactive molecules and antibodies dissociate before reaching target cells resulted in increasing toxicity while losing tagetability of ADCs.
  • Thio groups of antibody cysteine usually exist in the the form of disulfide bonds.
  • the disulfide bonds in the antibody can be opened to provide multiple free sulfhydryl groups as coupling sites.
  • One method of coupling with the sulfhydryl groups of the antibody is Michael addition reaction between the free sulfhydryl groups of the antibody and maleimide, or two Michael addition reactions between a specific substrate and free sulfhydryl groups of the antibody to form a sulfur bridge bond in a unique structure.
  • ADCs obtained by thiol-Michael addition methods will undergo reverse Michael additions in systemic circulation, resulting in toxic reactions.
  • the patent WO2016142049 discloses amatoxins as bioactive molecules, and structure comprising bioactive molecules having the structure of methylsulfonyl-substituted benzobisoxadiazole and linkers, but details of coupling with antibodies are not specifically described.
  • the invention discloses a novel bioactive molecule conjugate, which is obtained by improving the coupling way of the drug and the targeting moiety in an ADC or SMDC.
  • the conjugate has high stability, extremely high coupling efficiency (90%) and high DAR (5-8).
  • the disclosure is based on the above findings.
  • the ADC of the invention e.g. BT001021 (example 32)
  • the exposure of the bioactive small molecular toxin in tumor is significantly higher than that in plasma
  • Immu-132 has significantly higher plasma exposure than tumor exposure under the same administration route. Therefore, the ADC of the invention has a better therapeutic window than Immu-132.
  • We were also surprised that the ADC of the invention has a better efficacy than Immu-132 in animal models of gastric cancer, breast cancer and non-small cell lung cancer.
  • a first aspect of the disclosure provides a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof,
  • T is a fragment of a bioactive molecule, preferably a fragment of a molecule with antitumor bioactivity
  • L 1 is selected from an amino acid, a peptide composed of 2-10 amino acids, an oligosaccharide, -(CH 2 )t 1 -, -(CH 2 CH 2 O) t1 -(CH 2 ) t2 -,
  • L 1 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide composed of 2-5 amino acids,
  • each of R, R′, R 1 and R 2 is independently H(hydrogen), D (deuterium), C 1-6 alkyl, C 2-10 alkenyl, C 2-10 alkynyl or C 3-6 cycloalkyl
  • Z 1 is Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg or Ala-Ala-Asn
  • x 1 is 0, 1, 2 or 3
  • x 3 is 0, 1, 2, 3 or 4.
  • L 1 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Cit-Val, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn,
  • each of R, R′ and R 1 is independently H (hydrogen), D (deuterium), C 1-6 alkyl, C 2-10 alkenyl, C 2-10 alkynyl or C 3-6 cycloalkyl
  • Z 1 is Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly- Gly-Arg or Ala-Ala-Asn
  • each of x 1 and x 3 is independently 0, 1, 2 or 3.
  • L 1 is selected from Lys, Cit, Cit-Val, Val-Ala, Lys-Val,
  • each of R, R′ and R 1 is independently H(hydrogen), D (deuterium) or C 1-4 alkyl, Z 1 is Cit, Lys, Cit-Val, Cit-Ala, Val-Ala or Lys-Val, and each of x 1 and x 3 is independently 0, 1 or 2.
  • L 1 is selected from Lys, Cit, Cit-Val, Val-Ala, Lys-Val,
  • L 1 is selected from
  • L 2 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide composed of 2-5 amino acids,
  • each of R 3 , R 4 , R 5 and R 6 is independently selected from H (hydrogen), D (deuterium), halogen, a carboxylic acid group, a sulfonic acid group, CF 3 , CN, CH 2 CN, C 1-4 alkyl, C 1-4 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or C 3-6 cycloalkyl, each of y 1 and y 2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L 2 is bonded to L 1 at the position 1 of L 2 ;
  • n 1 0, 1, 2 or 3.
  • L 2 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn,
  • each of R 3 , R 4 , R 5 and R 6 is independently selected from H (hydrogen), D (deuterium), halogen, a carboxylic acid group, a sulfonic acid group, CF 3 , CN, CH 2 CN, C 1-4 alkyl, C 1-4 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or C 3-6 cycloalkyl, each of y 1 and y 2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L 2 is bonded to L 1 at the position 1 of L 2 ;
  • n 1 0, 1 or 2.
  • L 2 is selected from
  • each of R 3 , R 4 , R 5 and R 6 is independently selected from H (hydrogen), D (deuterium) or C 1-4 alkyl, each of y 1 and y 2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L 2 is bonded to L 1 at the position 1 of L 2 ;
  • L 2 is selected from
  • L 2 is selected from
  • L 3 is selected from the following groups optionally substituted with one or more R 7 : amino, 3-8 membered cycloalkylene, 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene, 6-12 membered fused heterocyclylene, 6-10 membered arylene, 5-12 membered heteroarylene or 3-8 membered cycloalkylene-W-; wherein W is oxygen or NR 8 , R 7 is independently selected from H (hydrogen), D (deuterium), halogen, ⁇ O, CF 3 , CN, CH 2 CN, carboxyl, sulfonic acid group, C 1-4 alkyl, C 1-4 alkoxy, C 2-6 alkenyl or C 2-6 alkynyl; preferably, the 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spirohetero
  • L 3 is selected from the following groups optionally substituted with one or more R 7 : amino, N-methylpiperidylene, pyrazolylene or triazolylene; wherein R 7 is independently selected from H (hydrogen), D (deuterium), halogen, ⁇ O, CF 3 , CN, CH 2 CN, carboxyl, sulfonic acid group, C 1-4 alkyl, C 1-4 alkoxy, C 2-6 alkenyl or C 2-6 alkynyl; m 2 is 0 or 1.
  • L 3 is selected from triazolylene; m 2 is 0 or 1.
  • L 3 is selected from
  • m 2 is 0 or 1. preferably, L 3 is bonded to L 2 at the position 1 of L 3 .
  • L 3 is selected from the following groups optionally substituted with one or more R 7 : amino,
  • L 3 is selected from
  • each R q is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 3-6 alkynyl or C 3-8 cycloalkyl; ( ⁇ 1 is 0, 1 or 2; and ⁇ 2 is 1, 2 or 3.
  • L 3 is selected from
  • L 4 is selected from
  • Z 4 is 6-10 membered aryl or 5-6 membered heteroaryl;
  • R 10 is selected from H (hydrogen) or C 1-6 alkyl;
  • Z 2 is selected from C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkynylene or C 3-8 cycloalkylene;
  • R 9 is selected from H (hydrogen) or C 1-6 alkyl;
  • Z 3 is absent or selected from C 1-6 alkylene; or R 9 and Z 3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene;
  • ⁇ is independently 0, 1, 2, 3, 4, 5 or 6, and L 4 is bonded to E at the position 2 of L4;
  • n 3 0, 1, 2 or 3.
  • L 4 is selected from
  • Z 4 is a benzene ring
  • R 10 is selected from H (hydrogen) and C 1-6 alkyl
  • Z 2 is selected from C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkynylene or C 3-8 cycloalkylene
  • R 9 is selected from H (hydrogen) or C 1-6 alkyl
  • Z 3 is absent or selected from C 1-6 alkylene or R 9 and Z 3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene
  • ⁇ is independently 0, 1, 2, 3, 4, 5 or 6, and L 4 is bonded to E at the position 2 of L 4 ;
  • n3 0, 1, 2 or 3.
  • L 4 is selected from
  • Z 4 is 5-6 membered heteroarylene;
  • R 10 is selected from H (hydrogen) or C 1-6 alkyl;
  • Z 2 is selected from C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkynylene or C 3-8 cycloalkylene;
  • R 9 is selected from H (hydrogen) or C 1- 6 alkyl;
  • Z 3 is absent or selected from C 1-6 alkylene; or R 9 and Z 3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene;
  • ⁇ is independently 0, 1, 2, 3,4, 5 or 6; and
  • L 4 is bonded to E at the position 2 of L4;
  • n3 0, 1, 2 or 3.
  • L 4 is selected from
  • L 4 is selected from
  • L 4 is selected from
  • E is selected from 5-10 membered heteroarylene optionally substituted with one or more R 12 ; wherein R 12 is independently selected from H (hydrogen), D (deuterium), halogen, CN, nitro, C 1-4 alkyl or halogenated C 1-4 alkyl.
  • E is selected from the following groups optionally substituted with one or more R 12 : pyrimidylene, quinolylene or pyrrolo [2,3-d] pyrimidylene; wherein R 12 is independently selected from H (hydrogen), D (deuterium), halogen, CN, nitro, C 1- 2 alkyl or halogenated C 1-2 alkyl.
  • E is selected from pyrimidinyl optionally substituted with one or more R 12 ; wherein R 12 is independently selected from H(hydrogen) or D (deuterium).
  • G is selected from halogen, OMs, OTs, OTf, nitro, or anyone of the following groups which is optionally substituted with one or more R 13 : alkylthio, arylthio, heteroarylthio, alkyl sulfinyl, aryl sulfinyl, heteroaryl sulfinyl, alkyl sulfonyl, aryl sulfonyl or heteroaryl sulfonyl; wherein R 13 is independently selected from H (hydrogen), D (deuterium), halogen, CN, nitro, C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, 6-10 membered aryl or 5-12 membered heteroaryl.
  • G is selected from F, Cl, Br, I, OMs, OTs, OTf, methylsulfonyl, ethylsulfonyl, p-toluenesulfonyl or naphthalenesulfonyl.
  • G is selected from F, Cl, Br, OMs, OTs, methylsulfonyl or p-toluenesulfonyl.
  • G is selected from Cl or methylsulfonyl.
  • G is preferably methylsulfonyl
  • E is preferably pyrimidylene
  • m 3 is 1.
  • m 4 is preferably an integer from 0 to 6
  • methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • m 5 is preferably an integer from 0 to 6
  • methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • m 6 is preferably an integer from 0 to 6
  • methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • m 7 is an integer from 1 to 5
  • methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • ms is an integer from 1 to 5
  • methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • m 9 is an integer from 1 to 5
  • R 13 is selected from hydrogen or C 1- 6 alkyl, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • m 10 is an integer from 0 to 6, and Z 4 is selected from 5-6 membered heteroarylene; methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • Z 4 is selected from pyridylene, pyrimidylene, pyrazolylene, thiazolylene, oxazolylene or triazolylene; methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring; more preferably, m 10 is an integer from 0-6.
  • Z 4 is selected from pyridylene, pyrimidylene, pyrazolylene or triazolylene. More preferably, m 10 is an integer from 0-6.
  • Z 4 is selected from oxazolylene or thiazolylene, and methylsulfonyl is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring. More preferably, m 10 is an integer from 0-6.
  • m 10 is an integer from 0-6, and Z 4 is selected from 6-10 membered arylene; and methylsulfonyl is a substituent of a carbon atom adjacent to a nitrogen atom. More preferably, m 10 is an integer from 0-6.
  • m 10 is an integer from 0-6, and Z 4 is a benzene ring.
  • T is a fragment of a bioactive molecule.
  • the bioactive molecule is selected from a metal complex, such as a platinum metal complex (e.g., oxaliplatin) or a gold metal complex; a glycopeptide antibiotic such as bleomycin or pingyangmycin; a DNA topoisomerase inhibitor, such as a topoisomerase I inhibitor (e.g., camptothecin, hydroxycamptothecin, 9-aminocamptothecin, SN-38, irinotecan, topotecan, bellotencian or rubitecan) or a topoisomerase II inhibitor (e.g., actinomycin D, adriamycin, doxorubicin, duocarmycin, daunorubicin, mitoxantrone, podophyllotoxin or etoposide); a drug interfering with DNA synthesis, such as methotrexate, 5-fluorouracil, 5-fluorour
  • the bioactive molecule is selected from
  • R 14 is selected from acyl or sulfonyl, which is substituted with R 15 , and R 15 is selected from C 1-6 alkyl, halogenated C 1-6 alkyl, 6-10 membered aryl or 5-12 membered heteroaryl;
  • R 16 is selected from H (hydrogen), D (deuterium), C 1-6 alkyl or C 1-6 alkyl substituted with R 17 , and R 17 is selected from aryl or heteroaryl, including but not limited to phenyl and pyridyl, and m 11 is 0, 1 or 2.
  • the bioactive molecule is selected from
  • R 14 is selected from acyl or sulfonyl, which is substituted with R 15 , and R 15 is selected from C 1-6 alkyl, halogenated C 1-6 alkyl, 6-10 membered aryl or 5-12 membered heteroaryl;
  • R 16 is selected from H (hydrogen), D (deuterium), C 1-6 alkyl, C 1-6 alkyl substituted with R 17 , and R 17 is selected from aryl or heteroaryl, including but not limited to phenyl or pyridyl, and m 11 is 0, 1, or 2.
  • the bioactive molecule is selected from
  • the bioactive molecule is selected from
  • the bioactive molecule is selected from
  • the bioactive molecule is selected from
  • the bioactive molecule is selected from
  • T is selected from
  • T is selected from
  • T is selected from
  • T is selected from
  • T is selected from
  • the compound shown in formula (I) is selected from
  • the compound is selected from:
  • the disclosure provides a conjugate, comprising a bioactive molecule, a linker and a targeting moiety.
  • the targeting moiety is linked to the linker via an active group (e.g., a thiol group) to form a conjugate.
  • a target of A is selected from epidermal growth factor, Trop-2, CD37, HER2, CD70, EGFRvIII, Mesothelin, Folate receptor1, Mucin 1, CD138, CD20, CD19, CD30, SLTRK6, Nectin 4, Tissue factor, Mucin16, Endothelin receptor, STEAP1, SLC39A6, Guanylylcyclase C, PSMA, CCD79b, CD22, Sodium phosphate cotransporter 2B, GPNMB, Trophoblast glycoprotein, AGS-16, EGFR, CD33, CD66e, CD74, CD56, PD-L1, TACSTD2, DR5, E16, STEAP1, 0772P, MPF, Napi3b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, NCA, MDP, IL20R ⁇ , Brevican, Eph
  • A is a small molecule ligand, such as a folic acid derivative, a glutamate urea derivative, a somatostatin derivative, an arylsulfonamide derivative (e.g., a carbonic anhydrase IX inhibitor), a polyene connecting two aliphatic indoles, a cyanine dye or IR-783 or a derivative thereof.
  • a small molecule ligand such as a folic acid derivative, a glutamate urea derivative, a somatostatin derivative, an arylsulfonamide derivative (e.g., a carbonic anhydrase IX inhibitor), a polyene connecting two aliphatic indoles, a cyanine dye or IR-783 or a derivative thereof.
  • A is selected from
  • A is an antibody such as a monoclonal antibody or an antigen binding fragment thereof, wherein the monoclonal antibody or the antigen binding fragment thereof comprises Fab, Fab′, F(ab′) 2 , Fd, Fv, dAb, a complementary determinant fragment, a single chain antibody (e.g., scFv), a non-human antibody, a humanized antibody, a chimeric antibody, a completely humanized antibody, a probody, a bispecific antibody or a multispecific antibody.
  • a monoclonal antibody or an antigen binding fragment thereof comprises Fab, Fab′, F(ab′) 2 , Fd, Fv, dAb, a complementary determinant fragment, a single chain antibody (e.g., scFv), a non-human antibody, a humanized antibody, a chimeric antibody, a completely humanized antibody, a probody, a bispecific antibody or a multispecific antibody.
  • A is an anti-Her 2 monoclonal antibody, such as Trastuzumab, Pertuzumab; or an anti-Trop-2 monoclonal antibody, such as Sacituzumab.
  • A is an anti-Trop-2 monoclonal antibody, such as antibody M1, M2 or M3.
  • Antibody M1 M2 M3 Heavy chain CDR1 GYTFTNY (SEQ ID No.: 1) GYTFTNY (SEQ ID No.: 1) GYTFTNY (SEQ ID No.: 1) Heavy chain CDR2 NTDSGE (SEQ ID No.:2) NTDSGE (SEQ ID No.:2) NTDSGE (SEQ ID No.:2) Heavy chain CDR3 GGFGSSYWYFDV (SEQ ID No.:3) GGFGSSYWYFDV (SEQ ID No.:3) GGFGSSYWYFDV (SEQ ID No.:3) GGFGSSYWYFDV (SEQ ID No.:3) Light chain CDR1 KASQDVSSAVA (SEQ ID No.:4) KASQDVSSAVA (SEQ ID No.:4) KASQDVSIAVA (SEQ ID No.:8) Light chain CDR2 SASYRYT (SEQ ID No.:5) SASYRYT (SEQ ID No.:5) SASYRYT (SEQ ID No.:
  • Heavy chain and light chain sequences of the hydrophobically modified antibody M1 Amino acid sequence of heavy chain variable region of M1: (121 aa)
  • Heavy chain and light chain sequences of the hydrophobically modified antibody M2 Amino acid sequence of heavy chain variable region of M2: (121 aa)
  • Heavy chain and light chain sequences of the hydrophobically modified antibody M3 Amino acid sequence of heavy chain variable region of M3: (121 aa)
  • Terminal Lys of heavy chains is easily deleted, but such deletion does not affect bioactivity. See Dick, L.W. et al., Biotechnol. Bioeng., 100: 1132-1143.
  • the above monoclonal antibodies M1, M2, M3 and sequences or fragments thereof with deleted Lys at terminal of heavy chains all belong to the M1, M2, M3 monoclonal antibodies of this invention.
  • A is selected from a RGD peptide that recognizes cell surface integrin receptor; a growth factor that recognizes cell surface growth factor receptor, such as EGF, PDGF or VEGF; or a peptide capable of recognizing functional cell surface plasminogen activator, bombesin, bradykinin, somatostatin or prostate-specific membrane antigen receptor.
  • A is selected from CD40 ligand, CD30 ligand, OX40 ligand, PD-1 ligand, ErbB ligand, Her2 ligand, TACSTD2 ligand, or DR5 ligand.
  • the conjugate is selected from: or wherein, y is an integer or a decimal from 1 to 10, and mAb is an anti-Trop-2 monoclonal antibody or an anti-Her 2 monoclonal antibody; preferably, the anti-Trop-2 monoclonal antibody is selected from antibodies of Sacituzumab, M1, M2 or M3, and the anti-Her 2 monoclonal antibody is Trastuzumab or Pertuzumab; preferably, y is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8).
  • the conjugate is selected from: wherein, y is an integer or a decimal from 1 to 10, and mAb is an anti-Trop-2 monoclonal antibody or an anti-Her 2 monoclonal antibody; preferably, the anti-Trop-2 monoclonal antibody is selected from Sacituzumab, and the anti-Her 2 monoclonal antibody is selected from Trastuzumab or Pertuzumab; preferably, y is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8).
  • the conjugate is: or wherein, A1 is Sacituzumab, and y is an integer or a decimal from 1 to 10; preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein, A1 is Sacituzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein, A1 is Sacituzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: wherein, A1 is a fragment of Sacituzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein, A2 is Trastuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein, A2 is Trastuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: wherein, A2 is Trastuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein, A3 is Pertuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein, A3 is Pertuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein, A4 is antibody M1, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: wherein, A4 is antibody M1, and y is an integer or a decimal from 1 to 10; and preferably, ⁇ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein, A5 is antibody M2, and ⁇ is an integer or a decimal from 1 to 10; and preferably, ⁇ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: wherein, A5 is antibody M2, and ⁇ is an integer or a decimal from 1 to 10; and preferably, ⁇ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: or wherein A6 is antibody M3, and ⁇ is an integer or a decimal from 1 to 10; and preferably, ⁇ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the conjugate is: wherein A6 is antibody M3, and ⁇ is an integer or a decimal from 1 to 10; and preferably, ⁇ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • the disclosure provides a method for preparing the conjugate of the second aspect, comprising a step of coupling the linker of the compound of formula (I) with an active group of the targeting moiety.
  • the method comprises a step of opening a disulfide bond of the targeting moiety by a reductant (e.g., TCEP) to obtain a sulfydryl group.
  • a reductant e.g., TCEP
  • the method comprises a step of forming a C-S bond between the linker of the compound of formula (I) and the sulfydryl group of the targeting moiety.
  • the targeting moiety is an anti-Her 2 monoclonal antibody (e.g., Trastuzumab, Pertuzumab) or an anti-Trop-2 monoclonal antibody (e.g., Sacituzumab, M1, M2 or M3), or an active fragment or mutant thereof.
  • an anti-Her 2 monoclonal antibody e.g., Trastuzumab, Pertuzumab
  • an anti-Trop-2 monoclonal antibody e.g., Sacituzumab, M1, M2 or M3
  • the molar ratio of the targeting moiety to the compound of formula (I) is 1:(1-20); preferably, the coupling is carried out in water and/or an organic solvent; preferably, the organic solvent is selected from N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone, nitriles (e.g., acetonitrile), alcohols (e.g., methanol, ethanol) or any combination thereof.
  • the organic solvent is selected from N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone, nitriles (e.g., acetonitrile), alcohols (e.g., methanol, ethanol) or any combination thereof.
  • the method further comprises a step of purifying the coupling product; preferably, the coupling product is purified by chromatography (e.g., one or more of ion exchange chromatography, hydrophobic chromatography, reverse phase chromatography or affinity chromatography).
  • chromatography e.g., one or more of ion exchange chromatography, hydrophobic chromatography, reverse phase chromatography or affinity chromatography.
  • the disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of the first aspect of the disclosure or a pharmaceutically acceptable salt thereof, or the conjugate of the second aspect, and one or more pharmaceutical excipients.
  • the disclosure provides use of the compound of the first aspect or a pharmaceutically acceptable salt thereof or the conjugate of the second aspect in the manufacturer of a medicament for the treatment of a disease associated with an abnormal cell activity (e.g., cancer).
  • a disease associated with an abnormal cell activity e.g., cancer
  • the cancer is a solid tumor or a non-solid tumor, such as esophageal cancer (e.g., esophageal adenocarcinoma, esophageal squamous cell carcinoma), a brain tumor, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer), squamous cell carcinoma, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, non Hodgkin’s lymphoma, central nervous system tumors (e.g., neuroglioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer and thyroid cancer.
  • esophageal cancer e.g., esophageal adenocarcinoma, esophageal squamous cell carcinoma
  • a brain tumor e.g
  • the disclosure provides use of the compound of the first aspect or a pharmaceutically acceptable salt thereof or the conjugate or pharmaceutical composition of the second aspect in treating a disease associated with an abnormal cell activity (e.g., cancer).
  • a disease associated with an abnormal cell activity e.g., cancer
  • the disclosure provides a method of treating a disease associated with an abnormal cell activity (e.g., cancer), comprising a step of administering an effective amount of the compound of the first aspect or a pharmaceutically acceptable salt thereof or the conjugate or pharmaceutical composition of the second aspect to an individual in need thereof.
  • a disease associated with an abnormal cell activity e.g., cancer
  • the pharmaceutical excipients refer to excipients and additives used in drug manufacturing and formulating, and are substances that have been reasonably evaluated in terms of safety and are contained in pharmaceutical preparations in addition to active ingredients.
  • pharmaceutical excipients also have important functions such as solubilization, sustained release, and are important ingredients that may affect the quality, safety and efficacy of drugs.
  • compositions can be divided by sources into natural substances, semi-synthetic substances and full-synthetic substances; divided by effects and uses into solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, filling agents, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, aromatics, anti-adhesion agents, antioxidants, chelating agents, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids and release retardants; and divided by administration routes into oral administration, injection, mucosal, transdermal or local administration, nasal or oral inhalation and ophthalmic administration.
  • the same pharmaceutical excipient can
  • the pharmaceutical composition can be formulated into various suitable dosage forms depending on administration routes, such as tablets, capsules, granules, oral solutions, oral suspensions, oral emulsions, powders, tinctures, syrups, injections, suppositories, ointments, creams, pastes, ophthalmic preparations, pills, subdermals, aerosols, powders and sprays.
  • the pharmaceutical composition or suitable dosage forms may contain 0.01 mg to 1000 mg of the compound of the disclosure or a pharmaceutically acceptable salt or conjugate thereof, suitably 0.1 mg to 800 mg, preferably 0.5 to 500 mg, preferably 0.5 to 350 mg, and particularly preferably 1 to 1-250 mg.
  • the pharmaceutical composition can be administered in the form of injections, including liquids for injection, sterilized powders for injection, and concentrated solutions for injection.
  • Acceptable carriers and solvents include water, Ringer’s solution and isotonic sodium chloride solution.
  • sterilized non-volatile oil can also be used as a solvent or suspending medium, such as monoglyceride or diglyceride.
  • the term “individual” include a human individual or a non-human animal.
  • exemplary human individual includes a human individual with a disease (e.g., a disease described herein) (referred to as a patient) or a normal individual.
  • non-human animal in the disclosure includes all vertebrates, such as a non-mammal (e.g., a bird, an amphibian and a reptile) and a mammal, such as a non-human primate, a domestic animal, and/or a domesticated animal (e.g., a sheep, a dog, a cat, a cow and a pig).
  • the term “effective amount” refers to the amount of the compound that, after being administered, relieves one or more symptoms of the treated disease to some extent.
  • the term “conjugate” refers to a substance obtained by linking a bioactive molecule with a targeting moiety.
  • the bioactive molecule is linked to the targeting moiety via a linker.
  • the linker can be cleaved in a specific environment (e.g., an intracellular low pH environment) or under a specific action (e.g., the action of lysosomal protease), thereby dissociating the bioactive molecule from the target moiety.
  • the linker comprises cleavable or non-cleavable units, such as a peptide or disulfide bond.
  • the bioactive molecule is linked directly to the targeting moiety via a covalent bond that can be cleaved under a specific environment or action, thereby dissociating the bioactive molecule from the targeting moiety.
  • bioactive substance and “bioactive molecule” refer to a substance that inhibits or prevents cell functions and/or cause cell death or destruction.
  • bioactive substance or bioactive molecule in the conjugate is a molecule with anti-tumor bioactivity.
  • a radioisotope such as At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 or a radioisotope of Lu; a metal complex such as a platinum metal complex, a gold metal complex or oxaliplatin; a glycopeptide antibiotic such as bleomycin or pingyangmycin; a DNA topoisomerase inhibitor such as a topoisomerase I inhibitor, e.g., camptothecin, hydroxycamptothecin, 9- aminocamptothecin, SN-38, irinotecan, topotecan, bellotencian or rubitecan, or a topoisomerase II inhibitor, e.g., actinomycin D, adriamycin, doxorubicin, duocarmycin, daunorubicin, mitoxantrone, podophyl
  • small molecule refers to a small molecule drug with bioactivity.
  • linker refers to a fragment linking a bioactive molecule with a targeting moiety.
  • targeting moiety refers to a moiety of the conjugate that can specifically bind to a target (or a portion of the target) on the cell surface.
  • the conjugate can be delivered to a specific cell population by interaction between the targeting moiety and the target.
  • the conjugate can be referred to as a “drug-antibody conjugate” when the targeting moiety of the conjugate is an antibody.
  • the “drug-antibody conjugate” and “immune conjugate” are interchangeable.
  • the term “antibody” is interpreted in its broadest sense, including a complete monoclonal antibody, polyclonal antibody, and a multispecific antibody (e.g., a bispecific antibody) formed from at least two complete antibodies, provided that the antibody has required bioactivity.
  • a multispecific antibody e.g., a bispecific antibody
  • the terms “antibody” and “immunoglobulin” are interchangeable.
  • the term “monoclonal antibody” refers to an antibody from a group of substantially uniform antibodies, i.e., antibodies that make up the group are identical except for a small number of possible natural mutations.
  • a monoclonal antibody has high specificity for one determinant (epitope) of an antigen, while a comparative polyclonal antibody contains different antibodies for different determinants (epitopes).
  • the monoclonal antibody has the advantage of being free from contamination by other antibodies during synthesis.
  • the modifier “monoclonal” here indicates that the antibody is characterized by coming from a substantially uniform antibody group and should not be construed as being prepared by a special method.
  • the monoclonal antibody also specifically includes a chimeric antibody, i.e., a portion of a heavy chain and/or a light chain is the same as or homologous to a type, a class, or a subclass of antibodies, while the rest is the same as or homologous to another type, another class, or another subclass of antibodies, provided the antibody has required bioactivity (see, e.g., US 4,816,567; and Morrison et al., 1984, PNAS, 81: 6851-6855).
  • the chimeric antibody available in the disclosure includes a primatized antibody containing a variable region antigen binding sequence from a non-human primate (e.g., an ancient monkey or an orangutan) and a human constant region sequence.
  • antibody fragment refers to a portion of the antibody, preferably an antigen binding region or a variable region.
  • antibody fragment includes Fab, Fab′, F(ab′) 2 , Fd, Fv, dAb and complementary determinant fragment, diabody, linear antibody and single chain antibody molecule.
  • bispecific antibody also known as “bifunctional antibody conjugate” refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) through a coupling arm.
  • the conjugate retains the activity of each antibody and thus has bifunctional and bispecific properties.
  • multispecific antibody includes, for example, a trispecific antibody which is an antibody having three different antigen binding specificities, and a tetraspecific antibody which is an antibody having four different antigen binding specificities.
  • complete antibody refers to an antibody containing an antigen binding variable region, a light chain constant region (CL) and heavy chain constant regions (CH1, CH2 and CH3).
  • the constant regions can be natural sequences (e.g., human natural constant region sequences) or amino acid sequence variants thereof.
  • the complete antibody is preferably a complete antibody having one or more effector functions.
  • antibody is a modified antibody comprising an antibody or antibody fragment that can specifically bind to a target thereof and can be coupled with a masked group, and the masked group here refers that the cleavage constant for the binding capacity of the antibody or antibody fragment to the target is at least 100 times or 1000 times or 10000 times greater than that for the binding capacity of an antibody or antibody fragment not coupled with a masked group to a target thereof.
  • a “humanized” form of a non-human (e.g., mouse) antibody refers to a chimeric antibody that contains minimal non-human immunoglobulin sequences.
  • Most of the humanized antibodies are those in which residues in hypervariable regions of human recipient immunoglobulins are substituted with residues in non-human (e.g., mice, rats, rabbits or non-human primates) hypervariable regions (donor antibodies) with required specificity, affinity and functions.
  • residues in frame regions (FRs) of human immunoglobulins are also substituted with non-human residues.
  • the humanized antibody can also contain residues not present in recipient antibodies or donor antibodies. Such modifications are made to further optimize antibody performance.
  • a humanized antibody generally contains at least one variable region, typically two variable regions, in which all or almost all hypervanable loops correspond to non-human immunoglobulins, while all or almost all FRs are those of human immunoglobulin sequences.
  • a humanized antibody can also contain at least a portion of an immunoglobulin constant region (Fc, usually human immunoglobulin Fc).
  • Fc immunoglobulin constant region
  • Complete antibody can be classified into different “classes” according to amino acid sequences of heavy chain constant regions.
  • the main five classes are IgA, IgD, IgE, IgG and IgM, and several of which can also be further classified into different “subclasses” (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.
  • Different classes of heavy chain constant regions of antibodies are called ⁇ , ⁇ , ⁇ , ⁇ and ⁇ respectively.
  • Different classes of subunit structures and 3D configurations of immunoglobulins are well known in the art.
  • an antibody peptide chain can contain one or more D-amino acids.
  • Peptides containing D-amino acids may be more stable and less degradable in oral cavity, intestinal tract or plasma than peptides containing only L-amino acids.
  • Monoclonal antibody used in the disclosure can be produced by multiple methods.
  • the monoclonal antibody used in the disclosure can be obtained by hybridoma methods using multiple species (including cells of mice, hamsters, rats and humans) (see, for example, Kohler et al., 1975, Nature, 256: 495), or by recombinant DNA techniques (see, for example, US 4,816,567), or isolated from phage antibody libraries (see, for example, Clackson et al., 1991, Nature, 352: 624-628; and Marks et al., 1991, Journal of Molecular Biology, 222: 581-597).
  • Monoclonal antibody that can be used in the disclosure includes, but is not limited to anti-Her 2 monoclonal antibody such as Trastuzumab and Pertuzumab, or anti-Trop-2 monoclonal antibody such as Sacituzumab (i.e., Isactuzumab or hRS7 antibody), M1, M2 or M3.
  • anti-Her 2 monoclonal antibody such as Trastuzumab and Pertuzumab
  • anti-Trop-2 monoclonal antibody such as Sacituzumab (i.e., Isactuzumab or hRS7 antibody), M1, M2 or M3.
  • a target of A is selected from epidermal growth factor, Trop-2, CD37, HER2, CD70, EGFRvIII, Mesothelin, Folate receptor1, Mucin 1, CD138, CD20, CD19, CD30, SLTRK6, Nectin 4, Tissue factor, Mucin16, Endothelin receptor, STEAP1, SLC39A6, Guanylylcyclase C, PSMA, CCD79b, CD22, Sodium phosphate cotransporter 2B, GPNMB, Trophoblast glycoprotein, AGS-16, EGFR, CD33, CD66e, CD74, CD56, PD-L1, TACSTD2, DR5, E16, STEAP1, 0772P, MPF, Napi3b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, NCA, MDP, IL20Ra, Brevican, Eph
  • the target of the targeting moiety A is slected from a RGD peptide that recognizes cell surface integrin receptor; a growth factor that recognizes cell surface growth factor receptor, such as EGF, PDGF or VEGF; and a peptide capable of recognizing functional cell surface plasminogen activator, bombesin, bradykinin, somatostatin or prostate-specific membrane antigen receptor.
  • the target of the targeting moiety A is selected from a CD40 ligand, a CD30 ligand, an OX40 ligand, a PD-1 ligand, an ErbB ligand, a Her2 ligand, a TACSTD2 ligand and a DR5 ligand.
  • the targeting moiety A is an anti-Her 2 monoclonal antibody, such as Trastuzumab or Pertuzumab; or an anti-Trop-2 monoclonal antibody, such as Sacituzumab, M1, M2 or M3.
  • the targeting moiety is Trastuzumab or Pertuzumab.
  • Tratuzumab is an anti-Her 2 monoclonal antibody, an amino acid sequence thereof is known to a person skilled in the art, for a schematic sequence thereof, refer to, for example, CN103319599.
  • terminal Lys of heavy chains of the targeting moiety is easily deleted, but such deletion does not affect bioactivity. See Dick, L.W. et al., Biotechnol. Bioeng., 100: 1132-1143.
  • the targeting moiety is an anti-Trop-2 monoclonal antibody, such as Sacituzumab, M1, M2 or M3 deleted terminal Lys of heavy chains, for example, the targeting moiety is an anti-Her 2 monoclonal antibody, such as Trastuzumab or Pertuzumab deleted terminal Lys of heavy chains.
  • Exemplary heavy and light chain sequences of Trastuzumab refer to SEQ ID No.: 17 and SEQ ID No.:18.
  • heavy and light chain sequences of Trastuzumab referred to or involved are described using the sequences shown in SEQ ID No.: 17 and SEQ ID No.: 18, respectively.
  • Exemplary heavy and light chain sequences of Pertuzumab refer to SEQ ID No.: 16 and SEQ ID No.: 15 of US7560111.
  • the anti-Trop-2 antibody of the targeting moiety is RS7 (i.e., Sacituzumab of the disclosure) described in U.S. pat. 7,517,964; and hRS7 (i.e., Sacituzumab of the disclosure) described in US2012/0237518.
  • the anti-Trop-2 antibody available in the disclosure can also be obtained by screening through carrier design, construction and construction of an antibody library displaying antibodies as disclosed in CN103476941A, or can be obtained by screening a G-MAB® library of Sorrento Therapeutics, Inc.
  • heavy chain sequence and light chain amino acid sequence of the monoclonal antibody Sacituzumab refer to, for example, SEQ ID No.: 19 and SEQ ID No.:20, respectively.
  • Terminal K (or lys) of heavy chains is easily deleted, but such deletion does not affect bioactivity. See Dick, L.W. et al., Biotechnol. Bioeng., 100: 1132-1143.
  • ErbB2 and Her2/neu are interchangeable, both of which represent human Her2 proteins of natural sequences (Genebank CAS No.: X03363, see, for example, Semba et al., 1985, PNAS, 82: 6497-6501; and Yamamoto et al., 1986, Nature, 319: 230-234) and functional derivatives thereof, such as amino acid sequence variants.
  • ErbB2 represents a gene encoding human Her2 and neu represents a gene encoding rat p185neu.
  • the compound or conjugate of the disclosure can inhibit or kill cells that express ErbB2 receptors, such as breast cancer cells, ovarian cancer cells, gastric cancer cells, endometrial cancer cells, salivary gland cancer cells, lung cancer cells, kidney cancer cells, colon cancer cells, thyroid cancer cells, pancreatic cancer cells, bladder cancer cells or liver cancer cells.
  • cells that express ErbB2 receptors such as breast cancer cells, ovarian cancer cells, gastric cancer cells, endometrial cancer cells, salivary gland cancer cells, lung cancer cells, kidney cancer cells, colon cancer cells, thyroid cancer cells, pancreatic cancer cells, bladder cancer cells or liver cancer cells.
  • Trop-2 or TROP2 refers to human trophoblast cell-surface antigen 2, also known as TACSTD2, M1S1, GA733-1, EGP-1, which is a cell surface receptor expressed in many human tumors (e.g., breast cancer, colorectal cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer and cervical cancer).
  • the compound or conjugates of the disclosure can inhibit or kill cells that express TROP2 receptors, such as breast cancer cells, colorectal cancer cells, lung cancer cells, pancreatic cancer cells, ovarian cancer cells, prostate cancer cells or cervical cancer cells.
  • the conjugate of the invention indicates a specific linking mode of a sulfydryl group and a linker in the antibody when the targeting moiety is an antibody.
  • C 1-6 alkyl refers to linear or branched alkyl containing 1-6 carbon atoms, including, for example, “C 1-4 alkyl” and “C 1-3 alkyl”. Specific examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, 2-methyl butyl, neopentyl, 1-ethyl propyl, n-hexyl, isohexyl, 3-methyl pentyl, 2-methyl pentyl, 1-methyl pentyl, 3,3-dimethyl butyl, 2,2-dimethyl butyl, 1,1-dimethyl butyl, 1,2-dimethyl butyl, 1,3-dimethyl butyl, 2,3-dimethyl butyl, 2-ethyl buty
  • C 2-6 alkenyl refers to linear, branched or cyclic alkenyl containing at least a double bond and 2-6 carbon atoms, including, for example, “C 2-4 alkenyl”. Examples thereof include, but are not limited to vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,4-hexadienyl, cyclopentenyl, 1,3-cyclopentadienyl, cyclohexenyl and 1,4-cyclohexadienyl.
  • C 2-6 alkynyl refers to linear or branched alkynyl containing at least a triple bond and 2-6 carbon atoms, including, for example, “C 2-4 alkynyl”. Examples thereof include, but are not limited to ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 4-methyl-2-pentynyl, 2-hexynyl, 3-hexynyl and 5-methyl-2-hexynyl.
  • halogen includes fluorine, chlorine, bromine and iodine.
  • 3-8 membered cycloalkyl or “C 3-8 cycloalkyl” refers to saturated cyclic alkyl containing 3-8 carbon atoms, including, for example, “3-6 membered cycloalkyl”, “4-6 membered cycloalkyl”, “5-7 membered cycloalkyl” or “5-6 membered cycloalkyl”. Specific examples include, but are not limited to cyclopropanyl, cyclobutylalkyl, cyclopentanyl, cyclohexyl, cycloheptyl and cyclooctadecyl.
  • C 1-6 alkoxy refers to a group having a structure of C 1-6 alkyl-O-, wherein C 1-6 alkyl is as defined previously. Specific examples include, but are not limited to methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy and hexyloxy.
  • 3-8 membered aliphatic heterocyclyl refers to a cyclic group containing 3-8 ring-forming atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom).
  • a heteroatom such as a nitrogen atom, an oxygen atom or a sulfur atom.
  • the ring-forming atoms e.g., carbon atoms, nitrogen atoms or sulfur atoms
  • the ring-forming atoms e.g., carbon atoms, nitrogen atoms or sulfur atoms
  • the “3-8 membered aliphatic heterocyclyl” includes, for example, “3-8 membered nitrogen-containing aliphatic heterocyclyl,” “3-8 membered oxygen-containing aliphatic heterocyclyl,” “3-6 membered aliphatic heterocyclyl,” “3-6 membered oxygen-containing aliphatic heterocyclyl,” “4-7 membered aliphatic heterocyclyl,” “4-6 membered aliphatic heterocyclyl,” “5-7 membered aliphatic heterocyclyl,” “5-6 membered aliphatic heterocyclyl,” “5-6 membered nitrogen-containing aliphatic heterocyclyl,” including but not limited to oxiranyl, oxocyclobutyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl and homopiperazinyl.
  • 6-12 membered spirocyclyl refers to a cyclic structure containing 6-12 ring-forming carbon atoms and formed by two or more cyclic structures sharing one carbon atom.
  • the carbon atoms in the cyclic structure can be substituted with oxygen.
  • the “6-12 membered spirocyclyl” includes, for example, “6-11 membered spirocyclyl”, “6-10 membered spirocyclyl”, “7-10 membered spirocyclyl”, “7-9 membered spirocyclyl”, “7-8 membered spirocyclyl”, “9-10 membered spirocyclyl” and “3-10 membered spirocyclyl”.
  • 6-12 membered bridged cyclyl refers to a cyclic structure containing 6-12 ring-forming carbon atoms and formed by two or more cyclic structures sharing two nonadjacent carbon atoms, Optionally, the carbon atoms in the cyclic structure can be substituted with oxygen.
  • the “6-12 membered bridged cyclyl” includes, for example, “6-11 membered bridged cyclyl”, “5-10 membered bridged cyclyl”, “7-10 membered bridged cyclyl”, “7-9 membered bridged cyclyl”, “7-8 membered bridged cyclyl”, “9-10 membered bridged cyclyl” and “3-10 membered bridged cyclyl”. Specific examples include, but are not limited to
  • 6-12 membered fused cyclyl refers to a cyclic structure containing 6-12 ring-forming carbon atoms and formed by two or more cyclic structures sharing two adjacent atoms, including “6-11 membered fused cyclyl”, “6-10 membered fused cyclyl”, “6-8 membered fused cyclyl”, “10-12 membered fused cyclyl”, “7-10 membered fused cyclyl”.
  • Examples thereof include, but are not limited to
  • 6-12 membered spiroheterocyclyl refers to a cyclic structure containing 6-12 ring-forming atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom) and formed by two or more cyclic structures sharing one ring-forming atom.
  • the ring-forming atoms e.g., carbon atoms, nitrogen atoms or sulfur atoms
  • the ring-forming atoms in the cyclic structure can be substituted with oxygen.
  • the “6-12 membered spiroheterocyclyl” includes, for example, “6-11 membered spiroheterocyclyl”, “5-10 membered spiroheterocyclyl”, “7-11 membered spiroheterocyclyl”, “7-10 membered spiroheterocyclyl”, “7-9 membered spiroheterocyclyl”, “7-8 membered spiroheterocyclyl”, “9-10 membered spiroheterocyclyl” and “3-10 membered spiroheterocyclyl”. Specific examples include, but are not limited to
  • 6-12 membered bridged heterocyclyl refers to a cyclic structure containing 6-12 ring-forming atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom) and formed by two or more cyclic structures sharing two nonadjacent ring-forming atoms.
  • the ring-forming atoms e.g., carbon atoms, nitrogen atoms or sulfur atoms
  • the ring-forming atoms e.g., carbon atoms, nitrogen atoms or sulfur atoms
  • the “6-12 membered bridged heterocyclyl” includes, for example, “6-11 membered bridged heterocyclyl”, “6-9 membered bridged heterocyclyl”, “6-10 membered bridged heterocyclyl”, “7-10 membered bridged heterocyclyl”, “7-9 membered bridged heterocyclyl”, “7-8 membered bridged heterocyclyl”, “8 membered bridged heterocyclyl”, “9-10 membered bridged heterocyclyl” and “3-10 membered bridged heterocyclyl”. Specific examples include, but are not limited to
  • 6-12 membered fused heterocyclyl refers to a cyclic structure containing 6-12 ring-forming atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom) and formed by two or more cyclic structures sharing two adjacent atoms.
  • the ring-forming atoms e.g., carbon atoms, nitrogen atoms or sulfur atoms
  • the ring-forming atoms e.g., carbon atoms, nitrogen atoms or sulfur atoms
  • the “6-12 membered fused heterocyclyl” includes, for example, “6-11 membered fused heterocyclyl,” “5-10 membered fused heterocyclyl”, “7-10 membered fused heterocyclyl”, “3-10 membered fused heterocyclyl”, “3-10 membered nitrogen-containing fused heterocyclyl”, “9-10 membered fused heterocyclyl”, “9-10 membered nitrogen-containing fused heterocyclyl” and “6-12 membered oxygen-containing fused heterocyclyl”.
  • Specific examples include, but are not limited to tetrahydroimidazo [4,5-c]pyridyl, 3,4-dihydroquinazolinyl, 1,2-dihydroquinoxalinyl, benzo[d][1,3]dioxolyl, 1,3-dihydroisobenzofuranyl, 4H-1,3-benzoxazinyl, 4,6-dihydro-1H-furo[3,4- ⁇ d]imidazolyl, 3a,4,6,6a-tetrahydro-1H-furo[3,4-d]imidazolyl, 4,6-dihydro-1H-thieno[3,4-d]imidazolyl, 4,6-dihydro-1H-pyrrolo[3,4-d]imidazolyl, benzoimidazolidinyl, octahydro-benzo[d]imidazolyl, decahydroquinolyl, hexahydrothienoi
  • aryl refers to a monocyclic or polycyclic hydrocarbonyl having aromaticity, such as 6-20 membered aryl, 6-10 membered aryl and 5-8 membered aryl. Specific examples include but are not limited to phenyl, naphthyl, anthracenyl and phenanthryl.
  • the “6-20 membered aryl” refers to aryl containing 6-20 ring-forming atoms.
  • heteroaryl refers to a cyclic group having aromaticity, wherein at least one ring-forming atom is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom.
  • ring-forming atoms e.g., carbon atoms, nitrogen atoms or sulfur atoms
  • the ring-forming atoms in the cyclic structure can be substituted with oxygen.
  • Specific examples include, but are not limited to 5-10 membered heteroaryl, 5-10 membered nitrogen-containing heteroaryl, 6-10 membered oxygen-containing heteroaryl, 6-8 membered nitrogen-containing heteroaryl and 5-8 membered oxygen-containing heteroaryl, such as furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, 2-pyridone, 4-pyridone, pyrimidinyl, 1,4-dioxacyclohexadienyl, 2H-1,2-oxazinyl
  • the disclosure obtains a kind of novel bioactive molecule conjugate by improving the coupling way of drugs and targeting moieties in ADCs or SMDCs.
  • the bioactive molecule conjugate is obtained through nucleophilic substitutions of the heteroaryl ring on the ADC linker by the free sulfhydryl in the antibody.
  • the conjugate obtained by the coupling can achieve at least one of the following technical effects:
  • the coupling method described in the disclosure has broad application scope and can be widely used in coupling bioactive molecules with antibodies or targeted small molecule ligands.
  • FIG. 1 shows a TIC (total ion chromatogram) of BT001002.
  • FIG. 2 shows a deconvolution diagram of a coupled light chain of BT001002.
  • FIG. 3 shows a deconvolution diagram of a coupled heavy chain of BT001002.
  • FIG. 4 shows a TIC (total ion chromatogram) of BT001004.
  • FIG. 5 shows a deconvolution diagram of a coupled light chain of BT001004.
  • FIG. 6 shows a deconvolution diagram of a coupled heavy chain of BT001004.
  • FIG. 7 shows a SEC chromatogram of BT001002.
  • FIG. 8 shows a SEC chromatogram of molecular weight Marker of BT001002.
  • FIG. 9 shows a SEC chromatogram of BT001004.
  • FIG. 10 shows a deconvolution diagram of a coupled light chain of BT001012.
  • FIG. 11 shows a deconvolution diagram of a coupled heavy chain of BT001012.
  • FIG. 12 shows a deconvolution diagram of a coupled light chain of BT001013.
  • FIG. 13 shows a deconvolution diagram of a coupled heavy chain of BT001013.
  • FIG. 14 shows a deconvolution diagram of a coupled light chain of BT001018.
  • FIG. 15 shows a deconvolution diagram of a coupled heavy chain of BT001018.
  • FIG. 16 shows a deconvolution diagram of a coupled light chain of BT001021.
  • FIG. 17 shows a deconvolution diagram of a coupled heavy chain of BT001021.
  • FIG. 18 shows a deconvolution diagram of a coupled light chain of BT001023.
  • FIG. 19 shows a deconvolution diagram of a coupled heavy chain of BT001023.
  • FIG. 20 shows a deconvolution diagram of a coupled light chain of BT001040.
  • FIG. 21 shows a deconvolution diagram of a coupled heavy chain of BT001040.
  • FIG. 22 shows a deconvolution diagram of a coupled light chain of BT001041.
  • FIG. 23 shows a deconvolution diagram of a coupled heavy chain of BT001041.
  • FIG. 24 shows a deconvolution diagram of a coupled light chain of BT001042.
  • FIG. 25 shows a deconvolution diagram of a coupled heavy chain of BT001042.
  • FIG. 26 shows a deconvolution diagram of a coupled light chain of BT001043.
  • FIG. 27 shows a deconvolution diagram of a coupled heavy chain of BT001043.
  • FIG. 28 shows a deconvolution diagram of a coupled light chain of BT001044.
  • FIG. 29 shows a deconvolution diagram of a coupled heavy chain of BT001044.
  • FIG. 30 shows a deconvolution diagram of a coupled light chain of BT001046.
  • FIG. 31 shows a deconvolution diagram of a coupled heavy chain of BT001046.
  • FIG. 32 shows a deconvolution diagram of a coupled light chain of BT001047.
  • FIG. 33 shows a deconvolution diagram of a coupled heavy chain of BT001047.
  • FIG. 34 shows a SEC chromatogram of BT001012.
  • FIG. 35 shows a SEC chromatogram of BT001013.
  • FIG. 36 shows a SEC chromatogram of BT001018.
  • FIG. 37 shows a SEC chromatogram of BT001021.
  • FIG. 38 shows a SEC chromatogram of BT001023.
  • FIG. 39 shows a SEC chromatogram of BT001042.
  • FIG. 40 shows a SEC chromatogram of BT001043.
  • FIG. 41 shows a SEC chromatogram of BT001044.
  • FIG. 42 shows a SEC chromatogram of BT001046.
  • FIG. 43 shows a SEC chromatogram of BT001047.
  • FIG. 44 shows changes in growth of tumor volume of each group of mice in a NCI-N87 human gastric cancer model.
  • FIG. 45 shows changes in body weight of each group of mice in a NCI-N87 human gastric cancer model.
  • FIG. 46 shows changes in growth of tumor volume of each group of mice in an HCC1806 human breast cancer model.
  • FIG. 47 A shows changes in growth of tumor volume of each group of mice in a xenograft model of HCC827 human non-small cell lung cancer.
  • FIG. 47 B shows changes in body weight of each group of mice in a xenograft model of HCC827 human non-small cell lung cancer.
  • FIG. 48 A shows changes in growth of tumor volume of each group of mice in a xenograft model of NCI-N87 human gastric cancer.
  • FIG. 48 B shows changes in body weight of each group of mice in a xenograft model of NCI-N87 human gastric cancer.
  • FIG. 49 A shows changes in growth of tumor volume of each group of mice in a tumor-bearing mice model of MDA-MB-231 human breast cancer.
  • FIG. 49 B shows changes in body weight of each group of mice in a tumor-bearing mice model of MDA-MB-231 human breast cancer.
  • OMs methylsulfonyloxy FA
  • OTs Trifluoromethylsulfonyloxy ACN
  • CCK8 reagent 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazole monosodium salt
  • TBS Tert-butyldimethylsilyl
  • FBS Fetal bovine serum MMT p-methoxytriphenylmethyl DMSO
  • Dimethyl sulfoxide PB/PBS Phosphate buffered saline
  • NMR nuclear magnetic resonance
  • MS Mass spectra
  • Step 1 synthesis of tert-butyl (4-((2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5 methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl) carbamate
  • Step 2 synthesis of (2S)-N-((3R,4S,5S)-1-((2S)-2-((1R,2R)-3-((1-((4-aminobenzyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-propionyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-heptanoyl-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutanamide
  • Example 2 Synthesis of (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-((S)-1-((4-aminobenzyl)amino) 1-oxo-3-phenylprop-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl) pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptyl-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyramide (T011)
  • Step 1 synthesis of tert-buty (S)-(4-((2-((((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-phenylpropionamido) methyl)phenyl) l carbamate
  • Step 2 synthesis of tert-butyl (S)-(4-((2-amino-3-phenylpropionamido) methyl)phenyl) carbamate
  • Lithium hydroxide monohydrate (21 mg, 0.51 mmol) was dissolved in water (1 mL) and added to a tetrahydrofuran (2 mL) solution of tert-butyl (S)-(4-((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-phenylpropionamido)methyl)phenyl) carbamate (102 mg, 0.17 mmol). The resulting mixture was reacted at room temperature for 2 hours. The reaction solution was added with water (20 mL) and extracted with ethyl acetate (30 mL ⁇ 4).
  • Step 3 synthesis of (4-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-3-((methylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy -5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)carbamate
  • Step 4 synthesis of (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-((S)-1-((4-aminobenzyl)amino)-1-oxo-3-phenylprop-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptyl-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyramide
  • Trifluoroacetic acid (0.5 mL) was added to a solution of (4-((S)-2-((2R,3R)-3-((S)-1-(3R,4S,5S)-4-((S)-3-(methylamino)-3-methylbutyrylamino)-N, 3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropionamido)methyl)phenyl) carbamate (14.0 mg, 0.015 mmol) in dichloromethane (1.5 mL). The resulting mixture was reacted at room temperature for 1 h.
  • Methylsulfonyl chloride (462 mg, 12.77 mmol, purity:about 70%) was added dropwise to a solution of belotecan hydrochloride (3 g, 6.38 mmol) and triethylamine (2.58 g, 25.54 mmol) in dichloromethane (40 mL). The resulting mixture was reacted at room temperature for 2 h. Suction filtration was performed, and the filter cake was washed three times with dichloromethane (3 mL) to obtain the title compound (2.2 g).
  • Step 1 synthesis of tert-butyl 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) butyrate (compound 1-2)
  • Step 2 synthesis of 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)butyric acid (compound 1-3)
  • Step 3 sysnthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)amino)-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compound 1-5)
  • Step 4 synthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(aminomethyl)phenyl))amino)-1-oxo-5-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compound 1-6)
  • Step 5 synthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(((R)-2-((t-butyloxycarboryl)amino)-3-phenylpropionamido)methyl)phenyl)amino-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compound 1-7)
  • Boc-D-phenylalanine 1.1 g, 4.2 mmol
  • the trifluoroacetate of compound 1-6 (3.0 g, 4.2 mmol) were dissolved in N,N-dimethylformamide (40 mL), cooled to 0° C., and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.2 g, 6.3 mmol), 1-hydroxybenzotriazole (0.9 g, 6.3 mmol) and N-methylmorpholine (1.7 g, 16.8 mmol) were successively added.
  • the reaction system was stirred for 1.0 h at the temperature.
  • Step 6 synthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(((R)-2-amino-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compound 1-8)
  • Step 7 synthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butyrylamido)-N,3-dimethylamino)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureidopent-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (compound 1-9)
  • Step 8 synthesis of (S)-2-((S)-2-amino-3-butyrylamino)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-5-ureidovaleramide (compound 1-10)
  • Step 9 synthesis of (S)-2-((S)-2-(4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)butyrylamido)-3-methylbutyrylamido)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-5-ureidovaleramide (compound TL001)
  • Step 1 synthesis of 4-(4-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)butyric acid (compound 2-2)
  • Step 2 synthesis of (S)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-2-((S)-3-methyl-2-(4-(4-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-butyrylamido)-butyrylamido)-5-ureidovaleramide (compound 2-3)
  • Step 3 synthesis of (S)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-2-((S)-3-methyl-2-(4-(4-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-butyrylamido)-butyrylamido)-5-ureidovaleramide (compound TL002)
  • Step 1 synthesis of methyl 6-(2-(methylthio)pyrimidin-5-yl)-5-hexynoate (compound 3-2)
  • methyl 5-hexynoate 500 mg, 3.97 mmol
  • 5-bromo-2-methylthiopyrimidine were dissolved in N,N-dimethylformamide (3 ml), then triethylamine (3 ml), cuprous iodide (75 mg, 0.4 mmol) and Bis (triphenylphosphine) palladium (II) dichloride (279 mg, 0.4 mmol) were successively added.
  • the resulting mixture was heated to 95° C. under nitrogen protection and reacted for 6 h under stirring, quenched with water, and extracted with ethyl acetate (20 mL ⁇ 3).
  • compound 3-2 (200 mg, 0.8 mmol) was dissolved in a mixed solution of tetrahydrofuran and water (4 mL/4 mL), and lithium hydroxide monohydrate (235 mg, 5.6 mmol) was added, and reacted at room temperature under stirring for 4 h, then diluted with water and extracted with ethyl acetate (20 ml x 2).
  • the desiccant was removed by filtration, and the solvent was evaporated under reduced pressure to obtain the title compound (120 mg).
  • Step 4 N-((S)-1-(((S)-1-((4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureido-2-yl)amino)-3-methyl-1-oxybutan-2-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide (compound TL003)
  • Example 8 (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)-ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′ ⁇ ,4 ⁇ ′ ⁇ ,6,7]-indolizino[1,2-b]-quinolin-4-yl(4-((S)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33-nonoxy-3,9,36-azatetracosan-41-amido)benzyl)carbonate
  • Step 1 synthesis of methyl (S)-(1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)-(9H-fluorenyl) carbamate (compound 19-2)
  • Step 2 synthesis of (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (compound 19-3)
  • Step 3 synthesis of (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonyloxa-6-azatriacetamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (compound 19-4)
  • Step 4 synthesis of 4-((S)-35-azido-4,8-dioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33-nonoxy-3,9-azatetracosane)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonylamino)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound 19-5)
  • Step 5 synthesis of 4-((S)-35-amino-4,8-dioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33-nonoxy-3,9-azatetracosane)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonylamino)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound 19-6)
  • Step 6 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33-nonoxy-3,9,36-azatetracosan-41-amido)benzyl)carbonate (compound TL019)
  • Step 1 methyl ((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidovalerylamido-2-yl)amino))-3-methyl-butyramido-2-yl)-(9H-fluorenyl) carbamate
  • Step 2 synthesis of (S)-2-((S)-2-amino-3-methylbutyramido)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (compound 28-2)
  • Step 3 synthesis of N-((S)-1-(((S)-1-((4-hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopent-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide(compound 28-4)
  • Step 4 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl-(4-((S)-2-((S)-3-methyl-2-(6-(2-(methylsulfonyl)pyrimidin-5-yl))-5-hexynamido)butyramido-5-ureidovalerylamido)benzyl)carbonate (compound TL028)
  • Step 1 synthesis of (S)-2-((S)-35-azido-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-azatetracosyl)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (compound 29-1)
  • Step 2 synthesis of 4-((2S,SS)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazatritriacontylamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound 29-2)
  • Step 3 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl-(4-((2S,5S)-5-isopropyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazotritriacontylamido)benzyl)carbonate (compound TL029)
  • Step 1 synthesis of (S)-2-((S)-35-amino-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide
  • compound 29-1 400 mg, 0.44 mmol was dissolved in methanol and tetrahydrofuran (2.0 mL: 4.0 mL). After complete dissolution, platinum dioxide (40 mg) was added in one batch under nitrogen protection, then the mixed solution was subject to hydrogen substitution for three times. Hydrogenation was conducted at 20° C. for 2 hours. The reaction solution was filtered. The filter cake was washed with methanol. The filtrate was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (200 mg). ESI-MS (m/z): 890.4[M+H] + .
  • Step 2 synthesis of N-((6S,9S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetraoxo-13,19,22,25,28,31,34,37,40-nonoxy-2,7,10,16-tetraazadotetracont-42-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide
  • compound 22-1 250 mg, 0.28 mmol was dissolved in N,N-dimethylformamide (1.0 mL), then HATU (160 mg, 0.42 mmol) and N,N-diisopropylethylamine (109 mg, 0.84 mmol) were successively added, followed by stirring overnight at room temperature. Purification was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (250 mg).
  • Step 3 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((2S,5S)-5-isopropyl-45-(2-(methylsulfonyl)pyrimidin-5-yl)-4,7,11,40-tetraoxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-3,6, 12,39-tetraazapentatetracontane-44-carbamoyl)benzyl)carbonate (compound TL022)
  • Example 12 4-((S)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkynamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonyl)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadotetracontyl-41-alkynamido)benzylcarbonate
  • 6-(-2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (12 mg, 0.045 mmol) was dissolved in dichloromethane (2 mL), then 2-(7-azobenzotriazol)-N,N,N′,N′-tetramethylureahexafluorophosphate (21.2 mg, 0.056 mmol) and N,N-diisopropylethylamine (8.6 mg, 0.067 mmol) were added and stirred for 10 min, and compound 24-1 (35 mg, 0.022 mmol) was added and reacted for 1h under stirring. Purification was performed on preparative high performance liquid chromatography (method B) to obtain the title compound (20 mg). ESI-MS (m/z): 1821.8[M+H] + .
  • Step 2 synthesis of 4-((S)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkynamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonyl)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL024)
  • Step 1 preparation of (S)-(9H-fluoren-9-yl)-methyl(1-((4-(hydroxymethyl)phenyl)amino)-1 -oxopropyl-2-yl)carbamate
  • Step 3 preparation of (9H-fluoren-9-yl)-methyl((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-carbamate
  • Step 4 preparation of (S)-2-amino-N-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxoprop-2-yl)-3-methylbutanamide
  • Step 5 preparation of (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-diazapentatriacontamido)-N-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropan-2-yl)-3-methylbutyramide
  • Step 6 preparation of 4-((2S,5S)-38 azido-5-isopropyl-2-methyl-4,7,11-trioxo-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazatriacontamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonylamino)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 7 preparation of (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7indolizino[1,2-b]quinolin-4-yl-4-((2S,5S)-5-isopropyl-2-methyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7,11-trioxo-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazatriacontazanamido)benzylcarbonate (compound TL030)
  • cuprous bromide (5 mg, 0.04 mmol) and compound 30-7 (20 mg, 15 umol) were added dropwise to a solution of 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)-hex-5-ynylamide (9 mg, 0.007 mmol) in water and N,N-dimethylformamide (0.2 ml: 0.8 ml) and reacted for 4 hours under stirring. Purification was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (4.15 mg). ESI-MS (m/z): 1672.7 [M+H] +
  • Example 14 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11 -(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)hex-5-ynamide
  • prop-2-ynyl-1-amine (189 mg, 3.4 mmol) and compound 3-4 (800 mg, 2.83 mmol) were dissolved in dichloromethane (10 mL), then N,N-diisopropylethylamine (738 mg, 5.67 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (1.63 g, 4.25 mmol) were successively added and reacted for 2 hours under stirring.
  • Step 2 synthesis of 4-((S)-35-azido-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonazo-3,9-diazapentatriacontamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-2H-pyrano[2,3-b]-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • T-030 250 mg, 0.49 mmol was dissolved in dichloromethane (10 mL) and cooled to 0° C., then a solution of 4-dimethylaminopyridine (478 mg, 3.91 mmol) in dichloromethane (3 mL) was added, followed by the slow and dropwise addition of a solution of triphosgene (72 mg, 0.24 mmol) in dichloromethane (10 mL) and reacted at 0° C. for 20 min under stirring.
  • Step 3 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl)carbonate
  • Step 4 synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL033)
  • Example 15 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-carbonate
  • Step 1 synthesis of 4-((S)-35-azido-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-4,8-dioxo 6,12,15,18,21,24,27-nonoxy-((S)-9-((tert-butyldimethylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1,2,3,4-tetrahydroquinolin-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • compound 34-1 (100 mg, 0.2 mmol) was dissolved in anhydrous dichloromethane (2 ml) under nitrogen protection, then cooled to 0° C., followed by an addition of a solution of 4-dimethylaminopyridine (144 mg, 1.18 mmol) in anhydrous dichloromethane (0.5 ml), then a solution of triphosgene (41 mg, 0.14 mmol) in dry dichloromethane (0.5 ml) was slowly added dropwise. The resulting mixture was reacted at 0° C. for 1h under stirring.
  • Step 2 synthesis of (S)-9-(tert-butyldimethylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl-4-((S)-2-(4-(((6-2-(methylsulfonyl)pyrimidin-5-yl)-35-(4-((6-2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-dioxo 6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)carbonate
  • Step 3 synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-carbonate(compound TL034)
  • Example 16 Synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of ((S)-35-azido-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1,2,3,6-triazacycloheptane-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 2 synthesis of (S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)-4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((6-2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido]carbonate
  • Step 3 synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL035)
  • Example 17 Synthesis of 4-((S,Z)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadotetracontyl-41-alkenamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of (Z)-6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-enoic acid
  • Step 2 synthesis of (S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S,Z)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadotetracontyl-41-alkenamido)benzylcarbonate
  • Step 3 synthesis of 4-((S,Z)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkenamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL045)
  • Example 18 4-((S)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkynamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of (S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadotetracontyl-41-alkynamido)benzylcarbonate
  • Step 2 synthesis of 4-((S)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkynamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL048)
  • Example 19 4-((S)-2-(4-aminobutyl)-35-(4-((2-(2-((methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of 2-(2-(methylthio)pyrimidin-5-yl)thiazol-4-carboxylic acid
  • Step 2 synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxylic acid
  • Step 3 synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)thiazo-4-carboxamide
  • Step 4 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl-(4-((S)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonazeza-3,9-diazapentatriacontamino)benzyl)carbonate
  • Step 5 synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((2-(2-((methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Example 20 4-((S)-2-(4-aminobutyric acid)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)-oxazol-4-formylamino)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of ethyl 2-(2-(methylthio)pyrimidin-5-yl)oxazol-4-carboxylate
  • ethyl 2-bromooxazol-4-carboxylate 100 mg, 0.45 mmol
  • compound 49-1 126 mg, 0.50 mmol
  • potassium carbonate 125 mg, 0.9 mmol
  • [1,1′-bis(diphenylphosphino)ferrocen]palladium dichloride 33 mg, 0.05 mmol
  • Step 2 synthesis of 2-(2-(methylthio)pyrimidin-5-yl)oxazol-4-carboxylic acid
  • compound 50-1 (50 mg, 0.19 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (4 mL/2 mL), after complete dissolution, lithium hydroxide monohydrate (40 mg, 0.94 mmol) was added thereto and reacted at 25° C. for 1 h.
  • the reaction solution was diluted with water (15 mL) and extracted with ethyl acetate (20 mL ⁇ 2).
  • Step 3 synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)oxazol-4-carboxylic acid
  • Step 4 synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)-oxazol-4-formamide
  • Step 5 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)oxazol-4-formylamino)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl)carbonate
  • Step 6 synthesis of 4-((S)-2-(4-aminobutyric acid)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)oxazol-4-formylamino)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of 9-fluorenylmethyl ((S)-1-(((S)-1-((4-(((S)2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butyrylamido)-N,3-dimethylbutyrylamido)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureidopent-2-yl)amino)-3-methyl-1-oxobutan-2-yl) carbamate
  • Step 2 synthesis of (S)-2-((S)-2-amino-3-butyrylamino)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-5-ureidovaleramide
  • Step 3 synthesis of (S)-2-((S)-35-azido-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanamido)methyl)phenyl)-5-ureidovaleramide
  • Step 4 synthesis of N-((1-((6S,9S)-1-amino-6-((4-(((S)-2-((2R,3R)-3-((S)1-((3R,4S,SS)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanamido)methyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetraoxy-13,19,22,25,28,31,34,37,40-nonaoxa-2,7,10,16-tetraazaanthracen-42-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(
  • Example 22 4-((2S,5S)-5-isopropyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7,1 1-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonaoxa-3,6,12-triazadotetracontyl)benzyl-((S)-1-(((S)-1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)
  • Step 1 4-((2S,SS)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonaoxa-3,6, 12-triazadotetracontyl)benzyl-((S)-1-(((S)1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
  • Step 2 synthesis of 4-((2S,5S)-5-isopropyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7, 11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonaoxa-3,6, 12-triazadotetracontyl)benzyl-((S)-1-(((S)-1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-y
  • Step 1 synthesis of 4-((2S,5S)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy- ⁇ 3,6,12-triazaoctatriacontamino)benzyl-(4-nitrophenyl)-carbonate
  • Step 2 synthesis of (S)-2-((2R ⁇ ,3R)-3-((2S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-((((4-((S)-2-((S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azatriacontamido)-3-methylbutyrylamino)-5-ureidopentanoylamino)benzyl)oxy)carbonyl)(methyl)amino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionyl)-L-phenylalanine
  • compound 53-1 60 mg, 0.06 mmol
  • compound 53-1 60 mg, 0.06 mmol
  • ((2R)-3-((2S)-1-((3R, 5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butyrylamino)butyrylamino)-3-methoxy-5-methylheptyl)pyrrolidine-2-yl)-3-methoxy-2-methypropionyl)-L-phenylalanine 41 mg, 0.06 mmol
  • N,N-dimethylformamide 2 mL
  • 1-hydroxybenzotriazole 8 mg, 0.06 mmol
  • Step 3 synthesis of (S)-2-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl2-(methyl(((4-((S)-2-((S)-3-methyl-2-(32-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-carbamoyl)methyl)-1H-1,2,3-triazol-1-yl)-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azatriacontamino)butyrylamino)-5-ureidovalerylamino)benzyl)oxy)carbonyl)amino)butyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionyl)-L-pheny
  • Example 24 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl-((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-o
  • Step 1 synthesis of (S)-4-(35-azido-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyryl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl-(4-nitrophenyl)-carbonate
  • Step 2 synthesis of 4-((S)-35-azide-2-(4-(((4-methoxyphenyl) benzhydryl)amino)butyryl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl((S)-1-(((S)-1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl
  • Step 3 synthesis of 4-((S)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyryl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl((S)-1-(((S)-1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyhept
  • Step 4 synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl-((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl
  • Example 25 Synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((4-(2-(methylsulfonyl)pyrimidin-5-yl)benzamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3 ⁇ ′ ⁇ ,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Step 1 synthesis of methyl 4-(2-(methylthio)pyrimidin-5-yl)benzoate
  • Step 3 synthesis of 4-(2-(methylsulfonyl)pyrimidin-5-yl)benzoic acid
  • Step 4 synthesis of 4-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)benzamide
  • benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate 100 mg, 0.26 mmol
  • dichloromethane 10 mL
  • propynylamine 10 mg, 0.2 mmol
  • N,N-diisopropylethylamine 70 mg, 0.5 mmol
  • the reaction solution was purified by silica gel column chromatography to obtain the title compound (20 mg).
  • Step 5 synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((4-(2-(methylsulfonyl)pyrimidin-5-yl)benzamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl)carbonate
  • cuprous iodide (10 mg, 0.05 mmol) and water (2 mL) were successively added to dimethyl sulfoxide solution (2 mL) of compound 55-4 (16 mg, 0.05 mmol) and compound 33-1 (80 mg, 0.05 mmol) and reacted for 1 h under stirring.
  • Purificaiton (method B) was performed to obtain the title compound (79 mg).
  • Step 6 synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((4-(2-(methylsulfonyl)pyrimidin-5-yl)benzamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)- ⁇ 3,14-dioxo- ⁇ 3,4,12,14-tetrahydro-1H-pyrano[3 ⁇ ′ ⁇ ,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • compound 55-5 (55 mg, 0.029 mmol) was added to trifluoroacetic acid (0.5 mL) in a mixed solvent of water/acetonitrile (0.1 mL/0.5 mL), and reacted for 15 min under stirring.
  • the reaction solution was purified by preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (42 mg).
  • ESI-MS (m/z):821.0[M/2+H] + .
  • Step 1 synthesis of 32-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azadotriacontanoic acid
  • Step 2 synthesis of (9H-fluoren-9-yl)methyl((S)-1-(((S)-1-((4-((S)-3-azido-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)amino)-1-oxo-5-ureidopentanoylamino-2-yl)amino)-3-methyl-1 -oxobutan-2-yl)carbamate
  • Step 3 synthesis of (S)-2-((S)-2-amino-3-methylbutyrylamino)-N-(4-((S)-3-azido-2-((2R,3R)-3-((S)-l-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)-5-ureidovaleramide
  • Step 4 synthesis of N-((1-((6S,9S)-1-amino-6-((4-((S)-3-azido-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetraoxo-13,19,22,25,28,31,34,37,40-nonoxy-2,7,10,16-tetraazadotetracont-42-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(2-(
  • antibody Sacituzumab (anti-Trop-2, 33.5 mg/mL) was diluted with 0.25 ml of a solution (pH 7.6) containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, to which 0.45 ml of a solution (pH 7.6) containing 20 mM PB and 150 mM NaCl was added and evenly mixed.
  • TCEP tris(2-carboxyethyl)phosphine
  • TL003 dissolved in dimethyl sulfoxide was added in an amount of 15 equiv. and evenly mixed, which was allowed to stand at room temperature for 2 hours. After the addition, 6.1 ⁇ l of 100 mM cysteine was added to terminate the reaction. At last, the buffer was replaced with a 20 mM PB buffer solution of pH 6.44 by G-25 gel column to obtain the coupling product of TL003 with Sacituzumab, which was named as BT001002.
  • Sacituzumab (anti-Trop-2, 17.6 mg/mL) was diluted with 0.095 mL of a diluent (a solution containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, pH 7.6). Then the diluted solution was adjusted with 1 M Na 2 HPO 4 solution to pH 7.4, and 10 mM TCEP solution was added and evenly mixed, which was allowed to stand at room temperature for 30 min. To the solution system, TL019 dissolved in dimethyl sulfoxide was added in an amount of 9 equiv. and evenly mixed, which was allowed to stand at room temperature for 2 h. At last, the buffer was replaced with a PBS buffer solution of pH 6.5 by G-25 gel column to obtain the coupling product of TL019 with Sacituzumab, which was named as BT001004.
  • a diluent a solution containing 20 mM PB, 150 mM NaCl and 20 mM sodium
  • Sacituzumab (anti-Trop-2, 33.5 mg/mL) was diluted with 0.25 ml of a solution (pH 7.6) containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, then 0.45 mL of a solution (pH 7.6) containing 20 mM PB and 150 mM NaCl was added and evenly mixed.
  • TCEP tris(2-carboxyethyl)phosphine
  • 0.3 mL of antibody M3 (anti-Trop-2, 33.5 mg/mL) was diluted with 0.25 ml of a solution (pH 7.6) containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, then 0.45 mL of a solution (pH 7.6) containing 20 mM PB and 150 mM NaCl was added and evenly mixed.
  • TCEP tris(2-carboxyethyl)phosphine
  • Example 48 Determination of Molecular Weight of BT001002 by LC-MS
  • mAb stands for a monoclonal antibody
  • LC stands for the light chain of an antibody
  • HC stands for the heavy chain of an antibody
  • DAR1 stands for a conjugate containing a light chain/heavy chain of an antibody and a bioactive molecule
  • DAR2 stands for a conjugate containing a light chain/heavy chain of an antibody and two bioactive molecules
  • DAR3 stands for a conjugate containing a light chain/heavy chain of an antibody and three bioactive molecules
  • DAR4 stands for a conjugate containing a light chain/heavy chain of an antibody and four bioactive molecules
  • glycoform stands for the structure of glycan of the two heavy chains:
  • G0F stands for fucosylation and free of galactosylation.
  • both the molecular weights of the light chain and the heavy chain of the antibody are changed after being coupled with TL003, wherein the light chain was coupled with 1 bioactive molecule and the heavy chain was coupled with 3 bioactive molecules. Therefore, it could be inferred that the DAR of the antibody to the bioactive molecule was 8.
  • the molecular weight of BT001004 obtained from coupling was analyzed by LC-MS.
  • LC stands for the light chain of an antibody
  • HC stands for the heavy chain of an antibody
  • the light chain of the antibody was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 14% and 86%, respectively), and the heavy chain was coupled with 1-3 bioactive molecules (DAR1, DAR2 and DAR3 accounted for 13%, 19% and 68%, respectively). Therefore, it could be calculated that the DAR of the antibody to the bioactive molecule was 7.0.
  • Example 50 Determination of Molecular Weight of BT001012 by LC-MS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Description

    FIELD OF THE INVENTION
  • The disclosure belongs to the technical field of medical technology, and relates to a bioactive molecule conjugate, preparation method thereof, and use in the prevention and/or treatment of a disease associated with an abnormal cell activity, including but not limited to the use in the prevention and/or treatment of a neoplastic disease.
    • BACKGROUND ART
  • Chemotherapy was once a standard therapy for cancer, but bioactive molecules having high killing effect can mistakenly kill normal cells, resulting in serious side effects. Targeted therapy has become a hot research topic in the field of oncology due to the targetability and anti-tumor activity. Since the 20th century, breakthroughs have been made in the development of anti-tumor drugs and tumor targeted therapies using bio-macromolecular drugs (e.g., therapeutic antibodies or antibody fragments) and targeted small molecule ligands. However, despite of their high targetability, bio-macromolecular drugs have limited curative effects on solid tumors; in addition, bioactive molecules often lack targetability and accidentally injure normal cells and cause serious toxic and side effects, despite of their high killing effect on cancer cells.
  • Recent studies have found that therapeutic antibodies can be linked to bioactive molecules to form antibody-drug conjugates (ADCs). The ADC combine the targeting effect of antibodies and the activity of bioactive molecules making it a “biological missile”. The ADC is guided by antibodies to bind to target cells, and then is internalized by cells to release drugs thereby treating relevant diseases. Due to the specificity and targetability to tumor cell related targets, the application values of antibodies not only are reflected in the treatment, but also become an ideal carrier for drug targeted delivery, and reduce side effects of drugs. Small molecule drug conjugates (SMDCs) are designed on the basis of same principle as antibody-drug conjugates (ADCs); that is, coupling bioactive molecules with some small molecule ligands which can selectively bind to receptors on the surfaces of tumor cells through chemical processes, thereby improving the targetability of effector molecules (bioactive molecules) to tumor cells. The difference between the SMDCs and the ADCs is that the SMDCs use small molecule ligands instead of antibodies, and there is not yet SMDC available on the market.
  • Currently, there are four commercially available ADCs: Mylotarg (Gemtuzumab Ozogamicin), Adcetris (Brentuximab Vedotin, CD30 monoclonal antibody-MMAE), Kadcyla (Trastuzumab Emtansine) and Besponsa (Inotuzumab ozogamicin, CD22 monoclonal antibody-calicheamicin). An ADC generally consists of an antibody, a bioactive molecule and a linker. The bioactive molecule is covalently coupled to the antibody via the linker; the antibody (e.g., monoclonal antibodies) can specifically recognize a specific target on the surface of a tumor cell, thus guiding the ADC to reach the surface of cancer cell and enabling the ADC to enter the cancer cell through endocytosis effect; then the bioactive molecule is released in the cancer cell to achieve the effect of specifically killing the cancer cell without damaging normal tissue cells.
  • Lysine is the most common linking site in antibodies, and ε-amino groups thereof can react with activated carboxyl groups of linkers to form amide bonds. Techniques for site-specific coupling are currently available, that is, carboxyl groups of linkers are activated, and then form amide bonds with specific lysine ε-amino groups in antibodies to complete the coupling. However, such amide bonds are prone to hydrolysis under the action of enzymes enzymes in vivo, as a result, bioactive molecules and antibodies dissociate before reaching target cells resulted in increasing toxicity while losing tagetability of ADCs.
  • Thio groups of antibody cysteine usually exist in the the form of disulfide bonds. The disulfide bonds in the antibody can be opened to provide multiple free sulfhydryl groups as coupling sites. One method of coupling with the sulfhydryl groups of the antibody is Michael addition reaction between the free sulfhydryl groups of the antibody and maleimide, or two Michael addition reactions between a specific substrate and free sulfhydryl groups of the antibody to form a sulfur bridge bond in a unique structure. However, many literatures have reported that ADCs obtained by thiol-Michael addition methods will undergo reverse Michael additions in systemic circulation, resulting in toxic reactions. The patent WO2016142049 discloses amatoxins as bioactive molecules, and structure comprising bioactive molecules having the structure of methylsulfonyl-substituted benzobisoxadiazole and linkers, but details of coupling with antibodies are not specifically described.
    • CONTENTS OF THE INVENTION
  • The invention discloses a novel bioactive molecule conjugate, which is obtained by improving the coupling way of the drug and the targeting moiety in an ADC or SMDC. The conjugate has high stability, extremely high coupling efficiency (90%) and high DAR (5-8). The disclosure is based on the above findings. Through intensive research, it was surprisingly found that, the ADC of the invention, e.g. BT001021 (example 32), after intravenous administration, the exposure of the bioactive small molecular toxin in tumor is significantly higher than that in plasma, whereas Immu-132 has significantly higher plasma exposure than tumor exposure under the same administration route. Therefore, the ADC of the invention has a better therapeutic window than Immu-132. We were also surprised that the ADC of the invention has a better efficacy than Immu-132 in animal models of gastric cancer, breast cancer and non-small cell lung cancer.
  • A first aspect of the disclosure provides a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof,
  • Figure US20230357259A1-20231109-C00001
  • wherein, T is a fragment of a bioactive molecule, preferably a fragment of a molecule with antitumor bioactivity;
  • L1 is selected from an amino acid, a peptide composed of 2-10 amino acids, an oligosaccharide, -(CH2)t1-, -(CH2CH2O)t1-(CH2)t2-,
  • Figure US20230357259A1-20231109-C00002
  • Figure US20230357259A1-20231109-C00003
  • Figure US20230357259A1-20231109-C00004
  • Figure US20230357259A1-20231109-C00005
  • Figure US20230357259A1-20231109-C00006
  • Figure US20230357259A1-20231109-C00007
  • Figure US20230357259A1-20231109-C00008
  • Figure US20230357259A1-20231109-C00009
  • Figure US20230357259A1-20231109-C00010
  • Figure US20230357259A1-20231109-C00011
  • Figure US20230357259A1-20231109-C00012
  • Figure US20230357259A1-20231109-C00013
  • Figure US20230357259A1-20231109-C00014
  • Figure US20230357259A1-20231109-C00015
  • Figure US20230357259A1-20231109-C00016
  • Figure US20230357259A1-20231109-C00017
  • Figure US20230357259A1-20231109-C00018
  • Figure US20230357259A1-20231109-C00019
  • Figure US20230357259A1-20231109-C00020
  • Figure US20230357259A1-20231109-C00021
  • Figure US20230357259A1-20231109-C00022
  • Figure US20230357259A1-20231109-C00023
    • wherein each of R, R′, R1 and R2 is independently H (hydrogen), D (deuterium), halogen, a carboxylic acid group, a sulfonic acid group, cyano, C1-6 alkyl, halogenated C1-6 alkyl (e.g., -CF3), C1-6 alkyl substituted with cyano (e.g., -CH2CN), C1-6 alkoxy, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, 6-10 membered aryl or 5-12 membered heteroaryl, each Z1 is independently an amino acid or a peptide composed of 2-10 amino acids, each of t1 and t2 is independently 0, 1, 2, 3, 4, 5 or 6, each of x1 and x2 is independently 0, 1, 2, 3, 4, 5 or 6, each x3 is independently 0, 1, 2, 3 or 4, and L1 is bonded to T at the position 1 of L1;
    • L2 is selected from an amino acid, a peptide composed of 2-10 amino acids, an oligosaccharide, -(CH2)t1-, -(CH2CH2O)t1-(CH2)t2-,
    • Figure US20230357259A1-20231109-C00024
    • Figure US20230357259A1-20231109-C00025
    • Figure US20230357259A1-20231109-C00026
    • Figure US20230357259A1-20231109-C00027
    • Figure US20230357259A1-20231109-C00028
    • Figure US20230357259A1-20231109-C00029
    • Figure US20230357259A1-20231109-C00030
    • Figure US20230357259A1-20231109-C00031
    • Figure US20230357259A1-20231109-C00032
    • wherein each of R3, R4, R5 and R6 is independently selected from H (hydrogen), D (deuterium), halogen, a carboxylic acid group, a sulfonic acid group, CN, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano, C1-6 alkoxy, C2-10 alkenyl, C2-10 alkynyl or C3-6 cycloalkyl, or R3/R4, R5/R6 or R3/R5 together with the carbon atoms attached thereto form a 3-8 membered ring, each of t1 and t2 is independently 0, 1, 2, 3, 4, 5 or 6, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and L2 is bonded to L1 at the position 1 of L2;
    • L3 is selected from the following groups optionally substituted with one or more R7: amino, 3-8 membered cycloalkylene, 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene, 6-12 membered fused heterocyclylene, 6-10 membered arylene (e.g., phenylene or naphthylene), 5-12 membered heteroarylene or 3-8 membered cycloalkylene-W-; wherein W is oxygen or NR8, R7 is independently selected from H (hydrogen), D (deuterium), halogen, =O, CN, carboxyl, sulfonic acid group, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano, C1-6 alkoxy, C2-10 alkenyl or C2-10 alkynyl, R8 is independently selected from H (hydrogen), D (deuterium), C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy or cyano C1-2 alkyl, and L3 is bonded to L2 at the position 1 of L3;
    • L4 is selected from
    • Figure US20230357259A1-20231109-C00033
    • wherein Z5 is preferably selected from C2-6 alkenylidene, C2-6 alkynylidene, amido group, sulfuryl, sulfinyl, 6-10 membered arylene or 5-6 membered heteroarylene; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene, C3-8 cycloalkylene, 6-10 membered arylene or 5-14 membered heteroarylene; R9 is selected from H (hydrogen) or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene, halogenated C1-6 alkylene or C1-6 alkylene substituted with alkoxy; or R9 and Z3 together with nitrogen atom attached thereto form a 4-8 membered heterocyclyl; α is independently 0, 1, 2, 3,4, 5 or 6; and L4 is bonded to E at the position 2 of L4;
    • E is selected from the following groups optionally substituted with one or more R12: 6-10 membered arylene or 5-14 membered heteroarylene; wherein R12 is independently selected from H (hydrogen), D (deuterium), halogen, CN, nitro, C1-6 alkyl or halogenated C1-6 alkyl;
    • G is a leaving group for nucleophilic substitutions; such as, halogen, sulfonyl, sulfonic acid ester group, nitro, etc.;
    • each of m1, m2, and m3 is independently 0, 1, 2, 3, 4,5, 6, 7, 8, 9 or 10.
  • In some preferred embodiments, L1 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide composed of 2-5 amino acids,
  • Figure US20230357259A1-20231109-C00034
  • Figure US20230357259A1-20231109-C00035
  • Figure US20230357259A1-20231109-C00036
  • Figure US20230357259A1-20231109-C00037
  • Figure US20230357259A1-20231109-C00038
  • Figure US20230357259A1-20231109-C00039
  • Figure US20230357259A1-20231109-C00040
  • Figure US20230357259A1-20231109-C00041
  • Figure US20230357259A1-20231109-C00042
  • Figure US20230357259A1-20231109-C00043
  • Figure US20230357259A1-20231109-C00044
  • Figure US20230357259A1-20231109-C00045
  • Figure US20230357259A1-20231109-C00046
  • wherein each of R, R′, R1 and R2 is independently H(hydrogen), D (deuterium), C1-6 alkyl, C2-10 alkenyl, C2-10 alkynyl or C3-6 cycloalkyl, Z1 is Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg or Ala-Ala-Asn, x1 is 0, 1, 2 or 3, and x3 is 0, 1, 2, 3 or 4.
  • In some preferred embodiments, L1 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Cit-Val, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn,
  • Figure US20230357259A1-20231109-C00047
  • Figure US20230357259A1-20231109-C00048
  • Figure US20230357259A1-20231109-C00049
  • wherein each of R, R′ and R1 is independently H (hydrogen), D (deuterium), C1-6 alkyl, C2-10 alkenyl, C2-10 alkynyl or C3-6 cycloalkyl, Z1 is Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly- Gly-Arg or Ala-Ala-Asn, and each of x1 and x3 is independently 0, 1, 2 or 3.
  • In some preferred embodiments, L1 is selected from Lys, Cit, Cit-Val, Val-Ala, Lys-Val,
  • Figure US20230357259A1-20231109-C00050
  • Figure US20230357259A1-20231109-C00051
  • wherein each of R, R′ and R1 is independently H(hydrogen), D (deuterium) or C1-4 alkyl, Z1 is Cit, Lys, Cit-Val, Cit-Ala, Val-Ala or Lys-Val, and each of x1 and x3 is independently 0, 1 or 2.
  • In some preferred embodiments, L1 is selected from Lys, Cit, Cit-Val, Val-Ala, Lys-Val,
  • Figure US20230357259A1-20231109-C00052
  • Figure US20230357259A1-20231109-C00053
  • Figure US20230357259A1-20231109-C00054
  • Figure US20230357259A1-20231109-C00055
  • Figure US20230357259A1-20231109-C00056
  • Figure US20230357259A1-20231109-C00057
  • Figure US20230357259A1-20231109-C00058
  • Figure US20230357259A1-20231109-C00059
  • Figure US20230357259A1-20231109-C00060
  • Figure US20230357259A1-20231109-C00061
  • Figure US20230357259A1-20231109-C00062
  • In some preferred embodiments, L1 is selected from
  • Figure US20230357259A1-20231109-C00063
  • In some preferred embodiments, L2 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide composed of 2-5 amino acids,
  • Figure US20230357259A1-20231109-C00064
  • Figure US20230357259A1-20231109-C00065
  • Figure US20230357259A1-20231109-C00066
  • Figure US20230357259A1-20231109-C00067
  • Figure US20230357259A1-20231109-C00068
  • Figure US20230357259A1-20231109-C00069
  • Figure US20230357259A1-20231109-C00070
  • Figure US20230357259A1-20231109-C00071
  • Figure US20230357259A1-20231109-C00072
  • wherein each of R3, R4, R5 and R6 is independently selected from H (hydrogen), D (deuterium), halogen, a carboxylic acid group, a sulfonic acid group, CF3, CN, CH2CN, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkyl, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L2 is bonded to L1 at the position 1 of L2;
  • m1 is 0, 1, 2 or 3.
  • In some preferred embodiments, L2 is selected from Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn,
  • Figure US20230357259A1-20231109-C00073
  • Figure US20230357259A1-20231109-C00074
  • Figure US20230357259A1-20231109-C00075
  • Figure US20230357259A1-20231109-C00076
  • Figure US20230357259A1-20231109-C00077
  • Figure US20230357259A1-20231109-C00078
  • wherein each of R3, R4, R5 and R6 is independently selected from H (hydrogen), D (deuterium), halogen, a carboxylic acid group, a sulfonic acid group, CF3, CN, CH2CN, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkyl, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L2 is bonded to L1 at the position 1 of L2;
  • m1 is 0, 1 or 2.
  • In some preferred embodiments, L2 is selected from
  • Figure US20230357259A1-20231109-C00079
  • Figure US20230357259A1-20231109-C00080
  • Figure US20230357259A1-20231109-C00081
  • Figure US20230357259A1-20231109-C00082
  • Figure US20230357259A1-20231109-C00083
  • Figure US20230357259A1-20231109-C00084
  • wherein each of R3, R4, R5 and R6 is independently selected from H (hydrogen), D (deuterium) or C1-4 alkyl, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L2 is bonded to L1 at the position 1 of L2;
  • m1 is 1.
  • In some preferred embodiments, L2 is selected from
  • Figure US20230357259A1-20231109-C00085
  • Figure US20230357259A1-20231109-C00086
  • Figure US20230357259A1-20231109-C00087
  • Figure US20230357259A1-20231109-C00088
  • Figure US20230357259A1-20231109-C00089
  • Figure US20230357259A1-20231109-C00090
  • Figure US20230357259A1-20231109-C00091
  • Figure US20230357259A1-20231109-C00092
  • In some preferred embodiments, L2 is selected from
  • Figure US20230357259A1-20231109-C00093
  • Figure US20230357259A1-20231109-C00094
  • In some preferred embodiments, L3 is selected from the following groups optionally substituted with one or more R7: amino, 3-8 membered cycloalkylene, 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene, 6-12 membered fused heterocyclylene, 6-10 membered arylene, 5-12 membered heteroarylene or 3-8 membered cycloalkylene-W-; wherein W is oxygen or NR8, R7 is independently selected from H (hydrogen), D (deuterium), halogen, ═O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl or C2-6 alkynyl; preferably, the 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene or 6-12 membered fused heterocyclylene has one or more nitrogen atoms; preferably, the 3-8 membered aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene or 6-12 membered fused heterocyclylene has one or more quaternized nitrogen atoms; preferably, the 3-8 membered aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene or 6-12 membered fused heterocyclylene has one or more nitrogen atoms, and at least one nitrogen atom is substituted with =O; R8 is independently selected from H (hydrogen), D (deuterium), C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, C1-6 alkoxy or cyano C1-2 alkyl;
    • m2 is 0, 1, 2 or 3.
    • In some preferred embodiments, L3 is selected from the following groups optionally substituted with one or more R7: amino, 3-6 membered aliphatic heterocyclylene or 5-10 membered heteroarylene; wherein R7 is independently selected from H (hydrogen), D (deuterium), halogen, =O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl or C2-6 alkynyl; preferably, the 3-6 membered aliphatic heterocyclylene has one or more nitrogen atoms; preferably, the 3-6 membered aliphatic heterocyclylene has one or more quaternized nitrogen atoms; preferably, the 3-6 membered aliphatic heterocyclylene has one or more nitrogen atoms, and at least one nitrogen atom is substituted with =O;
    • m2 is 0, 1 or 2.
    • In some preferred embodiments, L3 is selected from the following groups optionally substituted with one or more R7: amino or 5-6 membered heteroarylene; wherein R7 is independently selected from H (hydrogen), D (deuterium), halogen, =O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl or C2-6 alkynyl; m2 is 0 or 1.
  • In some preferred embodiments, L3 is selected from the following groups optionally substituted with one or more R7: amino, N-methylpiperidylene, pyrazolylene or triazolylene; wherein R7 is independently selected from H (hydrogen), D (deuterium), halogen, ═O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl or C2-6 alkynyl; m2 is 0 or 1.
  • In some preferred embodiments, L3 is selected from triazolylene; m2 is 0 or 1.
  • In some preferred embodiments, L3 is selected from
  • Figure US20230357259A1-20231109-C00095
  • . m2 is 0 or 1. preferably, L3 is bonded to L2 at the position 1 of L3.
  • In some preferred embodiments, L3 is selected from the following groups optionally substituted with one or more R7: amino,
  • Figure US20230357259A1-20231109-C00096
  • Figure US20230357259A1-20231109-C00097
  • Figure US20230357259A1-20231109-C00098
  • Figure US20230357259A1-20231109-C00099
  • Figure US20230357259A1-20231109-C00100
  • Figure US20230357259A1-20231109-C00101
  • Figure US20230357259A1-20231109-C00102
  • Figure US20230357259A1-20231109-C00103
  • Figure US20230357259A1-20231109-C00104
  • Figure US20230357259A1-20231109-C00105
  • Figure US20230357259A1-20231109-C00106
  • Figure US20230357259A1-20231109-C00107
    • R7 is independently selected from H (hydrogen), D (deuterium), =O, CN, CH2CN, methyl or CF3;
    • W is NR8, and R8 is selected from H (hydrogen), D (deuterium), C1-6 alkyl, C2-6 alkenyl, C3- 6 alkynyl or C3-6 cycloalkyl.
  • In some preferred embodiments, L3 is selected from
  • Figure US20230357259A1-20231109-C00108
  • Figure US20230357259A1-20231109-C00109
  • Figure US20230357259A1-20231109-C00110
  • Figure US20230357259A1-20231109-C00111
  • Figure US20230357259A1-20231109-C00112
  • Figure US20230357259A1-20231109-C00113
  • Figure US20230357259A1-20231109-C00114
  • Figure US20230357259A1-20231109-C00115
  • Figure US20230357259A1-20231109-C00116
  • wherein each Rq is independently selected from C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl or C3-8 cycloalkyl; (β1 is 0, 1 or 2; and β2 is 1, 2 or 3.
  • In some preferred embodiments, L3 is selected from
  • Figure US20230357259A1-20231109-C00117
  • In some preferred embodiments, L4 is selected from
  • Figure US20230357259A1-20231109-C00118
  • Figure US20230357259A1-20231109-C00119
  • Figure US20230357259A1-20231109-C00120
  • Figure US20230357259A1-20231109-C00121
  • Figure US20230357259A1-20231109-C00122
  • Figure US20230357259A1-20231109-C00123
  • Figure US20230357259A1-20231109-C00124
  • wherein Z4 is 6-10 membered aryl or 5-6 membered heteroaryl; R10 is selected from H (hydrogen) or C1-6 alkyl; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene or C3-8 cycloalkylene; R9 is selected from H (hydrogen) or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene; or R9 and Z3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene; α is independently 0, 1, 2, 3, 4, 5 or 6, and L4 is bonded to E at the position 2 of L4;
  • m3 is 0, 1, 2 or 3.
  • In some preferred embodiments, L4 is selected from
  • Figure US20230357259A1-20231109-C00125
  • Figure US20230357259A1-20231109-C00126
  • Figure US20230357259A1-20231109-C00127
  • Figure US20230357259A1-20231109-C00128
  • Figure US20230357259A1-20231109-C00129
  • Figure US20230357259A1-20231109-C00130
  • Figure US20230357259A1-20231109-C00131
  • wherein Z4 is a benzene ring, and R10 is selected from H (hydrogen) and C1-6 alkyl; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene or C3-8 cycloalkylene; R9 is selected from H (hydrogen) or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene or R9 and Z3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene; α is independently 0, 1, 2, 3, 4, 5 or 6, and L4 is bonded to E at the position 2 of L4;
  • m3 is 0, 1, 2 or 3.
  • In some preferred embodiments, L4 is selected from
  • Figure US20230357259A1-20231109-C00132
  • Figure US20230357259A1-20231109-C00133
  • Figure US20230357259A1-20231109-C00134
  • Figure US20230357259A1-20231109-C00135
  • Figure US20230357259A1-20231109-C00136
  • Figure US20230357259A1-20231109-C00137
  • Figure US20230357259A1-20231109-C00138
  • Z4 is 5-6 membered heteroarylene; R10 is selected from H (hydrogen) or C1-6 alkyl; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene or C3-8 cycloalkylene; R9 is selected from H (hydrogen) or C1- 6 alkyl; Z3 is absent or selected from C1-6 alkylene; or R9 and Z3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene; α is independently 0, 1, 2, 3,4, 5 or 6; and L4 is bonded to E at the position 2 of L4;
  • m3 is 0, 1, 2 or 3.
  • In some preferred embodiments, L4 is selected from
  • Figure US20230357259A1-20231109-C00139
  • Figure US20230357259A1-20231109-C00140
  • Figure US20230357259A1-20231109-C00141
  • Figure US20230357259A1-20231109-C00142
  • Figure US20230357259A1-20231109-C00143
  • Figure US20230357259A1-20231109-C00144
  • Figure US20230357259A1-20231109-C00145
  • Figure US20230357259A1-20231109-C00146
  • Figure US20230357259A1-20231109-C00147
  • Figure US20230357259A1-20231109-C00148
  • Figure US20230357259A1-20231109-C00149
  • Figure US20230357259A1-20231109-C00150
  • m3 is 1.
  • In some preferred embodiments, L4 is selected from
  • Figure US20230357259A1-20231109-C00151
  • Figure US20230357259A1-20231109-C00152
  • Figure US20230357259A1-20231109-C00153
  • Figure US20230357259A1-20231109-C00154
  • Figure US20230357259A1-20231109-C00155
  • Figure US20230357259A1-20231109-C00156
  • m3 is 1.
  • In some preferred embodiments, L4 is selected from
  • Figure US20230357259A1-20231109-C00157
  • Figure US20230357259A1-20231109-C00158
  • m3 is 1.
  • In some preferred embodiments, E is selected from 5-10 membered heteroarylene optionally substituted with one or more R12; wherein R12 is independently selected from H (hydrogen), D (deuterium), halogen, CN, nitro, C1-4 alkyl or halogenated C1-4alkyl.
  • In some preferred embodiments, E is selected from the following groups optionally substituted with one or more R12: pyrimidylene, quinolylene or pyrrolo [2,3-d] pyrimidylene; wherein R12 is independently selected from H (hydrogen), D (deuterium), halogen, CN, nitro, C1- 2 alkyl or halogenated C1-2 alkyl.
  • In some preferred embodiments, E is selected from pyrimidinyl optionally substituted with one or more R12; wherein R12 is independently selected from H(hydrogen) or D (deuterium).
  • In some preferred embodiments, G is selected from halogen, OMs, OTs, OTf, nitro, or anyone of the following groups which is optionally substituted with one or more R13: alkylthio, arylthio, heteroarylthio, alkyl sulfinyl, aryl sulfinyl, heteroaryl sulfinyl, alkyl sulfonyl, aryl sulfonyl or heteroaryl sulfonyl; wherein R13 is independently selected from H (hydrogen), D (deuterium), halogen, CN, nitro, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 6-10 membered aryl or 5-12 membered heteroaryl.
  • In some preferred embodiments, G is selected from F, Cl, Br, I, OMs, OTs, OTf, methylsulfonyl, ethylsulfonyl, p-toluenesulfonyl or naphthalenesulfonyl.
  • In some preferred embodiments, G is selected from F, Cl, Br, OMs, OTs, methylsulfonyl or p-toluenesulfonyl.
  • In some preferred embodiments, G is selected from Cl or methylsulfonyl.
  • In some preferred embodiments, in
  • Figure US20230357259A1-20231109-C00159
  • , G is preferably methylsulfonyl, E is preferably pyrimidylene, m3 is 1.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00160
  • Figure US20230357259A1-20231109-C00161
  • Figure US20230357259A1-20231109-C00162
  • wherein m4 is preferably an integer from 0 to 6, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00163
  • Figure US20230357259A1-20231109-C00164
  • Figure US20230357259A1-20231109-C00165
  • wherein m5 is preferably an integer from 0 to 6, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00166
  • Figure US20230357259A1-20231109-C00167
  • Figure US20230357259A1-20231109-C00168
  • wherein m6 is preferably an integer from 0 to 6, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00169
  • Figure US20230357259A1-20231109-C00170
  • Figure US20230357259A1-20231109-C00171
  • wherein m7 is an integer from 1 to 5, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00172
  • Figure US20230357259A1-20231109-C00173
  • Figure US20230357259A1-20231109-C00174
  • wherein ms is an integer from 1 to 5, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00175
  • Figure US20230357259A1-20231109-C00176
  • Figure US20230357259A1-20231109-C00177
  • wherein m9 is an integer from 1 to 5, R13 is selected from hydrogen or C1- 6 alkyl, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00178
  • Figure US20230357259A1-20231109-C00179
  • Figure US20230357259A1-20231109-C00180
  • wherein m10 is an integer from 0 to 6, and Z4 is selected from 5-6 membered heteroarylene; methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00181
  • Figure US20230357259A1-20231109-C00182
  • Figure US20230357259A1-20231109-C00183
  • Z4 is selected from pyridylene, pyrimidylene, pyrazolylene, thiazolylene, oxazolylene or triazolylene; methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring; more preferably, m10 is an integer from 0-6.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00184
  • Figure US20230357259A1-20231109-C00185
  • Figure US20230357259A1-20231109-C00186
  • , Z4 is selected from pyridylene, pyrimidylene, pyrazolylene or triazolylene. More preferably, m10 is an integer from 0-6.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00187
  • Figure US20230357259A1-20231109-C00188
  • Figure US20230357259A1-20231109-C00189
  • Z4 is selected from oxazolylene or thiazolylene, and methylsulfonyl is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring. More preferably, m10 is an integer from 0-6.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00190
  • Figure US20230357259A1-20231109-C00191
  • Figure US20230357259A1-20231109-C00192
  • wherein m10 is an integer from 0-6, and Z4 is selected from 6-10 membered arylene; and methylsulfonyl is a substituent of a carbon atom adjacent to a nitrogen atom. More preferably, m10 is an integer from 0-6.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00193
  • Figure US20230357259A1-20231109-C00194
  • Figure US20230357259A1-20231109-C00195
  • wherein m10 is an integer from 0-6, and Z4 is a benzene ring.
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00196
  • Figure US20230357259A1-20231109-C00197
  • Figure US20230357259A1-20231109-C00198
  • In some preferred embodiments,
  • Figure US20230357259A1-20231109-C00199
  • in formula (I) is selected from the following fragments:
  • Figure US20230357259A1-20231109-C00200
  • Figure US20230357259A1-20231109-C00201
  • Figure US20230357259A1-20231109-C00202
  • Figure US20230357259A1-20231109-C00203
    Figure US20230357259A1-20231109-C00204
  • Figure US20230357259A1-20231109-C00205
  • Figure US20230357259A1-20231109-C00206
    Figure US20230357259A1-20231109-C00207
  • Figure US20230357259A1-20231109-C00208
  • Figure US20230357259A1-20231109-C00209
    Figure US20230357259A1-20231109-C00210
    Figure US20230357259A1-20231109-C00211
    Figure US20230357259A1-20231109-C00212
    Figure US20230357259A1-20231109-C00213
    Figure US20230357259A1-20231109-C00214
    Figure US20230357259A1-20231109-C00215
    Figure US20230357259A1-20231109-C00216
    Figure US20230357259A1-20231109-C00217
    Figure US20230357259A1-20231109-C00218
    Figure US20230357259A1-20231109-C00219
    Figure US20230357259A1-20231109-C00220
    Figure US20230357259A1-20231109-C00221
    Figure US20230357259A1-20231109-C00222
    Figure US20230357259A1-20231109-C00223
    Figure US20230357259A1-20231109-C00224
    Figure US20230357259A1-20231109-C00225
    Figure US20230357259A1-20231109-C00226
    Figure US20230357259A1-20231109-C00227
    Figure US20230357259A1-20231109-C00228
    or
    Figure US20230357259A1-20231109-C00229
  • In some preferred embodiments, T is a fragment of a bioactive molecule. In some preferred embodiments, the bioactive molecule is selected from a metal complex, such as a platinum metal complex (e.g., oxaliplatin) or a gold metal complex; a glycopeptide antibiotic such as bleomycin or pingyangmycin; a DNA topoisomerase inhibitor, such as a topoisomerase I inhibitor (e.g., camptothecin, hydroxycamptothecin, 9-aminocamptothecin, SN-38, irinotecan, topotecan, bellotencian or rubitecan) or a topoisomerase II inhibitor (e.g., actinomycin D, adriamycin, doxorubicin, duocarmycin, daunorubicin, mitoxantrone, podophyllotoxin or etoposide); a drug interfering with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine, pentostatin, fludarabine, cladribine or narabine; a drugs acting on a structural protein, such as a tubulin inhibitor, a vinblastine alkaloid, a vincristine, vinblastine, paclitaxel, docetaxel or cabazitaxel; a tumor cell signaling pathway inhibitor, such as a serine/threonine kinase inhibitor, a tyrosine kinase inhibitor, a aspartokinase inhibitor or a histidine kinase inhibitor; a proteasome inhibitor; a histone deaceylase inhibitor; a tumor angiogenesis inhibitor; a cyclin inhibitor; a maytansine derivative; a calicheamicin derivative; a auristatin derivative; a pyrrolobenzodiazepine dimers (PBD) derivative; melphalan; mitomycin C; chlorambucil; and other active substances which inhibit the growth of tumor cells, promote the apoptosis or necrosis of tumor cells.
  • In some preferred embodiments, the bioactive molecule is selected from
  • Figure US20230357259A1-20231109-C00230
  • Figure US20230357259A1-20231109-C00231
  • Figure US20230357259A1-20231109-C00232
  • Figure US20230357259A1-20231109-C00233
  • Figure US20230357259A1-20231109-C00234
    wherein R14 is selected from acyl or sulfonyl, which is substituted with R15, and R15 is selected from C1-6 alkyl, halogenated C1-6 alkyl, 6-10 membered aryl or 5-12 membered heteroaryl; R16 is selected from H (hydrogen), D (deuterium), C1-6 alkyl or C1-6 alkyl substituted with R17, and R17 is selected from aryl or heteroaryl, including but not limited to phenyl and pyridyl, and m11 is 0, 1 or 2.
  • In some preferred embodiments, the bioactive molecule is selected from
  • Figure US20230357259A1-20231109-C00235
  • Figure US20230357259A1-20231109-C00236
    wherein R14 is selected from acyl or sulfonyl, which is substituted with R15, and R15 is selected from C1-6 alkyl, halogenated C1-6 alkyl, 6-10 membered aryl or 5-12 membered heteroaryl; R16 is selected from H (hydrogen), D (deuterium), C1-6 alkyl, C1-6 alkyl substituted with R17, and R17 is selected from aryl or heteroaryl, including but not limited to phenyl or pyridyl, and m11 is 0, 1, or 2.
  • In some preferred embodiments, the bioactive molecule is selected from
  • Figure US20230357259A1-20231109-C00237
  • Figure US20230357259A1-20231109-C00238
  • Figure US20230357259A1-20231109-C00239
  • Figure US20230357259A1-20231109-C00240
  • Figure US20230357259A1-20231109-C00241
    Figure US20230357259A1-20231109-C00242
    Figure US20230357259A1-20231109-C00243
    Figure US20230357259A1-20231109-C00244
    Figure US20230357259A1-20231109-C00245
    Figure US20230357259A1-20231109-C00246
    Figure US20230357259A1-20231109-C00247
    Figure US20230357259A1-20231109-C00248
    or
    Figure US20230357259A1-20231109-C00249
    .
  • In some preferred embodiments, the bioactive molecule is selected from
  • Figure US20230357259A1-20231109-C00250
  • Figure US20230357259A1-20231109-C00251
  • Figure US20230357259A1-20231109-C00252
    Figure US20230357259A1-20231109-C00253
    Figure US20230357259A1-20231109-C00254
    Figure US20230357259A1-20231109-C00255
    Figure US20230357259A1-20231109-C00256
    Figure US20230357259A1-20231109-C00257
    Figure US20230357259A1-20231109-C00258
    or
    Figure US20230357259A1-20231109-C00259
  • In some preferred embodiments, the bioactive molecule is selected from
  • Figure US20230357259A1-20231109-C00260
  • Figure US20230357259A1-20231109-C00261
  • Figure US20230357259A1-20231109-C00262
  • Figure US20230357259A1-20231109-C00263
  • Figure US20230357259A1-20231109-C00264
    or
    Figure US20230357259A1-20231109-C00265
  • In some preferred embodiments, the bioactive molecule is selected from
  • Figure US20230357259A1-20231109-C00266
  • Figure US20230357259A1-20231109-C00267
  • Figure US20230357259A1-20231109-C00268
  • In some preferred embodiments, the bioactive molecule is selected from
  • Figure US20230357259A1-20231109-C00269
  • Figure US20230357259A1-20231109-C00270
  • In some preferred embodiments, T is selected from
  • Figure US20230357259A1-20231109-C00271
  • Figure US20230357259A1-20231109-C00272
  • Figure US20230357259A1-20231109-C00273
  • Figure US20230357259A1-20231109-C00274
  • Figure US20230357259A1-20231109-C00275
  • Figure US20230357259A1-20231109-C00276
    Figure US20230357259A1-20231109-C00277
  • Figure US20230357259A1-20231109-C00278
  • Figure US20230357259A1-20231109-C00279
  • Figure US20230357259A1-20231109-C00280
  • Figure US20230357259A1-20231109-C00281
  • Figure US20230357259A1-20231109-C00282
  • Figure US20230357259A1-20231109-C00283
  • Figure US20230357259A1-20231109-C00284
  • Figure US20230357259A1-20231109-C00285
    Figure US20230357259A1-20231109-C00286
    Figure US20230357259A1-20231109-C00287
    Figure US20230357259A1-20231109-C00288
    Figure US20230357259A1-20231109-C00289
    Figure US20230357259A1-20231109-C00290
    Figure US20230357259A1-20231109-C00291
    Figure US20230357259A1-20231109-C00292
    Figure US20230357259A1-20231109-C00293
    Figure US20230357259A1-20231109-C00294
    Figure US20230357259A1-20231109-C00295
  • Figure US20230357259A1-20231109-C00296
  • Figure US20230357259A1-20231109-C00297
  • In some preferred embodiments, T is selected from
    Figure US20230357259A1-20231109-C00298
    Figure US20230357259A1-20231109-C00299
  • Figure US20230357259A1-20231109-C00300
  • Figure US20230357259A1-20231109-C00301
  • Figure US20230357259A1-20231109-C00302
  • Figure US20230357259A1-20231109-C00303
    Figure US20230357259A1-20231109-C00304
  • Figure US20230357259A1-20231109-C00305
  • Figure US20230357259A1-20231109-C00306
  • Figure US20230357259A1-20231109-C00307
  • Figure US20230357259A1-20231109-C00308
  • Figure US20230357259A1-20231109-C00309
  • Figure US20230357259A1-20231109-C00310
  • Figure US20230357259A1-20231109-C00311
  • Figure US20230357259A1-20231109-C00312
    Figure US20230357259A1-20231109-C00313
    Figure US20230357259A1-20231109-C00314
    Figure US20230357259A1-20231109-C00315
    Figure US20230357259A1-20231109-C00316
    Figure US20230357259A1-20231109-C00317
    Figure US20230357259A1-20231109-C00318
    Figure US20230357259A1-20231109-C00319
    Figure US20230357259A1-20231109-C00320
    or
    Figure US20230357259A1-20231109-C00321
  • In some preferred embodiments, T is selected from
  • Figure US20230357259A1-20231109-C00322
  • Figure US20230357259A1-20231109-C00323
  • Figure US20230357259A1-20231109-C00324
  • Figure US20230357259A1-20231109-C00325
  • Figure US20230357259A1-20231109-C00326
  • Figure US20230357259A1-20231109-C00327
  • Figure US20230357259A1-20231109-C00328
  • In some preferred embodiments, T is selected from
    Figure US20230357259A1-20231109-C00329
  • Figure US20230357259A1-20231109-C00330
  • Figure US20230357259A1-20231109-C00331
  • Figure US20230357259A1-20231109-C00332
  • In some preferred embodiments, T is selected from
  • Figure US20230357259A1-20231109-C00333
  • Figure US20230357259A1-20231109-C00334
  • In some preferred embodiments, the compound shown in formula (I) is selected from
    Figure US20230357259A1-20231109-C00335
    Figure US20230357259A1-20231109-C00336
    Figure US20230357259A1-20231109-C00337
    Figure US20230357259A1-20231109-C00338
    Figure US20230357259A1-20231109-C00339
    Figure US20230357259A1-20231109-C00340
    Figure US20230357259A1-20231109-C00341
    Figure US20230357259A1-20231109-C00342
    Figure US20230357259A1-20231109-C00343
    Figure US20230357259A1-20231109-C00344
    Figure US20230357259A1-20231109-C00345
    Figure US20230357259A1-20231109-C00346
    Figure US20230357259A1-20231109-C00347
    Figure US20230357259A1-20231109-C00348
    Figure US20230357259A1-20231109-C00349
    Figure US20230357259A1-20231109-C00350
    Figure US20230357259A1-20231109-C00351
    Figure US20230357259A1-20231109-C00352
    Figure US20230357259A1-20231109-C00353
    Figure US20230357259A1-20231109-C00354
    Figure US20230357259A1-20231109-C00355
    Figure US20230357259A1-20231109-C00356
    Figure US20230357259A1-20231109-C00357
    Figure US20230357259A1-20231109-C00358
    Figure US20230357259A1-20231109-C00359
    Figure US20230357259A1-20231109-C00360
    Figure US20230357259A1-20231109-C00361
    Figure US20230357259A1-20231109-C00362
    Figure US20230357259A1-20231109-C00363
    Figure US20230357259A1-20231109-C00364
    Figure US20230357259A1-20231109-C00365
    Figure US20230357259A1-20231109-C00366
    Figure US20230357259A1-20231109-C00367
    Figure US20230357259A1-20231109-C00368
    Figure US20230357259A1-20231109-C00369
    Figure US20230357259A1-20231109-C00370
    Figure US20230357259A1-20231109-C00371
    Figure US20230357259A1-20231109-C00372
    Figure US20230357259A1-20231109-C00373
    Figure US20230357259A1-20231109-C00374
    Figure US20230357259A1-20231109-C00375
    Figure US20230357259A1-20231109-C00376
    Figure US20230357259A1-20231109-C00377
    Figure US20230357259A1-20231109-C00378
    Figure US20230357259A1-20231109-C00379
    Figure US20230357259A1-20231109-C00380
    Figure US20230357259A1-20231109-C00381
  • In some preferred embodiments, the compound is selected from
    Figure US20230357259A1-20231109-C00382
    Figure US20230357259A1-20231109-C00383
    Figure US20230357259A1-20231109-C00384
    Figure US20230357259A1-20231109-C00385
    Figure US20230357259A1-20231109-C00386
    Figure US20230357259A1-20231109-C00387
    Figure US20230357259A1-20231109-C00388
    Figure US20230357259A1-20231109-C00389
    Figure US20230357259A1-20231109-P00001
    Figure US20230357259A1-20231109-C00390
    Figure US20230357259A1-20231109-C00391
    Figure US20230357259A1-20231109-C00392
    Figure US20230357259A1-20231109-C00393
    Figure US20230357259A1-20231109-C00394
    Figure US20230357259A1-20231109-C00395
    Figure US20230357259A1-20231109-C00396
    Figure US20230357259A1-20231109-C00397
    Figure US20230357259A1-20231109-C00398
    Figure US20230357259A1-20231109-C00399
    Figure US20230357259A1-20231109-C00400
    Figure US20230357259A1-20231109-C00401
    Figure US20230357259A1-20231109-C00402
    Figure US20230357259A1-20231109-C00403
    Figure US20230357259A1-20231109-C00404
    Figure US20230357259A1-20231109-C00405
    Figure US20230357259A1-20231109-C00406
    Figure US20230357259A1-20231109-C00407
    Figure US20230357259A1-20231109-C00408
    Figure US20230357259A1-20231109-C00409
    Figure US20230357259A1-20231109-C00410
    Figure US20230357259A1-20231109-C00411
    Figure US20230357259A1-20231109-C00412
    Figure US20230357259A1-20231109-C00413
    Figure US20230357259A1-20231109-C00414
    Figure US20230357259A1-20231109-C00415
    Figure US20230357259A1-20231109-C00416
    Figure US20230357259A1-20231109-C00417
  • In a second aspect, the disclosure provides a conjugate, comprising a bioactive molecule, a linker and a targeting moiety. The targeting moiety is linked to the linker via an active group (e.g., a thiol group) to form a conjugate.
  • In some preferred embodiments, the structure of the conjugate is shown in formula (II):
  • Figure US20230357259A1-20231109-C00418
    • where, wherein, A is a targeting moiety (e.g., a small molecule ligand, a protein, a polypeptide or a non-protein reagent (e.g., saccharide, RNA or DNA)); y is an integer or a decimal from 1 to 10; preferably, y is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8);
    • the rest groups are as described in the first aspect of the disclosure.
  • In some preferred embodiments, a target of A is selected from epidermal growth factor, Trop-2, CD37, HER2, CD70, EGFRvIII, Mesothelin, Folate receptor1, Mucin 1, CD138, CD20, CD19, CD30, SLTRK6, Nectin 4, Tissue factor, Mucin16, Endothelin receptor, STEAP1, SLC39A6, Guanylylcyclase C, PSMA, CCD79b, CD22, Sodium phosphate cotransporter 2B, GPNMB, Trophoblast glycoprotein, AGS-16, EGFR, CD33, CD66e, CD74, CD56, PD-L1, TACSTD2, DR5, E16, STEAP1, 0772P, MPF, Napi3b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, NCA, MDP, IL20Rα, Brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD22, CD79a, CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, IRTA2, TENB2, integrin α5β6, α4β7, FGF2, FGFR2, Her3, CD70, CA6, DLL3, DLL4, P-cadherin,EpCAM, pCAD, CD223, LYPD3, LY6E, EFNA4, ROR1, SLITRK6, 5T4, ENPP3, SLC39A6, Claudin18.2, BMPR1B, E16, STEAP1, Tyro7, 0772P, MPF, Napi3b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, NCA, MDP, IL20Rα, Brevican, EphB2R, ASLG659, PSCA, GEDA, CD22, CD79a, CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, IRTA2, c-Met, ApoE, CD1 1c, CD40, CD45 (PTPRC), CD49D (ITGA4), CD80, CSF1R, CTSD, GZMB, Ly86, MS4A7, PIK3AP1, PIK3CD, CCR5, IFNG, IL10RA1, IL-6, ACTA2, COL7A1, LOX, LRRC15, MCPT8, MMP10, NOG, SERPINE1, STAT1, TGFBR1, CTSS, PGF, VEGFA, C1QA, C1QB, ANGPTL4, EGLN, ANGPTL4, EGLN3, BNIP3, AIF1, CCL5, CXCL10, CXCL11, IFI6, PLOD2, KISS1R, STC2, DDIT4, PFKFB3, PGK1, PDK1, AKR1C1, AKR1C2, CADM1, CDH11, COL6A3, CTGF, HMOX1, KRT33A, LUM, WNT5A, IGFBP3, MMP14, CDCP1, PDGFRA, TCF4, TGF, TGFB1, TGFB2, CD1 lb, ADGRE1, EMR2, TNFRSF21, UPK1B, TNFSF9, MMP16, MFI2, IGF-1R, RNF43, NaPi2b, BCMA or TENB2.
  • In some preferred embodiments, A is a small molecule ligand, such as a folic acid derivative, a glutamate urea derivative, a somatostatin derivative, an arylsulfonamide derivative (e.g., a carbonic anhydrase IX inhibitor), a polyene connecting two aliphatic indoles, a cyanine dye or IR-783 or a derivative thereof.
  • In some preferred embodiments, A is selected from
  • Figure US20230357259A1-20231109-C00419
  • Figure US20230357259A1-20231109-C00420
  • Figure US20230357259A1-20231109-C00421
  • Figure US20230357259A1-20231109-C00422
  • Figure US20230357259A1-20231109-C00423
  • In some preferred embodiments, A is an antibody such as a monoclonal antibody or an antigen binding fragment thereof, wherein the monoclonal antibody or the antigen binding fragment thereof comprises Fab, Fab′, F(ab′)2, Fd, Fv, dAb, a complementary determinant fragment, a single chain antibody (e.g., scFv), a non-human antibody, a humanized antibody, a chimeric antibody, a completely humanized antibody, a probody, a bispecific antibody or a multispecific antibody.
  • In some preferred embodiments, A is an anti-Her 2 monoclonal antibody, such as Trastuzumab, Pertuzumab; or an anti-Trop-2 monoclonal antibody, such as Sacituzumab.
  • In some preferred embodiments, A is an anti-Trop-2 monoclonal antibody, such as antibody M1, M2 or M3.
  • Antibody M1 M2 M3
    Heavy chain CDR1 GYTFTNY (SEQ ID No.: 1) GYTFTNY (SEQ ID No.: 1) GYTFTNY (SEQ ID No.: 1)
    Heavy chain CDR2 NTDSGE (SEQ ID No.:2) NTDSGE (SEQ ID No.:2) NTDSGE (SEQ ID No.:2)
    Heavy chain CDR3 GGFGSSYWYFDV (SEQ ID No.:3) GGFGSSYWYFDV (SEQ ID No.:3) GGFGSSYWYFDV (SEQ ID No.:3)
    Light chain CDR1 KASQDVSSAVA (SEQ ID No.:4) KASQDVSSAVA (SEQ ID No.:4) KASQDVSIAVA (SEQ ID No.:8)
    Light chain CDR2 SASYRYT (SEQ ID No.:5) SASYRYT (SEQ ID No.:5) SASYRYT (SEQ ID No.: 5)
    Light chain CDR3 QQHYSTPLT (SEQ ID No.:6) QQHYITPLT (SEQ ID No.:7) QQHYSTPLT (SEQ ID No.:6)
  • The assignment of amino acids in each region or domain can follow Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; definition of Chothia et al. (1989) in Nature 342: 878-883.
  • 1. Heavy chain and light chain sequences of the hydrophobically modified antibody M1 Amino acid sequence of heavy chain variable region of M1: (121 aa)
  •    QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKW
    MGWINTDSGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCA
    RGGFGSSYWYFDVWGQGSLVTVSS (SEQ ID No.: 11)
  • Amino acid sequence of light chain variable region of M1: (107 aa)
  •    DIQLTQSPSSLSASVGDRVSITCKASQDVSSAVAWYQQKPGKAPKLL
    IYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYSTPLT
    FGAGTKVEIK (SEQ ID No.:12)
  • 2. Heavy chain and light chain sequences of the hydrophobically modified antibody M2 Amino acid sequence of heavy chain variable region of M2: (121 aa)
  •    QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKW
    MGWINTDSGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCA
    RGGFGSSYWYFDVWGQGSLVTVSS (SEQ ID No.: 13)
  • Amino acid sequence of light chain variable region of M2: (107 aa)
  •    DIQLTQSPSSLSASVGDRVSITCKASQDVSSAVAWYQQKPGKAPKLL
    IYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLT
    FGAGTKVEIK (SEQ ID No.:14)
  • 3. Heavy chain and light chain sequences of the hydrophobically modified antibody M3 Amino acid sequence of heavy chain variable region of M3: (121 aa)
  •    QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKW
    MGWINTDSGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCA
    RGGFGSSYWYFDVWGQGSLVTVSS (SEQ ID No.: 15)
  • Amino acid sequence of light chain variable region of M3: (107 aa)
  •    DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLL
    IYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYSTPLT
    FGAGTKVEIK (SEQ ID No.:16)
  • Sequence of light chain constant regions of M1, M2, M3: (107 aa)
  •    RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
    VTKSFNRGEC (SEQ IDNo.: 9)
  • Sequence of heavy chain constant regions of M1, M2, M3: (330 aa)
  •    ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT
    SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR
    VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
    DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
    NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
    LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
    SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID No.: 10)
  • Terminal Lys of heavy chains is easily deleted, but such deletion does not affect bioactivity. See Dick, L.W. et al., Biotechnol. Bioeng., 100: 1132-1143. The above monoclonal antibodies M1, M2, M3 and sequences or fragments thereof with deleted Lys at terminal of heavy chains all belong to the M1, M2, M3 monoclonal antibodies of this invention.
  • In some preferred embodiments, A is selected from a RGD peptide that recognizes cell surface integrin receptor; a growth factor that recognizes cell surface growth factor receptor, such as EGF, PDGF or VEGF; or a peptide capable of recognizing functional cell surface plasminogen activator, bombesin, bradykinin, somatostatin or prostate-specific membrane antigen receptor.
  • In some preferred embodiments, A is selected from CD40 ligand, CD30 ligand, OX40 ligand, PD-1 ligand, ErbB ligand, Her2 ligand, TACSTD2 ligand, or DR5 ligand.
  • In some preferred embodiments, the conjugate is selected from:
    Figure US20230357259A1-20231109-C00424
    Figure US20230357259A1-20231109-C00425
    Figure US20230357259A1-20231109-C00426
    Figure US20230357259A1-20231109-C00427
    Figure US20230357259A1-20231109-C00428
    Figure US20230357259A1-20231109-C00429
    Figure US20230357259A1-20231109-C00430
    Figure US20230357259A1-20231109-C00431
    Figure US20230357259A1-20231109-C00432
    Figure US20230357259A1-20231109-C00433
    Figure US20230357259A1-20231109-C00434
    Figure US20230357259A1-20231109-C00435
    Figure US20230357259A1-20231109-C00436
    Figure US20230357259A1-20231109-C00437
    Figure US20230357259A1-20231109-C00438
    Figure US20230357259A1-20231109-C00439
    Figure US20230357259A1-20231109-C00440
    Figure US20230357259A1-20231109-C00441
    Figure US20230357259A1-20231109-C00442
    Figure US20230357259A1-20231109-C00443
    Figure US20230357259A1-20231109-C00444
    Figure US20230357259A1-20231109-C00445
    Figure US20230357259A1-20231109-C00446
    Figure US20230357259A1-20231109-C00447
    Figure US20230357259A1-20231109-C00448
    Figure US20230357259A1-20231109-C00449
    Figure US20230357259A1-20231109-C00450
    Figure US20230357259A1-20231109-C00451
    Figure US20230357259A1-20231109-C00452
    Figure US20230357259A1-20231109-C00453
    Figure US20230357259A1-20231109-C00454
    Figure US20230357259A1-20231109-C00455
    Figure US20230357259A1-20231109-C00456
    Figure US20230357259A1-20231109-C00457
    Figure US20230357259A1-20231109-C00458
    Figure US20230357259A1-20231109-C00459
    Figure US20230357259A1-20231109-C00460
    Figure US20230357259A1-20231109-C00461
    Figure US20230357259A1-20231109-C00462
    Figure US20230357259A1-20231109-C00463
    Figure US20230357259A1-20231109-C00464
    Figure US20230357259A1-20231109-C00465
    Figure US20230357259A1-20231109-C00466
    Figure US20230357259A1-20231109-C00467
    or
    Figure US20230357259A1-20231109-C00468
    wherein, y is an integer or a decimal from 1 to 10, and mAb is an anti-Trop-2 monoclonal antibody or an anti-Her 2 monoclonal antibody; preferably, the anti-Trop-2 monoclonal antibody is selected from antibodies of Sacituzumab, M1, M2 or M3, and the anti-Her 2 monoclonal antibody is Trastuzumab or Pertuzumab; preferably, y is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8).
  • In some preferred embodiments, the conjugate is selected from:
    Figure US20230357259A1-20231109-C00469
    Figure US20230357259A1-20231109-C00470
    Figure US20230357259A1-20231109-C00471
    Figure US20230357259A1-20231109-C00472
    Figure US20230357259A1-20231109-C00473
    Figure US20230357259A1-20231109-C00474
    Figure US20230357259A1-20231109-C00475
    Figure US20230357259A1-20231109-C00476
    Figure US20230357259A1-20231109-C00477
    Figure US20230357259A1-20231109-C00478
    Figure US20230357259A1-20231109-C00479
    Figure US20230357259A1-20231109-C00480
    Figure US20230357259A1-20231109-C00481
    Figure US20230357259A1-20231109-C00482
    Figure US20230357259A1-20231109-C00483
    Figure US20230357259A1-20231109-C00484
    Figure US20230357259A1-20231109-C00485
    Figure US20230357259A1-20231109-C00486
    Figure US20230357259A1-20231109-C00487
    Figure US20230357259A1-20231109-C00488
    Figure US20230357259A1-20231109-C00489
    Figure US20230357259A1-20231109-C00490
    Figure US20230357259A1-20231109-C00491
    Figure US20230357259A1-20231109-C00492
    Figure US20230357259A1-20231109-C00493
    Figure US20230357259A1-20231109-C00494
    Figure US20230357259A1-20231109-C00495
    Figure US20230357259A1-20231109-C00496
    Figure US20230357259A1-20231109-C00497
    Figure US20230357259A1-20231109-C00498
    Figure US20230357259A1-20231109-C00499
    Figure US20230357259A1-20231109-C00500
    Figure US20230357259A1-20231109-C00501
    Figure US20230357259A1-20231109-C00502
    Figure US20230357259A1-20231109-C00503
    wherein, y is an integer or a decimal from 1 to 10, and mAb is an anti-Trop-2 monoclonal antibody or an anti-Her 2 monoclonal antibody; preferably, the anti-Trop-2 monoclonal antibody is selected from Sacituzumab, and the anti-Her 2 monoclonal antibody is selected from Trastuzumab or Pertuzumab; preferably, y is an integer or a decimal from 5 to 8 (e.g., 5, 6, 7 or 8).
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00504
    Figure US20230357259A1-20231109-C00505
    Figure US20230357259A1-20231109-C00506
    Figure US20230357259A1-20231109-C00507
    Figure US20230357259A1-20231109-C00508
    Figure US20230357259A1-20231109-C00509
    Figure US20230357259A1-20231109-C00510
    Figure US20230357259A1-20231109-C00511
    Figure US20230357259A1-20231109-C00512
    Figure US20230357259A1-20231109-C00513
    Figure US20230357259A1-20231109-C00514
    Figure US20230357259A1-20231109-C00515
    Figure US20230357259A1-20231109-C00516
    Figure US20230357259A1-20231109-C00517
    Figure US20230357259A1-20231109-C00518
    Figure US20230357259A1-20231109-C00519
    or
    Figure US20230357259A1-20231109-C00520
    wherein, A1 is Sacituzumab, and y is an integer or a decimal from 1 to 10; preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00521
    Figure US20230357259A1-20231109-C00522
    Figure US20230357259A1-20231109-C00523
    Figure US20230357259A1-20231109-C00524
    Figure US20230357259A1-20231109-C00525
    Figure US20230357259A1-20231109-C00526
    Figure US20230357259A1-20231109-C00527
    Figure US20230357259A1-20231109-C00528
    or
    Figure US20230357259A1-20231109-C00529
    wherein, A1 is Sacituzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00530
    Figure US20230357259A1-20231109-C00531
    Figure US20230357259A1-20231109-C00532
    Figure US20230357259A1-20231109-C00533
    or
    Figure US20230357259A1-20231109-C00534
    wherein, A1 is Sacituzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00535
    wherein, A1 is a fragment of Sacituzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00536
    Figure US20230357259A1-20231109-C00537
    Figure US20230357259A1-20231109-C00538
    Figure US20230357259A1-20231109-C00539
    Figure US20230357259A1-20231109-C00540
    Figure US20230357259A1-20231109-C00541
    Figure US20230357259A1-20231109-C00542
    Figure US20230357259A1-20231109-C00543
    Figure US20230357259A1-20231109-C00544
    Figure US20230357259A1-20231109-C00545
    Figure US20230357259A1-20231109-C00546
    Figure US20230357259A1-20231109-C00547
    Figure US20230357259A1-20231109-C00548
    Figure US20230357259A1-20231109-C00549
    Figure US20230357259A1-20231109-C00550
    Figure US20230357259A1-20231109-C00551
    or
    Figure US20230357259A1-20231109-C00552
    wherein, A2 is Trastuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00553
    Figure US20230357259A1-20231109-C00554
    Figure US20230357259A1-20231109-C00555
    Figure US20230357259A1-20231109-C00556
    Figure US20230357259A1-20231109-C00557
    Figure US20230357259A1-20231109-C00558
    Figure US20230357259A1-20231109-C00559
    Figure US20230357259A1-20231109-C00560
    or
    Figure US20230357259A1-20231109-C00561
    wherein, A2 is Trastuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00562
    wherein, A2 is Trastuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00563
    Figure US20230357259A1-20231109-C00564
    Figure US20230357259A1-20231109-C00565
    Figure US20230357259A1-20231109-C00566
    Figure US20230357259A1-20231109-C00567
    Figure US20230357259A1-20231109-C00568
    Figure US20230357259A1-20231109-C00569
    Figure US20230357259A1-20231109-C00570
    Figure US20230357259A1-20231109-C00571
    Figure US20230357259A1-20231109-C00572
    Figure US20230357259A1-20231109-C00573
    Figure US20230357259A1-20231109-C00574
    Figure US20230357259A1-20231109-C00575
    Figure US20230357259A1-20231109-C00576
    Figure US20230357259A1-20231109-C00577
    Figure US20230357259A1-20231109-C00578
    or
    Figure US20230357259A1-20231109-C00579
    wherein, A3 is Pertuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00580
    Figure US20230357259A1-20231109-C00581
    Figure US20230357259A1-20231109-C00582
    Figure US20230357259A1-20231109-C00583
    Figure US20230357259A1-20231109-C00584
    Figure US20230357259A1-20231109-C00585
    Figure US20230357259A1-20231109-C00586
    Figure US20230357259A1-20231109-C00587
    or
    Figure US20230357259A1-20231109-C00588
    wherein, A3 is Pertuzumab, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00589
    Figure US20230357259A1-20231109-C00590
    Figure US20230357259A1-20231109-C00591
    Figure US20230357259A1-20231109-C00592
    Figure US20230357259A1-20231109-C00593
    Figure US20230357259A1-20231109-C00594
    Figure US20230357259A1-20231109-C00595
    Figure US20230357259A1-20231109-C00596
    Figure US20230357259A1-20231109-C00597
    Figure US20230357259A1-20231109-C00598
    Figure US20230357259A1-20231109-C00599
    Figure US20230357259A1-20231109-C00600
    Figure US20230357259A1-20231109-C00601
    Figure US20230357259A1-20231109-C00602
    Figure US20230357259A1-20231109-C00603
    Figure US20230357259A1-20231109-C00604
    or
    Figure US20230357259A1-20231109-C00605
    wherein, A4 is antibody M1, and y is an integer or a decimal from 1 to 10; and preferably, y is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00606
    wherein, A4 is antibody M1, and y is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00607
    Figure US20230357259A1-20231109-C00608
    Figure US20230357259A1-20231109-C00609
    Figure US20230357259A1-20231109-C00610
    Figure US20230357259A1-20231109-C00611
    Figure US20230357259A1-20231109-C00612
    Figure US20230357259A1-20231109-C00613
    Figure US20230357259A1-20231109-C00614
    Figure US20230357259A1-20231109-C00615
    Figure US20230357259A1-20231109-C00616
    Figure US20230357259A1-20231109-C00617
    Figure US20230357259A1-20231109-C00618
    Figure US20230357259A1-20231109-C00619
    Figure US20230357259A1-20231109-C00620
    Figure US20230357259A1-20231109-C00621
    Figure US20230357259A1-20231109-C00622
    or
    Figure US20230357259A1-20231109-C00623
    wherein, A5 is antibody M2, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00624
    wherein, A5 is antibody M2, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00625
    Figure US20230357259A1-20231109-C00626
    Figure US20230357259A1-20231109-C00627
    Figure US20230357259A1-20231109-C00628
    Figure US20230357259A1-20231109-C00629
    Figure US20230357259A1-20231109-C00630
    Figure US20230357259A1-20231109-C00631
    Figure US20230357259A1-20231109-C00632
    Figure US20230357259A1-20231109-C00633
    Figure US20230357259A1-20231109-C00634
    Figure US20230357259A1-20231109-C00635
    Figure US20230357259A1-20231109-C00636
    Figure US20230357259A1-20231109-C00637
    Figure US20230357259A1-20231109-C00638
    Figure US20230357259A1-20231109-C00639
    Figure US20230357259A1-20231109-C00640
    or
    Figure US20230357259A1-20231109-C00641
    wherein A6 is antibody M3, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In some preferred embodiments, the conjugate is:
    Figure US20230357259A1-20231109-C00642
    wherein A6 is antibody M3, and γ is an integer or a decimal from 1 to 10; and preferably, γ is an integer or a decimal from 5 to 8, such as an integer or a decimal from 6-7, 6-7.5, 6-8, 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
  • In another aspect, the disclosure provides a method for preparing the conjugate of the second aspect, comprising a step of coupling the linker of the compound of formula (I) with an active group of the targeting moiety.
  • In some preferred embodiments, the method comprises a step of opening a disulfide bond of the targeting moiety by a reductant (e.g., TCEP) to obtain a sulfydryl group.
  • In some preferred embodiments, the method comprises a step of forming a C-S bond between the linker of the compound of formula (I) and the sulfydryl group of the targeting moiety.
  • In some preferred embodiments, the targeting moiety is an anti-Her 2 monoclonal antibody (e.g., Trastuzumab, Pertuzumab) or an anti-Trop-2 monoclonal antibody (e.g., Sacituzumab, M1, M2 or M3), or an active fragment or mutant thereof.
  • In some preferred embodiments, the molar ratio of the targeting moiety to the compound of formula (I) is 1:(1-20); preferably, the coupling is carried out in water and/or an organic solvent; preferably, the organic solvent is selected from N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone, nitriles (e.g., acetonitrile), alcohols (e.g., methanol, ethanol) or any combination thereof.
  • In some preferred embodiments, the method further comprises a step of purifying the coupling product; preferably, the coupling product is purified by chromatography (e.g., one or more of ion exchange chromatography, hydrophobic chromatography, reverse phase chromatography or affinity chromatography).
  • In another aspect, the disclosure provides a pharmaceutical composition comprising the compound of the first aspect of the disclosure or a pharmaceutically acceptable salt thereof, or the conjugate of the second aspect, and one or more pharmaceutical excipients.
  • In another aspect, the disclosure provides use of the compound of the first aspect or a pharmaceutically acceptable salt thereof or the conjugate of the second aspect in the manufacturer of a medicament for the treatment of a disease associated with an abnormal cell activity (e.g., cancer).
  • In some preferred embodiments, the cancer is a solid tumor or a non-solid tumor, such as esophageal cancer (e.g., esophageal adenocarcinoma, esophageal squamous cell carcinoma), a brain tumor, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer), squamous cell carcinoma, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, non Hodgkin’s lymphoma, central nervous system tumors (e.g., neuroglioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer and thyroid cancer.
  • In another aspect, the disclosure provides use of the compound of the first aspect or a pharmaceutically acceptable salt thereof or the conjugate or pharmaceutical composition of the second aspect in treating a disease associated with an abnormal cell activity (e.g., cancer).
  • In another aspect, the disclosure provides a method of treating a disease associated with an abnormal cell activity (e.g., cancer), comprising a step of administering an effective amount of the compound of the first aspect or a pharmaceutically acceptable salt thereof or the conjugate or pharmaceutical composition of the second aspect to an individual in need thereof.
  • Unless otherwise specified, all scientific and technical terms used in the disclosure have the meanings commonly understood by those skilled in the art. Moreover, cell culture, molecular genetics, nucleic acid chemistry and immunology laboratory procedures used herein are all routine steps widely used in the corresponding art. In addition, definitions and explanations of relevant terms are given below for a better understanding of the disclosure.
  • In the disclosure, the pharmaceutical excipients refer to excipients and additives used in drug manufacturing and formulating, and are substances that have been reasonably evaluated in terms of safety and are contained in pharmaceutical preparations in addition to active ingredients. In addition to being used as excipients, carriers and stability enhancers, pharmaceutical excipients also have important functions such as solubilization, sustained release, and are important ingredients that may affect the quality, safety and efficacy of drugs. Pharmaceutical excipients can be divided by sources into natural substances, semi-synthetic substances and full-synthetic substances; divided by effects and uses into solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, filling agents, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, aromatics, anti-adhesion agents, antioxidants, chelating agents, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids and release retardants; and divided by administration routes into oral administration, injection, mucosal, transdermal or local administration, nasal or oral inhalation and ophthalmic administration. The same pharmaceutical excipient can be used for pharmaceutical preparations with different administration routes, and has different effects and uses.
  • The pharmaceutical composition can be formulated into various suitable dosage forms depending on administration routes, such as tablets, capsules, granules, oral solutions, oral suspensions, oral emulsions, powders, tinctures, syrups, injections, suppositories, ointments, creams, pastes, ophthalmic preparations, pills, subdermals, aerosols, powders and sprays. The pharmaceutical composition or suitable dosage forms may contain 0.01 mg to 1000 mg of the compound of the disclosure or a pharmaceutically acceptable salt or conjugate thereof, suitably 0.1 mg to 800 mg, preferably 0.5 to 500 mg, preferably 0.5 to 350 mg, and particularly preferably 1 to 1-250 mg.
  • The pharmaceutical composition can be administered in the form of injections, including liquids for injection, sterilized powders for injection, and concentrated solutions for injection. Acceptable carriers and solvents include water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterilized non-volatile oil can also be used as a solvent or suspending medium, such as monoglyceride or diglyceride.
  • In the disclosure, the term “individual” include a human individual or a non-human animal. Exemplary human individual includes a human individual with a disease (e.g., a disease described herein) (referred to as a patient) or a normal individual. The term “non-human animal” in the disclosure includes all vertebrates, such as a non-mammal (e.g., a bird, an amphibian and a reptile) and a mammal, such as a non-human primate, a domestic animal, and/or a domesticated animal (e.g., a sheep, a dog, a cat, a cow and a pig).
  • In the disclosure, the term “effective amount” refers to the amount of the compound that, after being administered, relieves one or more symptoms of the treated disease to some extent.
  • In the disclosure, the term “conjugate” refers to a substance obtained by linking a bioactive molecule with a targeting moiety. In some embodiments of the disclosure, the bioactive molecule is linked to the targeting moiety via a linker. The linker can be cleaved in a specific environment (e.g., an intracellular low pH environment) or under a specific action (e.g., the action of lysosomal protease), thereby dissociating the bioactive molecule from the target moiety. In some embodiments of the disclosure, the linker comprises cleavable or non-cleavable units, such as a peptide or disulfide bond. In some embodiments of the disclosure, the bioactive molecule is linked directly to the targeting moiety via a covalent bond that can be cleaved under a specific environment or action, thereby dissociating the bioactive molecule from the targeting moiety.
  • In the disclosure, the terms “bioactive substance” and “bioactive molecule” refer to a substance that inhibits or prevents cell functions and/or cause cell death or destruction. In some embodiments of the disclosure, the bioactive substance or bioactive molecule in the conjugate is a molecule with anti-tumor bioactivity. For example: a radioisotope such as At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 or a radioisotope of Lu; a metal complex such as a platinum metal complex, a gold metal complex or oxaliplatin; a glycopeptide antibiotic such as bleomycin or pingyangmycin; a DNA topoisomerase inhibitor such as a topoisomerase I inhibitor, e.g., camptothecin, hydroxycamptothecin, 9- aminocamptothecin, SN-38, irinotecan, topotecan, bellotencian or rubitecan, or a topoisomerase II inhibitor, e.g., actinomycin D, adriamycin, doxorubicin, duocarmycin, daunorubicin, mitoxantrone, podophyllotoxin, etoposide and so on; a drug interfering with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine, pentostatin, fludarabine, cladribine, narabine and so on; a drug acting on a structural protein, such as a tubulin inhibitor, a vinblastine alkaloid, a vincristine, vinblastine, paclitaxel, docetaxel, cabazitaxel and so on; a tumor cell signaling pathway inhibitor such as a serine/threonine kinase inhibitor, a tyrosine kinase inhibitor, a aspartokinase inhibitor or a histidine kinase inhibitor and so on; also includes a proteasome inhibitor; a histone deaceylase inhibitor; a tumor angiogenesis inhibitor; a cyclin inhibitor; a maytansine derivative; a calicheamicin derivative; a auristatin derivative; a Pyrrolobenzodiazepines (PBD) derivative; melphalan; mitomycin C; chlorambucil; and other active substances which inhibit the growth of tumor cells, promote the apoptosis or necrosis of tumor cells; an enzymes and fragment thereof, such as karyolytic enzyme; an antibiotic; a toxin such as a small molecule toxin or an enzymatically active toxin originated from bacterium, fungus, plants or animals, including fragment and/or variant thereof; a growth inhibitor; and a drug module. The term “toxin” refers to a substance that has deleterious effects on the growth or proliferation of cells.
  • In the disclosure, the term “small molecule” refers to a small molecule drug with bioactivity.
  • In the disclosure, the term “linker” refers to a fragment linking a bioactive molecule with a targeting moiety.
  • In the disclosure, the term “targeting moiety” refers to a moiety of the conjugate that can specifically bind to a target (or a portion of the target) on the cell surface. The conjugate can be delivered to a specific cell population by interaction between the targeting moiety and the target.
  • In the disclosure, the conjugate can be referred to as a “drug-antibody conjugate” when the targeting moiety of the conjugate is an antibody. In the disclosure, the “drug-antibody conjugate” and “immune conjugate” are interchangeable.
  • In the disclosure, the term “antibody” is interpreted in its broadest sense, including a complete monoclonal antibody, polyclonal antibody, and a multispecific antibody (e.g., a bispecific antibody) formed from at least two complete antibodies, provided that the antibody has required bioactivity. In the disclosure, the terms “antibody” and “immunoglobulin” are interchangeable.
  • In the disclosure, the term “monoclonal antibody” refers to an antibody from a group of substantially uniform antibodies, i.e., antibodies that make up the group are identical except for a small number of possible natural mutations. A monoclonal antibody has high specificity for one determinant (epitope) of an antigen, while a comparative polyclonal antibody contains different antibodies for different determinants (epitopes). In addition to specificity, the monoclonal antibody has the advantage of being free from contamination by other antibodies during synthesis. The modifier “monoclonal” here indicates that the antibody is characterized by coming from a substantially uniform antibody group and should not be construed as being prepared by a special method.
  • In some embodiments of the disclosure, the monoclonal antibody also specifically includes a chimeric antibody, i.e., a portion of a heavy chain and/or a light chain is the same as or homologous to a type, a class, or a subclass of antibodies, while the rest is the same as or homologous to another type, another class, or another subclass of antibodies, provided the antibody has required bioactivity (see, e.g., US 4,816,567; and Morrison et al., 1984, PNAS, 81: 6851-6855). The chimeric antibody available in the disclosure includes a primatized antibody containing a variable region antigen binding sequence from a non-human primate (e.g., an ancient monkey or an orangutan) and a human constant region sequence.
  • The term “antibody fragment” refers to a portion of the antibody, preferably an antigen binding region or a variable region. Examples of antibody fragment includes Fab, Fab′, F(ab′)2, Fd, Fv, dAb and complementary determinant fragment, diabody, linear antibody and single chain antibody molecule.
  • The term “bispecific antibody”, also known as “bifunctional antibody conjugate”, refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) through a coupling arm. The conjugate retains the activity of each antibody and thus has bifunctional and bispecific properties.
  • The term “multispecific antibody” includes, for example, a trispecific antibody which is an antibody having three different antigen binding specificities, and a tetraspecific antibody which is an antibody having four different antigen binding specificities.
  • The term “complete antibody” refers to an antibody containing an antigen binding variable region, a light chain constant region (CL) and heavy chain constant regions (CH1, CH2 and CH3). The constant regions can be natural sequences (e.g., human natural constant region sequences) or amino acid sequence variants thereof. The complete antibody is preferably a complete antibody having one or more effector functions.
  • The term “probody” is a modified antibody comprising an antibody or antibody fragment that can specifically bind to a target thereof and can be coupled with a masked group, and the masked group here refers that the cleavage constant for the binding capacity of the antibody or antibody fragment to the target is at least 100 times or 1000 times or 10000 times greater than that for the binding capacity of an antibody or antibody fragment not coupled with a masked group to a target thereof.
  • In the disclosure, a “humanized” form of a non-human (e.g., mouse) antibody refers to a chimeric antibody that contains minimal non-human immunoglobulin sequences. Most of the humanized antibodies are those in which residues in hypervariable regions of human recipient immunoglobulins are substituted with residues in non-human (e.g., mice, rats, rabbits or non-human primates) hypervariable regions (donor antibodies) with required specificity, affinity and functions. In some embodiments, residues in frame regions (FRs) of human immunoglobulins are also substituted with non-human residues. Furthermore, the humanized antibody can also contain residues not present in recipient antibodies or donor antibodies. Such modifications are made to further optimize antibody performance. A humanized antibody generally contains at least one variable region, typically two variable regions, in which all or almost all hypervanable loops correspond to non-human immunoglobulins, while all or almost all FRs are those of human immunoglobulin sequences. A humanized antibody can also contain at least a portion of an immunoglobulin constant region (Fc, usually human immunoglobulin Fc). For details, see, for example, Jones et al., 1986, Nature, 321: 522-525; Riechmann et al., 1988, Nature, 332: 323-329; and Presta, 1992, Curr Op Struct Bwl 2: 593-596.
  • Complete antibody can be classified into different “classes” according to amino acid sequences of heavy chain constant regions. The main five classes are IgA, IgD, IgE, IgG and IgM, and several of which can also be further classified into different “subclasses” (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. Different classes of heavy chain constant regions of antibodies are called α, β, ε, γ and µ respectively. Different classes of subunit structures and 3D configurations of immunoglobulins are well known in the art.
  • In the disclosure, although amino acid substitutions in antibodies are substituted with L-amino acids in most cases, the embodiments are not limited thereto. In some embodiments, an antibody peptide chain can contain one or more D-amino acids. Peptides containing D-amino acids may be more stable and less degradable in oral cavity, intestinal tract or plasma than peptides containing only L-amino acids.
  • Monoclonal antibody used in the disclosure can be produced by multiple methods. For example, the monoclonal antibody used in the disclosure can be obtained by hybridoma methods using multiple species (including cells of mice, hamsters, rats and humans) (see, for example, Kohler et al., 1975, Nature, 256: 495), or by recombinant DNA techniques (see, for example, US 4,816,567), or isolated from phage antibody libraries (see, for example, Clackson et al., 1991, Nature, 352: 624-628; and Marks et al., 1991, Journal of Molecular Biology, 222: 581-597). Monoclonal antibody that can be used in the disclosure includes, but is not limited to anti-Her 2 monoclonal antibody such as Trastuzumab and Pertuzumab, or anti-Trop-2 monoclonal antibody such as Sacituzumab (i.e., Isactuzumab or hRS7 antibody), M1, M2 or M3.
  • In some preferred embodiments, a target of A is selected from epidermal growth factor, Trop-2, CD37, HER2, CD70, EGFRvIII, Mesothelin, Folate receptor1, Mucin 1, CD138, CD20, CD19, CD30, SLTRK6, Nectin 4, Tissue factor, Mucin16, Endothelin receptor, STEAP1, SLC39A6, Guanylylcyclase C, PSMA, CCD79b, CD22, Sodium phosphate cotransporter 2B, GPNMB, Trophoblast glycoprotein, AGS-16, EGFR, CD33, CD66e, CD74, CD56, PD-L1, TACSTD2, DR5, E16, STEAP1, 0772P, MPF, Napi3b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, NCA, MDP, IL20Ra, Brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD22, CD79a, CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, IRTA2, TENB2, integrin α5β6, α4β7, FGF2, FGFR2, Her3, CD70, CA6, DLL3, DLL4, P-cadherin,EpCAM, pCAD, CD223, LYPD3, LY6E, EFNA4, ROR1, SLITRK6, 5T4, ENPP3, SLC39A6, Claudin18.2, BMPR1B, E16, STEAP1, Tyro7, 0772P, MPF, Napi3b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, NCA, MDP, IL20Ra, Brevican, EphB2R, ASLG659, PSCA, GEDA, CD22, CD79a, CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, IRTA2, c-Met, ApoE, CD1 lc, CD40, CD45 (PTPRC), CD49D (ITGA4), CD80, CSF1R, CTSD, GZMB, Ly86, MS4A7, PIK3AP1, PIK3CD, CCR5, IFNG, IL10RA1, IL-6, ACTA2, COL7A1, LOX, LRRC15, MCPT8, MMP10, NOG, SERPINE1, STAT1, TGFBR1, CTSS, PGF, VEGFA, C1QA, C1QB, ANGPTL4, EGLN, ANGPTL4, EGLN3, BNIP3, AIF1, CCL5, CXCL10, CXCL11, IFI6, PLOD2, KISS1R, STC2, DDIT4, PFKFB3, PGK1, PDK1, AKR1C1, AKR1C2, CADM1, CDH11, COL6A3, CTGF, HMOX1, KRT33A, LUM, WNT5A, IGFBP3, MMP14, CDCP1, PDGFRA, TCF4, TGF, TGFB1, TGFB2, CD1 lb, ADGRE1, EMR2, TNFRSF21, UPK1B, TNFSF9, MMP16, MFI2, IGF-1R, RNF43, NaPi2b, BCMA and TENB2.
  • In some embodiments of the disclosure, the target of the targeting moiety A is slected from a RGD peptide that recognizes cell surface integrin receptor; a growth factor that recognizes cell surface growth factor receptor, such as EGF, PDGF or VEGF; and a peptide capable of recognizing functional cell surface plasminogen activator, bombesin, bradykinin, somatostatin or prostate-specific membrane antigen receptor.
  • In some embodiments of the disclosure, the target of the targeting moiety A is selected from a CD40 ligand, a CD30 ligand, an OX40 ligand, a PD-1 ligand, an ErbB ligand, a Her2 ligand, a TACSTD2 ligand and a DR5 ligand.
  • In some embodiments of the disclosure, the targeting moiety A is an anti-Her 2 monoclonal antibody, such as Trastuzumab or Pertuzumab; or an anti-Trop-2 monoclonal antibody, such as Sacituzumab, M1, M2 or M3.
  • In some embodiments of the disclosure, the targeting moiety is Trastuzumab or Pertuzumab. Tratuzumab is an anti-Her 2 monoclonal antibody, an amino acid sequence thereof is known to a person skilled in the art, for a schematic sequence thereof, refer to, for example, CN103319599.
  • In some embodiments of the disclosure, terminal Lys of heavy chains of the targeting moiety is easily deleted, but such deletion does not affect bioactivity. See Dick, L.W. et al., Biotechnol. Bioeng., 100: 1132-1143. For example, the targeting moiety is an anti-Trop-2 monoclonal antibody, such as Sacituzumab, M1, M2 or M3 deleted terminal Lys of heavy chains, for example, the targeting moiety is an anti-Her 2 monoclonal antibody, such as Trastuzumab or Pertuzumab deleted terminal Lys of heavy chains.
  • Exemplary heavy and light chain sequences of Trastuzumab, refer to SEQ ID No.: 17 and SEQ ID No.:18. In the disclosure, heavy and light chain sequences of Trastuzumab referred to or involved are described using the sequences shown in SEQ ID No.: 17 and SEQ ID No.: 18, respectively. Exemplary heavy and light chain sequences of Pertuzumab, refer to SEQ ID No.: 16 and SEQ ID No.: 15 of US7560111.
  • SEQ ID No.: 17 (heavy chain sequence)
  •    EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEW
    VARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCS
    RWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
    LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP
    PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
    QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR
    EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
    PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
    PG(K)
  • SEQ ID No.: 18 (light chain sequence)
  •    DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLL
    IYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPT
    FGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
    WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVT
    HQGLSSPVTKSFNRGEC
  • In some embodiments of the disclosure, the anti-Trop-2 antibody of the targeting moiety is RS7 (i.e., Sacituzumab of the disclosure) described in U.S. pat. 7,517,964; and hRS7 (i.e., Sacituzumab of the disclosure) described in US2012/0237518. The anti-Trop-2 antibody available in the disclosure can also be obtained by screening through carrier design, construction and construction of an antibody library displaying antibodies as disclosed in CN103476941A, or can be obtained by screening a G-MAB® library of Sorrento Therapeutics, Inc.
  • For the heavy chain sequence and light chain amino acid sequence of the monoclonal antibody Sacituzumab, refer to, for example, SEQ ID No.: 19 and SEQ ID No.:20, respectively.
  • SEQ ID No.:19 (heavy chain sequence)
  •    QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKW
    MGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCA
    RGGFGSSYWYFDVWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
    CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
    GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLF
    PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
    EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
    REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
    TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
    SPG(K)
  • Terminal K (or lys) of heavy chains is easily deleted, but such deletion does not affect bioactivity. See Dick, L.W. et al., Biotechnol. Bioeng., 100: 1132-1143.
  • SEQ ID No.:20 (light chain sequence)
  •    DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLL
    IYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLT
    FGAGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
    WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVT
    HQGLSSPVTKSFNRGEC
  • In the disclosure, ErbB2 and Her2/neu are interchangeable, both of which represent human Her2 proteins of natural sequences (Genebank CAS No.: X03363, see, for example, Semba et al., 1985, PNAS, 82: 6497-6501; and Yamamoto et al., 1986, Nature, 319: 230-234) and functional derivatives thereof, such as amino acid sequence variants. ErbB2 represents a gene encoding human Her2 and neu represents a gene encoding rat p185neu. In some embodiments, the compound or conjugate of the disclosure can inhibit or kill cells that express ErbB2 receptors, such as breast cancer cells, ovarian cancer cells, gastric cancer cells, endometrial cancer cells, salivary gland cancer cells, lung cancer cells, kidney cancer cells, colon cancer cells, thyroid cancer cells, pancreatic cancer cells, bladder cancer cells or liver cancer cells.
  • In the disclosure, Trop-2 or TROP2 refers to human trophoblast cell-surface antigen 2, also known as TACSTD2, M1S1, GA733-1, EGP-1, which is a cell surface receptor expressed in many human tumors (e.g., breast cancer, colorectal cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer and cervical cancer). In some embodiments, the compound or conjugates of the disclosure can inhibit or kill cells that express TROP2 receptors, such as breast cancer cells, colorectal cancer cells, lung cancer cells, pancreatic cancer cells, ovarian cancer cells, prostate cancer cells or cervical cancer cells.
  • As used herein,
  • Figure US20230357259A1-20231109-C00643
  • Figure US20230357259A1-20231109-C00644
  • contained in the conjugate of the invention indicates a specific linking mode of a sulfydryl group and a linker in the antibody when the targeting moiety is an antibody.
  • As used herein, the term “C1-6 alkyl” refers to linear or branched alkyl containing 1-6 carbon atoms, including, for example, “C1-4 alkyl” and “C1-3 alkyl”. Specific examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, 2-methyl butyl, neopentyl, 1-ethyl propyl, n-hexyl, isohexyl, 3-methyl pentyl, 2-methyl pentyl, 1-methyl pentyl, 3,3-dimethyl butyl, 2,2-dimethyl butyl, 1,1-dimethyl butyl, 1,2-dimethyl butyl, 1,3-dimethyl butyl, 2,3-dimethyl butyl, 2-ethyl butyl and 1,2-dimethyl propyl.
  • As used herein, the term “C2-6 alkenyl” refers to linear, branched or cyclic alkenyl containing at least a double bond and 2-6 carbon atoms, including, for example, “C2-4 alkenyl”. Examples thereof include, but are not limited to vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,4-hexadienyl, cyclopentenyl, 1,3-cyclopentadienyl, cyclohexenyl and 1,4-cyclohexadienyl.
  • As used herein, the term “C2-6 alkynyl” refers to linear or branched alkynyl containing at least a triple bond and 2-6 carbon atoms, including, for example, “C2-4 alkynyl”. Examples thereof include, but are not limited to ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 4-methyl-2-pentynyl, 2-hexynyl, 3-hexynyl and 5-methyl-2-hexynyl.
  • As used herein, the term “halogen” includes fluorine, chlorine, bromine and iodine.
  • As used herein, the terms “3-8 membered cycloalkyl” or “C3-8 cycloalkyl” refers to saturated cyclic alkyl containing 3-8 carbon atoms, including, for example, “3-6 membered cycloalkyl”, “4-6 membered cycloalkyl”, “5-7 membered cycloalkyl” or “5-6 membered cycloalkyl”. Specific examples include, but are not limited to cyclopropanyl, cyclobutylalkyl, cyclopentanyl, cyclohexyl, cycloheptyl and cyclooctadecyl.
  • As used herein, the term “C1-6 alkoxy” refers to a group having a structure of C1-6 alkyl-O-, wherein C1-6 alkyl is as defined previously. Specific examples include, but are not limited to methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy and hexyloxy.
  • As used herein, the term “3-8 membered aliphatic heterocyclyl” refers to a cyclic group containing 3-8 ring-forming atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom). Optionally, the ring-forming atoms (e.g., carbon atoms, nitrogen atoms or sulfur atoms) in the cyclic structure can be substituted with oxygen. The “3-8 membered aliphatic heterocyclyl” includes, for example, “3-8 membered nitrogen-containing aliphatic heterocyclyl,” “3-8 membered oxygen-containing aliphatic heterocyclyl,” “3-6 membered aliphatic heterocyclyl,” “3-6 membered oxygen-containing aliphatic heterocyclyl,” “4-7 membered aliphatic heterocyclyl,” “4-6 membered aliphatic heterocyclyl,” “5-7 membered aliphatic heterocyclyl,” “5-6 membered aliphatic heterocyclyl,” “5-6 membered nitrogen-containing aliphatic heterocyclyl,” including but not limited to oxiranyl, oxocyclobutyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl and homopiperazinyl.
  • As used herein, the term “6-12 membered spirocyclyl” refers to a cyclic structure containing 6-12 ring-forming carbon atoms and formed by two or more cyclic structures sharing one carbon atom. Optionally, the carbon atoms in the cyclic structure can be substituted with oxygen. The “6-12 membered spirocyclyl” includes, for example, “6-11 membered spirocyclyl”, “6-10 membered spirocyclyl”, “7-10 membered spirocyclyl”, “7-9 membered spirocyclyl”, “7-8 membered spirocyclyl”, “9-10 membered spirocyclyl” and “3-10 membered spirocyclyl”.
  • Specific examples include, but are not limited to
  • Figure US20230357259A1-20231109-C00645
  • Figure US20230357259A1-20231109-C00646
  • Figure US20230357259A1-20231109-C00647
  • Figure US20230357259A1-20231109-C00648
  • Figure US20230357259A1-20231109-C00649
  • Figure US20230357259A1-20231109-C00650
  • Figure US20230357259A1-20231109-C00651
  • Figure US20230357259A1-20231109-C00652
  • Figure US20230357259A1-20231109-C00653
  • Figure US20230357259A1-20231109-C00654
  • Figure US20230357259A1-20231109-C00655
  • Figure US20230357259A1-20231109-C00656
  • Figure US20230357259A1-20231109-C00657
  • Figure US20230357259A1-20231109-C00658
  • Figure US20230357259A1-20231109-C00659
  • Figure US20230357259A1-20231109-C00660
  • Figure US20230357259A1-20231109-C00661
  • Figure US20230357259A1-20231109-C00662
  • Figure US20230357259A1-20231109-C00663
  • As used herein, the term “6-12 membered bridged cyclyl” refers to a cyclic structure containing 6-12 ring-forming carbon atoms and formed by two or more cyclic structures sharing two nonadjacent carbon atoms, Optionally, the carbon atoms in the cyclic structure can be substituted with oxygen. The “6-12 membered bridged cyclyl” includes, for example, “6-11 membered bridged cyclyl”, “5-10 membered bridged cyclyl”, “7-10 membered bridged cyclyl”, “7-9 membered bridged cyclyl”, “7-8 membered bridged cyclyl”, “9-10 membered bridged cyclyl” and “3-10 membered bridged cyclyl”. Specific examples include, but are not limited to
  • Figure US20230357259A1-20231109-C00664
  • Figure US20230357259A1-20231109-C00665
  • Figure US20230357259A1-20231109-C00666
  • Figure US20230357259A1-20231109-C00667
  • Figure US20230357259A1-20231109-C00668
  • Figure US20230357259A1-20231109-C00669
  • Figure US20230357259A1-20231109-C00670
  • Figure US20230357259A1-20231109-C00671
  • Figure US20230357259A1-20231109-C00672
  • Figure US20230357259A1-20231109-C00673
  • Figure US20230357259A1-20231109-C00674
  • Figure US20230357259A1-20231109-C00675
  • Figure US20230357259A1-20231109-C00676
  • Figure US20230357259A1-20231109-C00677
  • Figure US20230357259A1-20231109-C00678
  • Figure US20230357259A1-20231109-C00679
  • As used herein, the term “6-12 membered fused cyclyl” refers to a cyclic structure containing 6-12 ring-forming carbon atoms and formed by two or more cyclic structures sharing two adjacent atoms, including “6-11 membered fused cyclyl”, “6-10 membered fused cyclyl”, “6-8 membered fused cyclyl”, “10-12 membered fused cyclyl”, “7-10 membered fused cyclyl”.
  • Examples thereof include, but are not limited to
  • Figure US20230357259A1-20231109-C00680
  • Figure US20230357259A1-20231109-C00681
  • Figure US20230357259A1-20231109-C00682
  • Figure US20230357259A1-20231109-C00683
  • Figure US20230357259A1-20231109-C00684
  • Figure US20230357259A1-20231109-C00685
  • Figure US20230357259A1-20231109-C00686
  • Figure US20230357259A1-20231109-C00687
  • Figure US20230357259A1-20231109-C00688
  • Figure US20230357259A1-20231109-C00689
  • Figure US20230357259A1-20231109-C00690
  • Figure US20230357259A1-20231109-C00691
  • Figure US20230357259A1-20231109-C00692
  • Figure US20230357259A1-20231109-C00693
  • As used herein, the term “6-12 membered spiroheterocyclyl” refers to a cyclic structure containing 6-12 ring-forming atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom) and formed by two or more cyclic structures sharing one ring-forming atom. Optionally, the ring-forming atoms (e.g., carbon atoms, nitrogen atoms or sulfur atoms) in the cyclic structure can be substituted with oxygen. The “6-12 membered spiroheterocyclyl” includes, for example, “6-11 membered spiroheterocyclyl”, “5-10 membered spiroheterocyclyl”, “7-11 membered spiroheterocyclyl”, “7-10 membered spiroheterocyclyl”, “7-9 membered spiroheterocyclyl”, “7-8 membered spiroheterocyclyl”, “9-10 membered spiroheterocyclyl” and “3-10 membered spiroheterocyclyl”. Specific examples include, but are not limited to
  • Figure US20230357259A1-20231109-C00694
  • Figure US20230357259A1-20231109-C00695
  • Figure US20230357259A1-20231109-C00696
  • Figure US20230357259A1-20231109-C00697
  • Figure US20230357259A1-20231109-C00698
  • Figure US20230357259A1-20231109-C00699
  • Figure US20230357259A1-20231109-C00700
  • Figure US20230357259A1-20231109-C00701
  • Figure US20230357259A1-20231109-C00702
  • Figure US20230357259A1-20231109-C00703
  • Figure US20230357259A1-20231109-C00704
  • Figure US20230357259A1-20231109-C00705
  • Figure US20230357259A1-20231109-C00706
  • Figure US20230357259A1-20231109-C00707
  • Figure US20230357259A1-20231109-C00708
  • Figure US20230357259A1-20231109-C00709
  • Figure US20230357259A1-20231109-C00710
  • Figure US20230357259A1-20231109-C00711
  • Figure US20230357259A1-20231109-C00712
  • Figure US20230357259A1-20231109-C00713
  • Figure US20230357259A1-20231109-C00714
  • Figure US20230357259A1-20231109-C00715
  • As used herein, the term “6-12 membered bridged heterocyclyl” refers to a cyclic structure containing 6-12 ring-forming atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom) and formed by two or more cyclic structures sharing two nonadjacent ring-forming atoms. Optionally, the ring-forming atoms (e.g., carbon atoms, nitrogen atoms or sulfur atoms) in the cyclic structure can be substituted with oxygen. The “6-12 membered bridged heterocyclyl” includes, for example, “6-11 membered bridged heterocyclyl”, “6-9 membered bridged heterocyclyl”, “6-10 membered bridged heterocyclyl”, “7-10 membered bridged heterocyclyl”, “7-9 membered bridged heterocyclyl”, “7-8 membered bridged heterocyclyl”, “8 membered bridged heterocyclyl”, “9-10 membered bridged heterocyclyl” and “3-10 membered bridged heterocyclyl”. Specific examples include, but are not limited to
  • Figure US20230357259A1-20231109-C00716
  • Figure US20230357259A1-20231109-C00717
  • Figure US20230357259A1-20231109-C00718
  • Figure US20230357259A1-20231109-C00719
  • Figure US20230357259A1-20231109-C00720
  • Figure US20230357259A1-20231109-C00721
  • Figure US20230357259A1-20231109-C00722
  • Figure US20230357259A1-20231109-C00723
  • Figure US20230357259A1-20231109-C00724
  • Figure US20230357259A1-20231109-C00725
  • Figure US20230357259A1-20231109-C00726
  • Figure US20230357259A1-20231109-C00727
  • Figure US20230357259A1-20231109-C00728
  • Figure US20230357259A1-20231109-C00729
  • Figure US20230357259A1-20231109-C00730
  • Figure US20230357259A1-20231109-C00731
  • Figure US20230357259A1-20231109-C00732
  • Figure US20230357259A1-20231109-C00733
  • Figure US20230357259A1-20231109-C00734
  • Figure US20230357259A1-20231109-C00735
  • Figure US20230357259A1-20231109-C00736
  • Figure US20230357259A1-20231109-C00737
  • Figure US20230357259A1-20231109-C00738
  • Figure US20230357259A1-20231109-C00739
  • Figure US20230357259A1-20231109-C00740
  • Figure US20230357259A1-20231109-C00741
  • Figure US20230357259A1-20231109-C00742
  • Figure US20230357259A1-20231109-C00743
  • Figure US20230357259A1-20231109-C00744
  • Figure US20230357259A1-20231109-C00745
  • Figure US20230357259A1-20231109-C00746
  • As used herein, the term “6-12 membered fused heterocyclyl” refers to a cyclic structure containing 6-12 ring-forming atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom) and formed by two or more cyclic structures sharing two adjacent atoms. Optionally, the ring-forming atoms (e.g., carbon atoms, nitrogen atoms or sulfur atoms) in the cyclic structure can be substituted with oxygen. The “6-12 membered fused heterocyclyl” includes, for example, “6-11 membered fused heterocyclyl,” “5-10 membered fused heterocyclyl”, “7-10 membered fused heterocyclyl”, “3-10 membered fused heterocyclyl”, “3-10 membered nitrogen-containing fused heterocyclyl”, “9-10 membered fused heterocyclyl”, “9-10 membered nitrogen-containing fused heterocyclyl” and “6-12 membered oxygen-containing fused heterocyclyl”. Specific examples include, but are not limited to tetrahydroimidazo [4,5-c]pyridyl, 3,4-dihydroquinazolinyl, 1,2-dihydroquinoxalinyl, benzo[d][1,3]dioxolyl, 1,3-dihydroisobenzofuranyl, 4H-1,3-benzoxazinyl, 4,6-dihydro-1H-furo[3,4-<d]imidazolyl, 3a,4,6,6a-tetrahydro-1H-furo[3,4-d]imidazolyl, 4,6-dihydro-1H-thieno[3,4-d]imidazolyl, 4,6-dihydro-1H-pyrrolo[3,4-d]imidazolyl, benzoimidazolidinyl, octahydro-benzo[d]imidazolyl, decahydroquinolyl, hexahydrothienoimidazolyl, hexahydrofuroimidazolyl, 4,5,6,7-tetrahydro-IH-benzo[d]imidazolyl, octahydrocyclopenteno[c]pyrrolyl, dihydroindolyl, dihydroisoindolyl, benzooxazolidinyl, benzothiazolidinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinolinyl and 4H-1,3-benzoxazinyl.
  • As used herein, the term “aryl” refers to a monocyclic or polycyclic hydrocarbonyl having aromaticity, such as 6-20 membered aryl, 6-10 membered aryl and 5-8 membered aryl. Specific examples include but are not limited to phenyl, naphthyl, anthracenyl and phenanthryl. The “6-20 membered aryl” refers to aryl containing 6-20 ring-forming atoms.
  • As used herein, the term “heteroaryl” refers to a cyclic group having aromaticity, wherein at least one ring-forming atom is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom. Optionally, the ring-forming atoms (e.g., carbon atoms, nitrogen atoms or sulfur atoms) in the cyclic structure can be substituted with oxygen. Specific examples include, but are not limited to 5-10 membered heteroaryl, 5-10 membered nitrogen-containing heteroaryl, 6-10 membered oxygen-containing heteroaryl, 6-8 membered nitrogen-containing heteroaryl and 5-8 membered oxygen-containing heteroaryl, such as furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, 2-pyridone, 4-pyridone, pyrimidinyl, 1,4-dioxacyclohexadienyl, 2H-1,2-oxazinyl, 4H-1,2-oxazinyl, 6H-1,2-oxazinyl, 4H-1,3-oxazinyl, 6H-1,3-oxazinyl, 4H-1,4-oxazinyl, pyridazinyl, pyrazinyl, \1,2,3-triazinyl, \1,3,5-triazinyl, \1,2,4,5- tetrazinyl, azacycloheptatrienyl, 1,3-diazcycloheptatrienyl and azacyclooctatetraenyl.
    • Beneficial Effects of the Invention
  • The disclosure obtains a kind of novel bioactive molecule conjugate by improving the coupling way of drugs and targeting moieties in ADCs or SMDCs. In some embodiments of the disclosure, the bioactive molecule conjugate is obtained through nucleophilic substitutions of the heteroaryl ring on the ADC linker by the free sulfhydryl in the antibody. The conjugate obtained by the coupling can achieve at least one of the following technical effects:
    • (1) high stability;
    • (2) high DAR, the DAR values of the conjugate can reach 5-8 in some embodiments;
    • (3) extremely high coupling efficiency, the coupling efficiency can reach 90% in some embodiments;
    • (4) the conjugate obtained by the coupling can effectively improve the stability of the drug in the circulation and reduce unexpected dissociation of the drug in non-target cells;
    • (5) the conjugate can also increase effective release of the bioactive molecule in cells to attain the purposes of decreasing toxicity and increasing efficacy;
    • (6) the conjugate has good tumor tissue targetability; and
    • (7) the conjugate has good efficacy on animal models of tumors.
  • In addition, the coupling method described in the disclosure has broad application scope and can be widely used in coupling bioactive molecules with antibodies or targeted small molecule ligands.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows a TIC (total ion chromatogram) of BT001002.
  • FIG. 2 shows a deconvolution diagram of a coupled light chain of BT001002.
  • FIG. 3 shows a deconvolution diagram of a coupled heavy chain of BT001002.
  • FIG. 4 shows a TIC (total ion chromatogram) of BT001004.
  • FIG. 5 shows a deconvolution diagram of a coupled light chain of BT001004.
  • FIG. 6 shows a deconvolution diagram of a coupled heavy chain of BT001004.
  • FIG. 7 shows a SEC chromatogram of BT001002.
  • FIG. 8 shows a SEC chromatogram of molecular weight Marker of BT001002.
  • FIG. 9 shows a SEC chromatogram of BT001004.
  • FIG. 10 shows a deconvolution diagram of a coupled light chain of BT001012.
  • FIG. 11 shows a deconvolution diagram of a coupled heavy chain of BT001012.
  • FIG. 12 shows a deconvolution diagram of a coupled light chain of BT001013.
  • FIG. 13 shows a deconvolution diagram of a coupled heavy chain of BT001013.
  • FIG. 14 shows a deconvolution diagram of a coupled light chain of BT001018.
  • FIG. 15 shows a deconvolution diagram of a coupled heavy chain of BT001018.
  • FIG. 16 shows a deconvolution diagram of a coupled light chain of BT001021.
  • FIG. 17 shows a deconvolution diagram of a coupled heavy chain of BT001021.
  • FIG. 18 shows a deconvolution diagram of a coupled light chain of BT001023.
  • FIG. 19 shows a deconvolution diagram of a coupled heavy chain of BT001023.
  • FIG. 20 shows a deconvolution diagram of a coupled light chain of BT001040.
  • FIG. 21 shows a deconvolution diagram of a coupled heavy chain of BT001040.
  • FIG. 22 shows a deconvolution diagram of a coupled light chain of BT001041.
  • FIG. 23 shows a deconvolution diagram of a coupled heavy chain of BT001041.
  • FIG. 24 shows a deconvolution diagram of a coupled light chain of BT001042.
  • FIG. 25 shows a deconvolution diagram of a coupled heavy chain of BT001042.
  • FIG. 26 shows a deconvolution diagram of a coupled light chain of BT001043.
  • FIG. 27 shows a deconvolution diagram of a coupled heavy chain of BT001043.
  • FIG. 28 shows a deconvolution diagram of a coupled light chain of BT001044.
  • FIG. 29 shows a deconvolution diagram of a coupled heavy chain of BT001044.
  • FIG. 30 shows a deconvolution diagram of a coupled light chain of BT001046.
  • FIG. 31 shows a deconvolution diagram of a coupled heavy chain of BT001046.
  • FIG. 32 shows a deconvolution diagram of a coupled light chain of BT001047.
  • FIG. 33 shows a deconvolution diagram of a coupled heavy chain of BT001047.
  • FIG. 34 shows a SEC chromatogram of BT001012.
  • FIG. 35 shows a SEC chromatogram of BT001013.
  • FIG. 36 shows a SEC chromatogram of BT001018.
  • FIG. 37 shows a SEC chromatogram of BT001021.
  • FIG. 38 shows a SEC chromatogram of BT001023.
  • FIG. 39 shows a SEC chromatogram of BT001042.
  • FIG. 40 shows a SEC chromatogram of BT001043.
  • FIG. 41 shows a SEC chromatogram of BT001044.
  • FIG. 42 shows a SEC chromatogram of BT001046.
  • FIG. 43 shows a SEC chromatogram of BT001047.
  • FIG. 44 shows changes in growth of tumor volume of each group of mice in a NCI-N87 human gastric cancer model.
  • FIG. 45 shows changes in body weight of each group of mice in a NCI-N87 human gastric cancer model.
  • FIG. 46 shows changes in growth of tumor volume of each group of mice in an HCC1806 human breast cancer model.
  • FIG. 47A shows changes in growth of tumor volume of each group of mice in a xenograft model of HCC827 human non-small cell lung cancer.
  • FIG. 47B shows changes in body weight of each group of mice in a xenograft model of HCC827 human non-small cell lung cancer.
  • FIG. 48A shows changes in growth of tumor volume of each group of mice in a xenograft model of NCI-N87 human gastric cancer.
  • FIG. 48B shows changes in body weight of each group of mice in a xenograft model of NCI-N87 human gastric cancer.
  • FIG. 49A shows changes in growth of tumor volume of each group of mice in a tumor-bearing mice model of MDA-MB-231 human breast cancer.
  • FIG. 49B shows changes in body weight of each group of mice in a tumor-bearing mice model of MDA-MB-231 human breast cancer.
    •  SPECIFIC MODE FOR CARRYING OUT THE INVENTION
  • The disclosure will be further illustrated in combination with specific embodiments, but the disclosure is not limited thereto. It should be understood by a person skilled in the art that various modifications or improvements can be made according to the teachings of the disclosure without departing from the basic idea and scope of the disclosure.
  • Abbreviations in the invention have the following meanings:
  • OMs methylsulfonyloxy FA Formic acid
    OTs Trifluoromethylsulfonyloxy ACN Acetonitrile
    OTf p-toluenesulfonyloxy CCK8 reagent 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazole monosodium salt
    TBS Tert-butyldimethylsilyl FBS Fetal bovine serum
    MMT p-methoxytriphenylmethyl DMSO Dimethyl sulfoxide
    PB/PBS Phosphate buffered saline
    • Preparation Solutions
  • The structures of compounds described in the following examples were determined by nuclear magnetic resonance (1H NMR) or mass spectrometry (MS).
  • Nuclear magnetic resonance (1H NMR) was determined by using a Bruker 400 MHz NMR spectrometer. Deuterated methanol (CD3OD), deuterated chloroform (CDCl3) or deuterated dimethyl sulfoxide (DMSO-D6) was the solvent for determination, and tetramethylsilane (TMS) was an internal standard substance.
  • Abbreviations in nuclear magnetic resonance (NMR) spectra used in the examples were shown below.
  • s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, qd: quartet doublet, ddd: double double doublet, ddt: double double triplet, dddd: double double double doublet, m: multiplet, br: broad, J: coupling constant, Hz: hertz, DMSO-d6: deuterated dimethyl sulfoxide. δ value was expressed in ppm.
  • Mass spectra (MS) were determined using Agilent (ESI) mass spectrometer (model: Agilent 6120B).
  • Preparative liquid chromatography: Method A:
    • Chromatographic column: Daisogel C18 10 µm 100×250 mm
    • Mobile phase A: water; Mobile phase B: acetonitrile
  • Time [min] Mobile phase A [%] Mobile phase B [%] Flow rate [mL/min]
    0.00 70.0 30.0 300.0
    8.00 70.0 30.0
    50.00 20.0 80.0
  • Method B:
    • Chromatographic column: Daisogel C18 10 µm 50×250 mm
    • Mobile phase A: water; Mobile phase B: acetonitrile
  • Time [min] Mobile phase A [%] Mobile phase B [%] Flow rate [mL/min]
    0.00 70.0 30.0 80.0
    8.00 70.0 30.0
    50.00 20.0 80.0
  • Method C:
    • Chromatographic column: Daisogel C18 10 µm 50×250 mm
    • Mobile phase A: water containing 0.1% trifluoroacetic acid; Mobile phase B: acetonitrile
  • Time [min] Mobile phase A [%] Mobile phase B [%] Flow rate [mL/min]
    0.00 90.0 10.0 80.0
    10.00 90.0 10.0
    50.00 60.0 40.0
  • Method D: chromatographic column: Waters SunFire C18 5 µm19×250 mm
    • Mobile phase A: acetonitrile; Mobile phase B: water containing 0.05% formic acid
    • Time: 0 min-Y; Mobile phase A: 10%-90%; Flow rate: 28 mL/min
    I. Synthesis Of Bioactive Molecules Example 1: Synthesis of (2S)-N-((3R,4S,5S)-1-((2S)-2-((1R,2R)-3-((1-((4-aminobenzyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-propionyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-heptanoyl-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyramide (T001)
  • Figure US20230357259A1-20231109-C00747
  • Step 1: synthesis of tert-butyl (4-((2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5 methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl) carbamate
  • At room temperature, 1-hydroxybenzotriazole (2.0 mg, 14.74 µmol) was dissolved in N,N-dimethylformamide (4 mL), cooled to 0° C., and then tert-butyl 4-methylaminobenzyl carbamate (4.0 mg, 16.1 µmol), N,N-diisopropylethylamine (8.5 mg, 66.8 µmol), ((2R, 3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionyl)-L-phenylalanine (10.0 mg, 13.5 µmol, commercially available) were successively added. After being stirred for 5 min, 1H-benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (10.0 mg, 20.1 µmol) was added thereto, and stirred at 0° C. for 1 h. The reaction of raw materials was monitored by high performance liquid chromatography-mass spectrometry. After the raw materials were consumed up, the reaction solution was purified by preparative liquid chromatography (method D) to obtain the title compound (9.0 mg of white solid). ESI-MS (m/z): 950.5 [M + H] +.
  • Step 2: synthesis of (2S)-N-((3R,4S,5S)-1-((2S)-2-((1R,2R)-3-((1-((4-aminobenzyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-propionyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-heptanoyl-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutanamide
  • At room temperature, tert-butyl (4-((2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyryl)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionyl)-3-phenylpropanamide)methyl)phenyl) carbamate (9.0 mg, 0.02 mmol) was dissolved in 1,4-dioxane (0.5 mL), cooled to 0° C., and then the hydrogen chloride solution in dioxane (1 mL, 4.0 M) was added and reacted at room temperature for 3 hours under stirring. The reaction of raw materials was monitored by high performance liquid chromatography-mass spectrometry. After the raw materials were consumed up, the solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (5.0 mg of white solid). ESI-MS (m/z): 850.5 [M + H] +.
    • Example 2: Synthesis of (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-((S)-1-((4-aminobenzyl)amino) 1-oxo-3-phenylprop-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl) pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptyl-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyramide (T011)
  • Figure US20230357259A1-20231109-C00748
  • Step 1: synthesis of tert-buty (S)-(4-((2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-phenylpropionamido) methyl)phenyl) l carbamate
  • At 0° C., 4-aminobenzylamine (222 mg, 1.0 mmol) and N-methylmorpholine (306 mg, 1.5 mmol) were added to a solution of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-phenylpropionicacid (387 mg, 1.0 mmol) in N,N-dimethylformamide (5 mL), then 1-hydroxybenzotriazole (203 mg, 1.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (288 mg, 1.5 mmol) were successively added. The resulting mixture was reacted overnight at 0° C. The reaction solution was poured into water (50 mL), and a white solid was precipitated. The solid was filtered, the filter cake was washed with water (20 mL×3). The solid was purified by silica gel column chromatography to obtain the title compound (a 380 mg white solid). ESI-MS (m/z): 592.3 [M + H]+.
  • Step 2: synthesis of tert-butyl (S)-(4-((2-amino-3-phenylpropionamido) methyl)phenyl) carbamate
  • Lithium hydroxide monohydrate (21 mg, 0.51 mmol) was dissolved in water (1 mL) and added to a tetrahydrofuran (2 mL) solution of tert-butyl (S)-(4-((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-phenylpropionamido)methyl)phenyl) carbamate (102 mg, 0.17 mmol). The resulting mixture was reacted at room temperature for 2 hours. The reaction solution was added with water (20 mL) and extracted with ethyl acetate (30 mL×4). The organic phases were combined, washed with saturated saline (30 mL × 2) and dried over anhydrous sodium sulfate. Then the desiccant was removed by filtration, the solvent was evaporated under reduced pressure, and the residues were purified by preparative liquid chromatography (method D) to obtain the title compound (65 mg of white solid). ESI-MS (m/z): 370.2 [M + H]+.
  • Step 3: synthesis of (4-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-3-((methylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy -5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)carbamate
  • At 0° C., tert-butyl (S)-(4-((2-amino-3-phenylpropionamido)methyl)phenyl) carbamate (15 mg, 0.04 mmol) and N-methylmorpholine (12 mg, 0.12 mmol) were added to a solution of (2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl-3-methoxy-2-methylpropionic acid (24 mg, 0.04 mmol) in N,N-dimethylformamide (2 mL), then 1-hydroxybenzotriazole (8 mg, 0.06 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (12 mg, 0.06 mmol) were successively added. The resulting mixture was reacted overnight at 0° C. The reaction solution was purified by preparative liquid chromatography (method D) to obtain the title compound (24 mg of white solid). ESI-MS (m/z): 950.6 [M + H]+.
  • Step 4: synthesis of (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-((S)-1-((4-aminobenzyl)amino)-1-oxo-3-phenylprop-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptyl-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyramide
  • Trifluoroacetic acid (0.5 mL) was added to a solution of (4-((S)-2-((2R,3R)-3-((S)-1-(3R,4S,5S)-4-((S)-3-(methylamino)-3-methylbutyrylamino)-N, 3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropionamido)methyl)phenyl) carbamate (14.0 mg, 0.015 mmol) in dichloromethane (1.5 mL). The resulting mixture was reacted at room temperature for 1 h. Then the solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (4.2 mg of white solid). ESI-MS (m/z): 850.6 [M + H]+.
  • The following molecules can be synthesized by a similar synthetic method:
  • Name Structure ESI-MS
    T012
    Figure US20230357259A1-20231109-C00749
    		 850.6
    T013
    Figure US20230357259A1-20231109-C00750
    		 864.6
    T015
    Figure US20230357259A1-20231109-C00751
    		 760.6
    T021
    Figure US20230357259A1-20231109-C00752
    		 851.6
    • Example 3: Synthesis of (S)-N-(2-(4-ethyl-4-hydroxyl-3,14-dione-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-N-isopropylacetamide
  • Figure US20230357259A1-20231109-C00753
  • Belotecan hydrochloride (1.0 g, 2.13 mmol) and triethylamine (0.65 g, 0.9 mL) were dissolved in dichloromethane (50 mL) at room temperature, and acetic anhydride (0.22 g, 2.13 mmol) was slowly added dropwise. The resulting mixture was reacted at room temperature for 1h. The organic phase was washed with water (10 mL×2) and dried over anhydrous sodium sulfate. Insoluble substances were removed by filtration, the solvent was evaporated, and the residue was purified by silica gel column chromatography (dichloromethane/methanol=50/1) to obtain the title compound (1 g). ESI-MS (m/z): 476.2[M+H]+.
    • Example 4: Synthesis of (S)-N-(2-(4-ethyl-4-hydroxyl-3,14-dione-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-N-isopropylmethanesulfonamide
  • Figure US20230357259A1-20231109-C00754
  • Methylsulfonyl chloride (462 mg, 12.77 mmol, purity:about 70%) was added dropwise to a solution of belotecan hydrochloride (3 g, 6.38 mmol) and triethylamine (2.58 g, 25.54 mmol) in dichloromethane (40 mL). The resulting mixture was reacted at room temperature for 2 h. Suction filtration was performed, and the filter cake was washed three times with dichloromethane (3 mL) to obtain the title compound (2.2 g).
  • Structural characterization data are as follows:
  • 1H NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 8.4 Hz, 1H), 8.20 (dd, J = 8.4, 1.2 Hz, 1H), 7.93-7.84 (m, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.35 (s, 1H), 6.56 (s, 1H), 5.44 (d, J = 9.2 Hz, 4H), 3.98 (p, J = 6.7 Hz, 1H), 3.50 (t, J = 8.0 Hz, 2H), 3.42-3.35 (m, 2H), 3.00 (s, 3H), 1.93-1.82 (m, 2H), 1.15 (d, J = 6.7 Hz, 6H), 0.88 (t, J = 7.3 Hz, 3H). ESI-MS (m/z): 512.2 [M+H]+ . [α]D 20 is +28.19° (c =0.101 g/100 mL, CH3CN).
  • The rest bioactive molecules without illustration of synthetic method are commercially available or can be prepared by the method disclosed in the prior art.
    • II. Synthesis Of Compounds Containing Bioactive Molecules And Linkers Example 5: Synthesis of (S)-2-((S)-2-(4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)butyrylamido)-3-methylbutyrylamido)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-5-ureidovaleramide
  • Figure US20230357259A1-20231109-C00755
  • Step 1: synthesis of tert-butyl 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) butyrate (compound 1-2)
  • At room temperature, compound 1-1 (500 mg, 3.27 mmol) was dissolved in N,N-dimethylformamide (10 mL), sodium hydride (130 mg, 3.27 mmol) was slowly added in batches thereto. The resulting mixture was stirred at room temperature for 10 min, followed by the dropwise addition of t-butyl 4-bromobutyrate (725 mg, 3.27 mmol), and then reacted at room temperature for 2 hours. The reaction was quenched with saturated ammonium chloride aqueous solution, and extracted with ethyl acetate (50 mL×3). Then organic phases were combined, washed with saturated saline solution (50 mL×3) and dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and the solvent was evaporated under reduced pressure to obtain the title compound (500 mg). ESI-MS (m/z): 296.1 [M + H]+.
  • Step 2: synthesis of 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)butyric acid (compound 1-3)
  • At room temperature, compound 1-2 (500 mg, 1.69 mmol) was dissolved in dichloromethane (6 mL), and trifluoroacetic acid (3 mL) was added and reacted at room temperature for 4 hours. Then the solvent was evaporated under reduced pressure to obtain the title compound (400 mg). ESI-MS (m/z): 240.1 [M + H]+.
  • Step 3: sysnthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)amino)-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compound 1-5)
  • At room temperature, 4-(N-Boc-aminomethyl)-aniline (6.0 g, 27 mmol), compound 1-4 (3.35 g, 6.75 mmol), and 2-ethyoxyl-1-ethoxycarboxyl-1,2-dihydroquinoline (3.34 g, 13.5 mmol) were dissolved in the mixed solvent of dichloromethane (140 mL) and methanol (70 mL), then warmed to 45° C. and reacted at the temperature for 8.0 hours. After being cooled to room temperature, a large amount of solid was precipitated, which was subject to suction filtration to obtain the title compound (3.65 g). ESI-MS (m/z): 701.4 [M + H]+.
  • Step 4: synthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(aminomethyl)phenyl))amino)-1-oxo-5-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compound 1-6)
  • At room temperature, trifluoroacetic acid (15 mL) was added to compound 1-5 (3.0 g, 4.29 mmol) and stirred at room temperature for 1.0 h. Then the solvent was evaporated under reduced pressure to obtain a yellow oil. Anhydrous diethyl ether (20 mL) was added, and a large amount of solid was precipitated. After vigorous stirring for 0.5 h, suction filtration was carried out to obtain the trifluoroacetate of the title compound (3.06 g). ESI-MS (m/z): 601.3 [M + H]+.
  • Step 5: synthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(((R)-2-((t-butyloxycarboryl)amino)-3-phenylpropionamido)methyl)phenyl)amino-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compound 1-7)
  • At room temperature, Boc-D-phenylalanine (1.1 g, 4.2 mmol) and the trifluoroacetate of compound 1-6 (3.0 g, 4.2 mmol) were dissolved in N,N-dimethylformamide (40 mL), cooled to 0° C., and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.2 g, 6.3 mmol), 1-hydroxybenzotriazole (0.9 g, 6.3 mmol) and N-methylmorpholine (1.7 g, 16.8 mmol) were successively added. The reaction system was stirred for 1.0 h at the temperature. The reaction solution was then added dropwise to ice water (400 mL) and stirred vigorously for 0.5 h, a large amount of solid was precipitated, and suction filtration was carried out to obtain the title compound (3.3 g). ESI-MS (m/z): 848.4 [M + H]+.
  • Step 6: synthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(((R)-2-amino-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compound 1-8)
  • At room temperature, compound 1-7 (3.0 g, 3.3 mmol) was dissolved in trifluoroacetic acid (30 mL) and stirred at room temperature for 1.0 h. The solvent was evaporated under reduced pressure to obtain a yellow oil. Anhydrous diethyl ether (100 mL) was added and stirred vigorously for 0.5 h, and a large amount of solid was precipitated. Suction filtration was carried out to obtain the trifluoroacetate of the title compound (2.1 g). ESI-MS (m/z): 748.4 [M + H]+.
  • Step 7: synthesis of (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butyrylamido)-N,3-dimethylamino)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureidopent-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (compound 1-9)
  • At room temperature, (2R3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-(dimethylamino)-3-butyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionic acid (1.3 g, 2.17 mmol) and trifluoroacetate of compound 1-8 (1.8 g, 2.17 mmol) were dissolved in N,N-dimethylformamide (20 mL), cooled to 0° C., then 1-hydroxybenzotriazole (440 mg, 3.26 mmol) and N-methylmorpholine (658 mg, 6.51 mmol) were successively added, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (624 mg, 1.38 mmol) was added at last, the reaction solution was stirred at 0° C. for 5 hours, and purified by preparative liquid chromatography (method D) to obtain the title compound (1.8 g). ESI-MS (m/z): 1329.2 [M + H]+.
  • Step 8: synthesis of (S)-2-((S)-2-amino-3-butyrylamino)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-5-ureidovaleramide (compound 1-10)
  • At room temperature, compound 1-9 (500 mg, 0.38 mmol) was dissolved in N,N-dimethylformamide (5 mL), added with piperidine (324 mg, 3.8 mmol) and stirred at room temperature for 3 h. Then the purification was performed on preparative liquid chromatography (method D) to obtain the title compound (350 mg). ESI-MS (m/z): 1107.2 [M + H]+.
  • Step 9: synthesis of (S)-2-((S)-2-(4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)butyrylamido)-3-methylbutyrylamido)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-5-ureidovaleramide (compound TL001)
  • At room temperature, compound 1-10 (60 mg, 0.054 mmol) and 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)butyric acid (26 mg, 0.066 mmol) were dissolved in N,N-dimethylformamide (3 mL), cooled to 0° C., and N,N-diisopropylethylamine (105 mg, 0.81 mmol) and 1H-benzotriazole-1-oxytripyrrolidinophosphonium hexafluorophosphate (281 mg, 0.54 mmol) were successively added. The reaction system was stirred at room temperature for 3 hours. Then purificaiton was performed on preparative liquid chromatography (method D) to obtain the title compound (30 mg). ESI-MS (m/z): 664.5 [M/2 + H]+.
    • Example 6: (S)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-2-((S)-3-methyl-2-(4-(4-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-butyrylamido)-butyrylamido)-5-ureidovaleramide
  • Figure US20230357259A1-20231109-C00756
  • Step 1: synthesis of 4-(4-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)butyric acid (compound 2-2)
  • At room temperature, 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) butyric acid (300 mg, 1.25 mmol) was dissolved in methanol (8 mL), sodium methanethiol (351 mg, 5.02 mmol) was added in one batch, and then warmed to 50° C. and reacted overnight. Purification was performed on preparative liquid chromatography (method D) to obtain the title compound (120 mg). ESI-MS (m/z): 252.1 [M + H]+.
  • Step 2: synthesis of (S)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-2-((S)-3-methyl-2-(4-(4-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-butyrylamido)-butyrylamido)-5-ureidovaleramide (compound 2-3)
  • Operations similar to those described in step 9 of example 5, except that 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) butyric acid was replaced with 4-(4-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl) butyric acid, were carried out, and purification was performed by using preparative liquid chromatography (method D) to obtain the title compound (20 mg). ESI-MS (m/z): 670.5 [M/2 + H]+.
  • Step 3: synthesis of (S)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-2-((S)-3-methyl-2-(4-(4-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-butyrylamido)-butyrylamido)-5-ureidovaleramide (compound TL002)
  • At room temperature, compound 2-3 (20 mg, 0.015 mmol) was dissolved in dichloromethane (2 mL), and m-chloroperoxybenzoic acid (4.0 mg, 0.022 mmol) was added. The resulting mixture was reacted at room temperature for 2 hours. Purification was performed on preparative liquid chromatography (method D) to obtain the title compound (5.0 mg). ESI-MS (m/z): 686.5 [M/2 + H]+.
    • Example 7: N-((S)-1-(((S)-1-((4-(((S)-2-((2R,3R)-3-((S)-1-((3R4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureido-2-yl)amino)-3-methyl-1-oxybutan-2-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide
  • Figure US20230357259A1-20231109-C00757
  • Step 1: synthesis of methyl 6-(2-(methylthio)pyrimidin-5-yl)-5-hexynoate (compound 3-2)
  • At room temperature, methyl 5-hexynoate (500 mg, 3.97 mmol) and 5-bromo-2-methylthiopyrimidine were dissolved in N,N-dimethylformamide (3 ml), then triethylamine (3 ml), cuprous iodide (75 mg, 0.4 mmol) and Bis (triphenylphosphine) palladium (II) dichloride (279 mg, 0.4 mmol) were successively added. The resulting mixture was heated to 95° C. under nitrogen protection and reacted for 6 h under stirring, quenched with water, and extracted with ethyl acetate (20 mL×3). Organic phases were combined, washed with saturated saline (20 mL×2) and dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and the solvent was evaporated under reduced pressure. Purification was performed on preparative liquid chromatography (method D) to obtain the title compound (300 mg). ESI-MS (m/z): 251.3 [M + H]+.
  • Step 2: synthesis of 6-(2-(methylthio)pyrimidin-5-yl)-5-hexynoic acid (compound 3-3)
  • At room temperature, compound 3-2 (200 mg, 0.8 mmol) was dissolved in a mixed solution of tetrahydrofuran and water (4 mL/4 mL), and lithium hydroxide monohydrate (235 mg, 5.6 mmol) was added, and reacted at room temperature under stirring for 4 h, then diluted with water and extracted with ethyl acetate (20 ml x 2). The aqueous phase was adjusted to pH=3 with 1N hydrochloric acid, and extracted with ethyl acetate (20 mL×3), then organic phases were combined, washed with saturated saline (20 mL×2) and dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and the solvent was evaporated under reduced pressure to obtain the title compound (120 mg).
  • Step 3: synthesis of 6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynoic acid (compound 3-4)
  • At room temperature, compound 3-3 (20 mg, 0.085 mmol) was dissolved in dichloromethane (4 mL), and m-chloroperoxybenzoic acid (22 mg, 0.127 mmol) was added for reaction at room temperature overnight under stirring. Purification was performed on preparative liquid chromatography (method D) to obtain the title compound (20 mg). ESI-MS (m/z): 269.1 [M + H]+.
  • Step 4: N-((S)-1-(((S)-1-((4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureido-2-yl)amino)-3-methyl-1-oxybutan-2-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide (compound TL003)
  • Operations similar to those described in step 9 of example 5, except that 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) butyric acid was replaced with 6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynoic acid, were carried out, and purification was performed by using preparative liquid chromatography (method D) to obtain the title compound (14 mg). ESI-MS (m/z): 679.0 [M/2 + H]+.
    • Example 8: (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)-ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′\,4\′\,6,7]-indolizino[1,2-b]-quinolin-4-yl(4-((S)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33-nonoxy-3,9,36-azatetracosan-41-amido)benzyl)carbonate
  • Figure US20230357259A1-20231109-C00758
  • Step 1: synthesis of methyl (S)-(1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)-(9H-fluorenyl) carbamate (compound 19-2)
  • At room temperature, Fmoc-L-citrulline (5.0 g, 12.58 mmol), p-aminobenzyl alcohol (6.20 g, 50.32 mmol) and 2-ethoxy-1-ethoxycarboxyl-1, 2-dihydroquinoline (6.22 g, 25.16 mmol) were dissolved in dichloromethane (100 mL), and heated to 45° C. and reacted for 6 h. The reaction solution was concentrated under reduced pressure, and beaten with anhydrous diethyl ether (100 mL) to obtain the title compound (6.0 g). ESI-MS (m/z): 503.3[M+H]+.
  • Step 2: synthesis of (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (compound 19-3)
  • At room temperature, compound 19-2 (1.0 g, 1.99 mmol) was dissolved in N,N-dimethylformamide (8 mL), and piperidine (339 mg, 3.98 mmol) was added dropwise for reaction at room temperature for 30 min, then dichloromethane (10 mL) was added, followed by stirring for 10 min. The reaction solution was concentrated under reduced pressure, and purified by flash column chromatography to obtain the title compound (400 mg). ESI-MS (m/z): 281.2[M+H]+.
  • Step 3: synthesis of (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonyloxa-6-azatriacetamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (compound 19-4)
  • Compound 19-3 (150 mg, 0.54 mmol) and 32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azatricycloundecanoic acid (296 mg, 0.54 mmol) were dissolved in dichloromethane (10 mL) and cooled to 0° C., then 2-ethoxy-1-ethoxycarboxyl-1,2-dihydroquinoline (145 mg, 0.58 mmol) was added. The resulting mixture was moved to room temperature and reacted overnight. The reaction solution was concentrated under reduced pressure, and purified by flash column chromatography to obtain the title compound (200 mg). ESI-MS (m/z): 817.5[M+H]+.
  • Step 4: synthesis of 4-((S)-35-azido-4,8-dioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33-nonoxy-3,9-azatetracosane)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonylamino)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound 19-5)
  • At room temperature, (S)-N-(2-(4-ethyl-4-hydroxy-3,14-dione-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-N-isopropylmethanesulfonamide(200 mg, 0.39 mmol) was dissolved in dichloromethane (10 mL) and cooled to 0° C., a solution of 4-dimethylaminopyridine (573 mg, 4.69 mmol) in dichloromethane (1.0 ml) was added, and then a solution of triphosgene (116 mg, 0.39 mmol) in dichloromethane (1.0 ml) was slowly added dropwise. The resulting mixture was reacted at 0° C. for 1 h under stirring. A solution of the compound 19-4 (159 mg, 0.18 mmol) in dichloromethane (2.0 mL) was added to the reaction solution and reacted at room temperature for 1 h. Purification was perfomed on preparative high performance liquid chromatography (method D) to obtain the title compound (160 mg). ESI-MS (m/z): 678.0[M/2+H]+.
  • Step 5: synthesis of 4-((S)-35-amino-4,8-dioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33-nonoxy-3,9-azatetracosane)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonylamino)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound 19-6)
  • At room temperature, compound 19-5 (80 mg, 0.059 mmol) was dissolved in tetrahydrofuran (1.0 ml) and cooled to 0° C., then a solution of 4-dimethylaminopyridine (573 mg, 4.69 mmol) in dichloromethane (1.0 ml) was added, and platinum dioxide (15 mg, 0.059 mmol) was added in one batch under nitrogen protection, then air was substituted with hydrogen for three times and reacted at room temperature for 6 hours. The reaction solution was filtered, and the filtrate was concentrated to obtain a crude product which was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (40 mg). ESI-MS (m/z): 665.0[M/2+H]+.
  • Step 6: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33-nonoxy-3,9,36-azatetracosan-41-amido)benzyl)carbonate (compound TL019)
  • Compound 19-6 (30 mg, 0.016 mmol) and 6-(2-methylsulfonylpyrimidin-5-yl)-5-hexynoic acid (6.4 mg, 0.024 mmol) were dissolved in N,N-dimethylformamide (1 mL) and cooled to 0° C., then benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate (16.5 mg, 0.032 mmol), N,N-diisopropylethylamine (6.2 mg, 0.047 mmol) were successively added. The resulting mixture was reacted at room temperature for 2 hours. Purification was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (10 mg). ESI-MS (m/z): 790.0[M/2+H]+.
    • Example 9: (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl-(4-((S)-2-((S)-3-methyl-2-(6-(2-(methylsulfonyl)pyrimidin-5-yl))-5-hexynamido)butyramido-5-ureidovalerylamido)benzyl)carbonate
  • Figure US20230357259A1-20231109-C00759
  • Step 1: methyl ((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidovalerylamido-2-yl)amino))-3-methyl-butyramido-2-yl)-(9H-fluorenyl) carbamate
  • Operations similar to those described in step 1 of example 8 were carried out to obtain the title compound (310 mg), except that compound 19-1 was replaced with compound 28-1. ESI-MS (m/z):602.3[M+H]+.
  • Step 2: synthesis of (S)-2-((S)-2-amino-3-methylbutyramido)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (compound 28-2)
  • Operations similar to those described in step 2 of example 8 were carried out to obtain the title compound (150 mg), except that compound 19-2 was replaced with compound 28-2. ESI-MS (m/z): 380.3[M+H]+.
  • Step 3: synthesis of N-((S)-1-(((S)-1-((4-hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopent-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide(compound 28-4)
  • At room temperature, benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate (313 mg, 0.6 mmol) and N,N-diisopropylethylamine (194 mg, 1.50 mmol) were added to a solution of 6-(2-methylsulfonylpyrimidin-5-yl)-5-hexynoic acid (135 mg, 0.5 mmol) and (2S)-2-(((2S)-2-amino-3-methyl-butyryl)amino)-N-(4-(hydroxymethyl)phenyl)-5-ureido-valeramide (190 mg, 0.5 mmol) in N,N-dimethylformamide (10 mL) and reacted at room temperature for 3 hours under stirring. The reaction solution was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (78 mg). ESI-MS (m/z): 630.3 [M + H]+.
  • Step 4: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl-(4-((S)-2-((S)-3-methyl-2-(6-(2-(methylsulfonyl)pyrimidin-5-yl))-5-hexynamido)butyramido-5-ureidovalerylamido)benzyl)carbonate (compound TL028)
  • Operations similar to those described in step 4 of example 8 were carried out to obtain the title compound (1.76 mg), except that compound 19-4 was replaced with compound 28-4. ESI-MS (m/z): 1167.4 [M + H]+.
    • Example 10: (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl-(4-((2S,SS)-5-isopropyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazotritriacontylamido)benzyl)carbonate
  • Figure US20230357259A1-20231109-C00760
  • Step 1: synthesis of (S)-2-((S)-35-azido-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-azatetracosyl)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (compound 29-1)
  • Operations similar to those described in step 3 of example 8 were carried out to obtain the title compound (180 mg), except that compound 19-3 was replaced with compound 28-3. ESI-MS (m/z): 916.5[M+H]+.
  • Step 2: synthesis of 4-((2S,SS)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazatritriacontylamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound 29-2)
  • Operations similar to those described in step 4 of example 8 were carried out to obtain the title compound (30 mg), except that compound 19-4 was replaced with compound 29-1. ESI-MS (m/z): 727.5 [M/2+H]+.
  • Step 3: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinolin-4-yl-(4-((2S,5S)-5-isopropyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazotritriacontylamido)benzyl)carbonate (compound TL029)
  • At room temperature, compound 29-2 (20 mg, 0.014 mmol) and 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(2-propyn-1-yl)-5-hexynamide (4.3 mg, 0.014 mmol) were dissolved in a mixed solvent (1 mL/0.25 mL) of dimethyl sulfoxide and water, then cuprous bromide (3.95 mg, 0.027 mmol) was added and reacted for 1 h under stirring. Purification was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (15 mg). ESI-MS (m/z): 880.0[M/2+H]+.
    • Example 11: (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3\′\,4\′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((2S\,5S)-5-isopropyl-45-(2-(methylsulfonyl)pyrimidin-5-yl)-4,7,11,40-tetraoxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-3,6, 12,39-tetraazapentatetracontane-44-carbamoyl)benzyl)carbonate
  • Figure US20230357259A1-20231109-C00761
  • Step 1: synthesis of (S)-2-((S)-35-amino-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide
  • At 20° C., compound 29-1 (400 mg, 0.44 mmol) was dissolved in methanol and tetrahydrofuran (2.0 mL: 4.0 mL). After complete dissolution, platinum dioxide (40 mg) was added in one batch under nitrogen protection, then the mixed solution was subject to hydrogen substitution for three times. Hydrogenation was conducted at 20° C. for 2 hours. The reaction solution was filtered. The filter cake was washed with methanol. The filtrate was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (200 mg). ESI-MS (m/z): 890.4[M+H]+.
  • Step 2: synthesis of N-((6S,9S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetraoxo-13,19,22,25,28,31,34,37,40-nonoxy-2,7,10,16-tetraazadotetracont-42-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide
  • At 20° C., compound 22-1 (250 mg, 0.28 mmol) was dissolved in N,N-dimethylformamide (1.0 mL), then HATU (160 mg, 0.42 mmol) and N,N-diisopropylethylamine (109 mg, 0.84 mmol) were successively added, followed by stirring overnight at room temperature. Purification was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (250 mg).
  • Step 3: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((2S,5S)-5-isopropyl-45-(2-(methylsulfonyl)pyrimidin-5-yl)-4,7,11,40-tetraoxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-3,6, 12,39-tetraazapentatetracontane-44-carbamoyl)benzyl)carbonate (compound TL022)
  • At 20° C., (S)-N-(2-(4-ethyl-4-hydroxy-3,14-dione-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-N-isopropylmethanesulfonamide (70 mg, 0.14 mmol) was dissolved in dichloromethane (4.0 mL) and cooled to 0° C., then a solution of p-dimethylaminopyridine (200 mg, 1.64 mmol) in dichloromethane (1.0 ml) was added, and a solution of triphosgene (40.6 mg, 0.14 mmol) in dichloromethane (1.0 ml) was slowly added dropwise. The resulting mixture was reacted at 0° C. for 1 h under stirring. The unreacted triphosgene was blown off with nitrogen, and a solution of compound 22-2 (139 mg, 012 mmol) in dichloromethane (2.0 mL) was added to the reaction solution and reacted at 0° C. for 1 h under stirring. Purification was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (1.5 mg). ESI-MS (m/z): 839.5[M/2+H]+.
    • Example 12: 4-((S)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkynamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonyl)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Figure US20230357259A1-20231109-C00762
  • Step 1: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadotetracontyl-41-alkynamido)benzylcarbonate
  • At room temperature, 6-(-2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (12 mg, 0.045 mmol) was dissolved in dichloromethane (2 mL), then 2-(7-azobenzotriazol)-N,N,N′,N′-tetramethylureahexafluorophosphate (21.2 mg, 0.056 mmol) and N,N-diisopropylethylamine (8.6 mg, 0.067 mmol) were added and stirred for 10 min, and compound 24-1 (35 mg, 0.022 mmol) was added and reacted for 1h under stirring. Purification was performed on preparative high performance liquid chromatography (method B) to obtain the title compound (20 mg). ESI-MS (m/z): 1821.8[M+H]+.
  • Step 2: synthesis of 4-((S)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkynamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonyl)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL024)
  • At room temperature, compound 24-2 (20 mg, 0.011 mmol) was dissolved in acetonitrile (1 mL), and a solution of trifluoroacetic acid (0.5 ml) in acetonitrile (0.5 ml) was added dropwise and stirred for 20 min. Purification was performed on preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (12 mg). ESI-MS (m/z): 1549.6[M+H]+.
    • Example 13: Synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl-4-((2S,5S)-5-isopropyl-2-methyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7,11-trioxo-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazatriacontazanamido)benzyl)carbonate
  • Figure US20230357259A1-20231109-C00763
  • Step 1: preparation of (S)-(9H-fluoren-9-yl)-methyl(1-((4-(hydroxymethyl)phenyl)amino)-1 -oxopropyl-2-yl)carbamate
  • At room temperature, 2-ethoxy-1-ethoxycarboxyl-1,2-dihydroquinoline (1.31 g, 5.30 mmol) and p-aminobenzyl alcohol (593 mg, 4.82 mmol) were added to a solution of the compound 30-1 (1.5 g, 4.82 mmol) in dichloromethane (35 mL) and reacted for 3 hours under stirring. Purification was performed on silica gel column chromatography to obtain the title compound (1.8 g). ESI-MS (m/z): 417.2 [M+H]+
  • Step 2: preparation of (S)-2-amino-N-(4-(hydroxymethyl)phenyl)propionamide
  • At room temperature, ethylenediamine (5 mL) was added to a solution of compound 30-2 (1.8 g, 4.32 mmol) in dichloromethane (20 mL) and reacted for 2 hours. Purification was performed on silica gel column chromatography to obtain the title compound (820 mg). ESI-MS (m/z): 195.1 [M+H]+
  • Step 3: preparation of (9H-fluoren-9-yl)-methyl((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-carbamate
  • At room temperature, (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-methyl-butyricacid (875 mg, 2.58 mmol), O-benzotriazolyl-tetramethyluronium hexafluorophosphate (1.45 g, 3.83 mmol), N,N-diisopropylethylamine (1.00 g, 7.74 mmol) and 1-hydroxybenzotriazole (525 mg, 3.89 mmol) were successively added to a solution of the compound 30-3 (503 mg, 2.58 mmol) in dichloromethane (2 mL) and reacted for 4 hours under stirring. Purification was performed on silica gel column chromatography to obtain the title compound (1.1 g). ESI-MS (m/z): 516.2 [M+H]+
  • Step 4: preparation of (S)-2-amino-N-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxoprop-2-yl)-3-methylbutanamide
  • At room temperature, ethylenediamine (2 mL) was added to a solution of the compound 30-4 (1.1 g, 2.13 mmol) in dichloromethane (8 mL) and reacted for 1 h under stirring. Purification was performed on silica gel column chromatography to obtain the title compound (610 mg). ESI-MS (m/z): 294.2 [M+H]+
  • Step 5: preparation of (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-diazapentatriacontamido)-N-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropan-2-yl)-3-methylbutyramide
  • At room temperature, O-benzotriazolyl-tetramethyluroniumhexafluorophosphate (160 mg, 0.42 mmol), 1-hydroxybenzotriazole (57 mg, 0.42 mmol), N,N-diisopropylethylamine (109 mg, 0.84 mmol) and 32-azido-5-oxo-3.9,12,15,18,21,24,27,30-nonoxy-6-azatricyclodecane-1-acid (156 mg, 0.28 mmol) were added to a solution of compound 30-5 (84 mg, 0.28 mmol) in dichloromethane (3 mL) and reacted for 4 hours under stirring. Purification was performed on silica gel column chromatography to obtain the title compound (163 mg). ESI-MS (m/z): 830.4 [M+H]+
  • Step 6: preparation of 4-((2S,5S)-38 azido-5-isopropyl-2-methyl-4,7,11-trioxo-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazatriacontamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonylamino)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Under nitrogen protection and at 0° C., a solution of triphosgene (16 mg, 0.05 mmol) in dichloromethane (0.3 mL) was added dropwise to a mixed solution of 4-dimethylaminopyridine (65 mg, 0.53 mmol) and (S)-N-(2-(4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[30′,4′:6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-N-isopropylmethanesulfonamide (45 mg, 0.09 mmol) in dichloromethane (0.7 mL) and reacted at 0° C. for 1 h. Then a solution of the compound 30-6 (73 mg, 0.09 mmol) in dichloromethane (1 mL) was added dropwise to the reaction solution and reacted at 0° C. for 1 h. Purification was performed on silica gel column chromatography to obtain the title compound (33 mg). ESI-MS (m/z): 1367.6 [M+H]+
  • Step 7: preparation of (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7indolizino[1,2-b]quinolin-4-yl-4-((2S,5S)-5-isopropyl-2-methyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7,11-trioxo-9,15,18,21,24,27,30,33,36-nonoxy-3,6,12-triazatriacontazanamido)benzylcarbonate (compound TL030)
  • \\At room temperature, cuprous bromide (5 mg, 0.04 mmol) and compound 30-7 (20 mg, 15 umol) were added dropwise to a solution of 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)-hex-5-ynylamide (9 mg, 0.007 mmol) in water and N,N-dimethylformamide (0.2 ml: 0.8 ml) and reacted for 4 hours under stirring. Purification was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (4.15 mg). ESI-MS (m/z): 1672.7 [M+H]+
    • Example 14: 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11 -(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Figure US20230357259A1-20231109-C00764
  • Step 1: synthesis of 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)hex-5-ynamide
  • At 25° C., prop-2-ynyl-1-amine (189 mg, 3.4 mmol) and compound 3-4 (800 mg, 2.83 mmol) were dissolved in dichloromethane (10 mL), then N,N-diisopropylethylamine (738 mg, 5.67 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (1.63 g, 4.25 mmol) were successively added and reacted for 2 hours under stirring. The reaction solution was concentrated under reduced pressure, and the residue was purified by flash silica gel column chromatography (ethyl acetate/petroleum ether =3/1) to obtain the title compound (700 mg). ESI-MS (m/z): 306.1[M+H]+.
  • Step 2: synthesis of 4-((S)-35-azido-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonazo-3,9-diazapentatriacontamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-2H-pyrano[2,3-b]-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • At 25° C. and under nitrogen protection, T-030 (250 mg, 0.49 mmol) was dissolved in dichloromethane (10 mL) and cooled to 0° C., then a solution of 4-dimethylaminopyridine (478 mg, 3.91 mmol) in dichloromethane (3 mL) was added, followed by the slow and dropwise addition of a solution of triphosgene (72 mg, 0.24 mmol) in dichloromethane (10 mL) and reacted at 0° C. for 20 min under stirring. The reaction solution was bubbled with nitrogen for 20 min, then a solution of (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azatriacetamido)-N-(4-(hydroxymethyl)phenyl)-6(((4-methoxyphenyl)benzhydryl)amino)acetamide (518 mg, 0.49 mmol) in dichloromethane (7 mL) was added and reacted at 0° C. for 1 h under stirring. The reaction solution was concentrated under reduced pressure, the residue was purified by preparative high performance liquid chromatography (method A) to obtain the title compound (500 mg). ESI-MS (m/z): 1597.5[M+H]+.
  • Step 3: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl)carbonate
  • At room temperature, compound 33-1 (14 mg, 0.05 mmol) was dissolved in dimethyl sulfoxide and water (2.0 mL: 0.5 mL), followed by an addition of cuprous bromide (11 mg, 0.08 mmol) and reacted for 1 h under stirring. Purification was performed on preparative high performance liquid chromatography (method B) to obtain the title compound (30 mg). ESI-MS (m/z): 815.9[(M-273)/2+H]+.
  • Step 4: synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL033)
  • Compound 33-2 (30 mg, 0.02 mmol) was dissolved in dichloromethane (1.0 mL), and trifluoroacetic acid (0.2 mL) was added to the reaction solution and reacted at room temperature for 30 min. Purification was performed on preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (20.0 mg). Identification of the title compound is as follows:
  • 1H NMR (400 MHz, DMSO-d6) δ 10.18 (s, 1H), 9.10 (s, 2H), 8.38 (t, J= 5.56 Hz, 1H), 8.32 (d, J = 8.40 Hz, 1H), 8.22 - 8.20 (m, 2H), 8.09 (t, J = 5.68 Hz, 1H), 7.91 - 7.87 (m, 2H), 7.82 -7.78 (m, 1H), 7.69 (brs, 3H), 7.61 (d, J= 8.56 Hz, 2H), 7.32 (d, J= 8.56 Hz, 2H), 7.06 (s, 1H), 5.56 (d, J = 16.96 Hz, 1H), 5.51 (d, J = 16.96 Hz, 1H), 5.47 (d, J = 19.28 Hz, 1H), 5.42 (d, J = 19.28 Hz, 1H), 5.14 (d, J= 12.20 Hz, 1H), 5.07 (d, J= 12.16 Hz, 1H), 4.48 (t, J= 5.24 Hz, 2H), 4.46 - 4.43 (m, 1H), 4.29 (d, J = 5.60 Hz, 2H), 4.08 - 3.95 (m, 5H), 3.79 (t, J = 5.28 Hz, 2H), 3.51 - 3.43 (m, 32H), 3.40 (s, 3H), 3.39 - 3.35 (m, 2H), 3.30 - 3.26 (m, 2H), 3.00 (s, 3H), 2.82 - 2.74 (m, 2H), 2.56 (t, J= 7.08 Hz, 2H), 2.29 (t, J= 7.36 Hz, 2H), 2.23 - 2.13 (m, 2H), 1.82 (p, J= 7.24 Hz, 2H), 1.78 -1.63 (m, 2H), 1.61-1.49 (m, 2H), 1.42 -1.27 (m, 2H), 1.15 (d, J= 6.80 Hz, 3H), 1.13 (d, J = 6.76 Hz, 3H), 0.90 (t, J = 7.32 Hz, 3H). ESI-MS (m/z): 816.0[M/2+H]+. [α]D 20 is -19.55° (c =1.000 g/100 mL, CH3CN).
    • Example 15: 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-carbonate
  • Figure US20230357259A1-20231109-C00765
  • Step 1: synthesis of 4-((S)-35-azido-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-4,8- dioxo 6,12,15,18,21,24,27-nonoxy-((S)-9-((tert-butyldimethylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1,2,3,4-tetrahydroquinolin-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • At room temperature, compound 34-1 (100 mg, 0.2 mmol) was dissolved in anhydrous dichloromethane (2 ml) under nitrogen protection, then cooled to 0° C., followed by an addition of a solution of 4-dimethylaminopyridine (144 mg, 1.18 mmol) in anhydrous dichloromethane (0.5 ml), then a solution of triphosgene (41 mg, 0.14 mmol) in dry dichloromethane (0.5 ml) was slowly added dropwise. The resulting mixture was reacted at 0° C. for 1h under stirring. Then a solution of (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azatriacetamido)-N-(4-(hydroxymethyl)phenyl)-6(((4-methoxyphenyl)benzhydryl)amino)acetamide(160 mg, 0.15 µmol) in dry dichloromethane (0.5 mL) was added to the reaction solution and reacted at room temperature for 1h. Purification was performed on preparative high performance liquid chromatography (method B) to obtain the title compound (60 mg). ESI-MS (m/z): 1592.7[M+H]+.
  • Step 2: synthesis of (S)-9-(tert-butyldimethylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl-4-((S)-2-(4-(((6-2-(methylsulfonyl)pyrimidin-5-yl)-35-(4-((6-2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)- dioxo 6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)carbonate
  • At room temperature, compound 34-2 (40 mg, 0.03 mmol) and 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)hex-5-ynylamide (11.50 mg, 0.04 mmol) were dissolved in dimethyl sulfoxide and water (0.5 ml: 0.1 ml), and cuprous bromide (9.01 mg, 0.06 mmol) was added. The resulting mixture was reacted for 1h under stirring. Purification was performed on preparative high performance liquid chromatography (method B) to obtain the title compound (20 mg). ESI-MS (m/z): 1897.5[M+H].
  • Step 3: synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-carbonate(compound TL034)
  • At room temperature, compound 34-3 (30 mg, 0.018 mmol) was dissolved in acetonitrile and water (0.4 mL: 0.1 mL), then a mixed solution of trifluoroacetic acid and acetonitrile (0.5 mL: 0.5 mL) was added dropwise, and stirred at room temperature for 2 hours. Purification was performed on preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (12 mg). ESI-MS (m/z): 1511.5[M+H]+.
    • Example 16: Synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Figure US20230357259A1-20231109-C00766
  • Step 1: synthesis of ((S)-35-azido-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1,2,3,6-triazacycloheptane-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Operations similar to those described in step 1 of example 15 were carried out to obtain the title compound (60 mg), except that compound 34-1 was replaced with compound 35-1. ESI-MS (m/z): 1561.5[M+H]+.
  • Step 2: synthesis of (S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)-4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((6-2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido]carbonate
  • A synthetic method similar to that as described in step 2 of example 15 was adopted to obtain the title compound (20 mg), except that compound 34-2 was replaced with compound 35-2. ESI-MS (m/z): 1866.5[M+H].
  • Step 3: synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL035)
  • A synthetic method similar to that as described in step 3 of example 15 was adopted to obtain the trifluoroacetate of the title compound (4.9 mg), except that compound 34-3 was replaced with compound 35-3. ESI-MS (m/z): 1594.5[M+H]+.
    • Example 17: Synthesis of 4-((S,Z)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadotetracontyl-41-alkenamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Figure US20230357259A1-20231109-C00767
  • Step 1: synthesis of (Z)-6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-enoic acid
  • At 20° C., compound 3-4 (200 mg, 0.67 mmol) was dissolved in methanol (8.0 mL), and a Lindlar catalyst (20 mg) was added under nitrogen protection, then the solution was subject to hydrogen substitution for three times. Hydrogenation was conducted at 20° C. for 3 hours. After filtration, the filtrate was subject to spin drying to obtain the title compound (150 mg). ESI-MS (m/z):271.1 [M+H]+.
  • Step 2: synthesis of (S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S,Z)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadotetracontyl-41-alkenamido)benzylcarbonate
  • At room temperature, compound 45-2 (8 mg, 0.030 mmol) was dissolved in dichloromethane (2 mL), then 2-(7-azobenzotriazol)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (14.9 mg, 0.039 mmol) and N,N-diisopropylethylamine (8.8 mg, 0.068 mmol) were added. The reaction solution was stirred at room temperature for 10 min, then compound 48-1 (30 mg, 0.020 mmol) was added and reacted at room temperature for 1 h under stirring. Purificaiton was performed on preparative high performance liquid chromatography (method B) to obtain the title compound (30 mg). ESI-MS (m/z): 1787.8[M+H]+.
  • Step 3: synthesis of 4-((S,Z)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkenamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL045)
  • At room temperature, compound 45-3 (30 mg, 0.017 mmol) was dissolved in acetonitrile (1 ml), and a solution of trifluoroacetic acid (0.5 ml) in acetonitrile (0.5 ml) was added dropwise. The reaction solution was stirred at room temperature for 20 min. Purificaiton was performed on preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (9 mg). ESI-MS (m/z): 1515.6[M+H]+.
    • Example 18: 4-((S)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkynamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Figure US20230357259A1-20231109-C00768
  • Step 1: synthesis of (S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadotetracontyl-41-alkynamido)benzylcarbonate
  • A synthetic method similar to that described in step 1 of example 12 was adopted to obtain the title compound (15 mg), except that compound 24-1 was replaced with compound 48-1. ESI-MS (m/z): 1785.8[M+H]+.
  • Step 2: synthesis of 4-((S)-2-(4-aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazadedotetracontyl-41-alkynamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (compound TL048)
  • A synthetic method similar to that described in step 2 of example 12 was adopted to obtain the trifluoroacetate of the title compound (11.35 mg), except that compound 24-2 was replaced with compound 48-2. ESI-MS (m/z): 1513.7[M+H]+.
    • Example 19: 4-((S)-2-(4-aminobutyl)-35-(4-((2-(2-((methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Figure US20230357259A1-20231109-C00769
  • Step 1: synthesis of 2-(2-(methylthio)pyrimidin-5-yl)thiazol-4-carboxylic acid
  • Compound 49-1 (100 mg, 0.40 mmol), 2-bromo-4-thiazolecarboxylic acid (99.01 mg, 0.48 mmol), potassium carbonate (137.03 mg, 0.99 mmol) and [1,1′-bis(diphenylphosphino)ferrocenyl]palladium dichloride (29.02 mg, 0.04 mmol) were dissolved in N,N-dimethylformamide (4 mL) and water (1 ml), under nitrogen protection, the reaction system was heated to 100° C. and stirred for 4 h. Then the reaction solution was cooled to room temperature and dropped into water. After filtration, the filtrate was collected and extracted with ethyl acetate (10 mL× 3). The aqueous phase was collected and adjusted with dilute hydrochloric acid to pH=3 to precipitate a solid, and filtered. The filter cake was collected to obtain the title compound (70 mg). ESI-MS (m/z):254.0[M+H]+.
  • Step 2: synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxylic acid
  • Compound 49-2 (73 mg, 0.29 mmol) was dissolved in dichloromethane (15 mL), and m-chloroperoxybenzoic acid (175.53 mg, 0.87 mmol, 85%) was added. The reaction system was stirred overnight at room temperature. The solvent was concentrated under reduced pressure. Purificaiton was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (20 mg). ESI-MS (m/z):286.0[M+H]+.
  • Step 3: synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)thiazo-4-carboxamide
  • Compound 49-3 (20 mg, 0.07 mmol) was dissolved in dichloromethane (2 mL), and O-(7-benzotriazol)-N,N,N,N-tetramethyluronium hexafluorophosphate (39.98 mg, 0.11 mmol) was added. The obtained reaction system was cooled to 0° C., then N, N-diisopropylethylamine (22.65 mg, 0.18 mmol) and propargylamine (4.63 mg, 0.09 mmol) were added thereto. Thereaction solution was stirred at room temperature for 3 hours. Purificaiton was performed on preparative high performance liquid chromatography (method D) to obtain the title compound (10 mg). ESI-MS (m/z):323.0[M+H]+.
  • Step 4: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl-(4-((S)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyl)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonazeza-3,9-diazapentatriacontamino)benzyl)carbonate
  • At room temperature, compound 33-1 (30 mg, 0.02 mmol) and compound 49-4 (9.08 mg, 0.03 mmol) were dissolved in dimethyl sulfoxide and water (2 mL/0.5 mL), and cuprous bromide (5.39 mg, 0.04 mmol) was added and reacted for 2 hours under stirring. After filtration, the filtrate was purified by preparative high performance liquid chromatography (method B) to obtain the title compound (20 mg). ESI-MS (m/z): 1647.3[M+H-273]+.
  • Step 5: synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((2-(2-((methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • At room temperature, compound 49-5 (20 mg, 0.01 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.2 mL) was added dropwise. The obtained reaction solution was stirred at room temperature for 20 min. The reaction solution was then concentrated. The residue was purified by preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (8 mg). ESI-MS (m/z): 1647.9[M+H]+.
    • Example 20: 4-((S)-2-(4-aminobutyric acid)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)-oxazol-4-formylamino)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Figure US20230357259A1-20231109-C00770
  • Step 1: synthesis of ethyl 2-(2-(methylthio)pyrimidin-5-yl)oxazol-4-carboxylate
  • At 25° C., ethyl 2-bromooxazol-4-carboxylate (100 mg, 0.45 mmol) and compound 49-1 (126 mg, 0.50 mmol) were dissolved in a mixed solvent of 1,4-dioxane and water (4 mL/2 mL), then potassium carbonate (125 mg, 0.9 mmol) and [1,1′-bis(diphenylphosphino)ferrocen]palladium dichloride (33 mg, 0.05 mmol) were successively added, under N2 protection, the mixture was heated to 90° C. and reacted for 3 hours. The reaction solution was filtered through diatomite. The filtrate was diluted with water (50 mL) and extracted with ethyl acetate (30 mL×3). The organic phases were combined and dried. The desiccant was removed by filtration, the filtrate was concentrated under reduced pressure to obtain a crude product which was purified by preparative thin layer chromatography (petroleum ether/ethyl acetate =2/1) to obtain the title compound (40 mg). ESI-MS (m/z):266.1[M+H]+.
  • Step 2: synthesis of 2-(2-(methylthio)pyrimidin-5-yl)oxazol-4-carboxylic acid
  • At 25° C., compound 50-1 (50 mg, 0.19 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (4 mL/2 mL), after complete dissolution, lithium hydroxide monohydrate (40 mg, 0.94 mmol) was added thereto and reacted at 25° C. for 1 h. The reaction solution was diluted with water (15 mL) and extracted with ethyl acetate (20 mL× 2). The aqueous phase was adjusted with 1N dilute hydrochloric acid to pH=2-3, then extracted with a mixed solvent of dichloromethane/methanol (v:v=10:1) (20 mL×3). The organic phases were combined, washed with saturated saline (30 mL×1) and dried over anhydrous sodium sulfate. The desiccant was removed by filtration and the filtrate was concentrated to obtain the title compound (40 mg), which was directly used in further reaction without purification. ESI-MS (m/z):238.1 [M+H]+.
  • Step 3: synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)oxazol-4-carboxylic acid
  • At 25° C., compound 50-2 (40 mg, 0.17 mmol) was dissolved in dichloromethane (6 mL), after complete dissolution, m-chloroperoxybenzoic acid (29 mg, 0.17 mmol) was added thereto and reacted at 25° C. for 14 hours under stirring. The reaction solution was concentrated, and the residue was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (20 mg). ESI-MS (m/z):269.9[M+H]+.
  • Step 4: synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)-oxazol-4-formamide
  • At 25° C., compound 50-3 (20 mg, 0.07 mmol) was dissolved in dichloromethane (4 mL), then O-(7-azabenzotriazol-1-yl)-N,N,N′,N′- tetramethyluronium hexafluorophosphate (42 mg, 0.11 mmol) and N,N-diisopropylethylamine (19 mg, 0.15 mmol) were successively added and stirred for 5 min, followed by an addition of propargylamine (5.0 mg, 0.09 mmol) and then the resulting mixture was stirred at room temperature for 30 min. The reaction solution was concentrated, the residue was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (5.0 mg). ESI-MS (m/z): 306.9 [M+H]+.
  • Step 5: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)oxazol-4-formylamino)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl)carbonate
  • At 25° C., compound 50-4 (6.0 mg, 0.02 mmol) and compound 33-1 (30 mg, 0.02 mmol) were dissolved in a mixed solvent (2 mL/0.5 mL) of dimethyl sulfoxide and water, and cuprous bromide (5.0 mg, 0.04 mmol) was added in one batch. The resulting mixture was reacted at room temperature for 2 hours. The reaction solution was filtered and purified by preparative high performance liquid chromatography (method B) to obtain the title compound (25 mg). ESI-MS (m/z): 1631.3[(M-273+H]+.
  • Step 6: synthesis of 4-((S)-2-(4-aminobutyric acid)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)oxazol-4-formylamino)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • At 25° C., compound 50-5 (20 mg, 0.01 mmol) was dissolved in dichloromethane (2.0 mL). After complete dissolution, the reaction mixture was added with trifluoroacetic acid (0.2 mL) and reacted at 25° C. for 10 min. The reaction solution was concentrated, and the residue was purified by preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (3.0 mg). ESI-MS (m/z):816.5[M/2 + H]+.
    • Example 21: N-((1-((6S,9S)-1-amino-6-((4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,SS)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanamido)methyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetraoxy-13,19,22,25,28,31,34,37,40-nonaoxa-2,7,10,16-tetraazaanthracen-42-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide
  • Figure US20230357259A1-20231109-C00771
  • Step 1: synthesis of 9-fluorenylmethyl ((S)-1-(((S)-1-((4-(((S)2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butyrylamido)-N,3-dimethylbutyrylamido)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo-5-ureidopent-2-yl)amino)-3-methyl-1-oxobutan-2-yl) carbamate
  • At room temperature, compound 51-1 (100 mg, 0.17 mmol) and 9-fluorenylmethyl ((S)-1-(((S)-1-((4-(((S)-2-amino-3-phenylpropanamido)methyl)phenyl)amino)-1-oxo-5-pentylureido-2-yl)amino)-3-methyl-1-oxobutan-2-yl) carbamate trifluoroacetate (144 mg, 0.17 mmol) were dissolved in N,N-dimethylformamide (2 mL) and cooled to 0° C., then 1-hydroxybenzotriazole (34 mg, 0.25 mmol), N-methylmorpholine (51 mg, 0.51 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride(48 mg, 0.25 mmol) were successively added. After addition, the reaction solution was stirred at 0° C. for 5 hours. The reaction solution was poured into water (20 mL) to precipitate a white solid, followed by suction filtration. The filter cake was washed and dried to obtain the title compound (200 mg). ESI-MS (m/z): 1329.2 [M + H]+.
  • Step 2: synthesis of (S)-2-((S)-2-amino-3-butyrylamino)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrro-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-5-ureidovaleramide
  • At room temperature, compound 51-2 (200 mg, 0.12 mmol) was dissolved in N, N-dimethylformamide (5 mL), and piperidine (0.5 mL) was added. The reaction solution was stirred at room temperature for 2 hours, and then purified by preparative high performance liquid chromatography (method D) to obtain the title compound (65 mg). ESI-MS (m/z): 1107.2 [M + H]+.
  • Step 3: synthesis of (S)-2-((S)-35-azido-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanamido)methyl)phenyl)-5-ureidovaleramide
  • 32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azatricarboxylic acid (33.1 mg, 0.06 mmol) was dissolved in N,N-dimethylformamide (5 mL), then O-(7-azabenzotriazol)-N,N,N,N-tetramethyluronium hexafluorophosphate (38 mg, 0.10 mmol) and N,N-diisopropylethylamine (26 mg, 0.20 mmol) were added. The reaction solution was stirred at room temperature for 10 min, then cooled to 0° C., and added with compound 51-3 (55 mg, 0.05 mmol). The reaction solution was stirred at room temperature for 2 hours, and purified by preparative high performance liquid chromatography (method D) to obtain the title compound (56 mg). ESI-MS (m/z): 821.8 [M/2 + H]+.
  • Step 4: synthesis of N-((1-((6S,9S)-1-amino-6-((4-(((S)-2-((2R,3R)-3-((S)1-((3R,4S,SS)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanamido)methyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetraoxy-13,19,22,25,28,31,34,37,40-nonaoxa-2,7,10,16-tetraazaanthracen-42-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide
  • At room temperature, compound 51-4 (56 mg, 0.04 mmol) and 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)-5-hexynamide (16 mg, 0.05 mmol) were dissolved in a mixed solution of dimethyl sulfoxide and water (2 mL/0.5 mL), and cuprous bromide (10 mg, 68.17 umol) was added. The obtained mixture was stirred for 2 hours, and then filtered. The filtrate was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (50 mg). ESI-MS (m/z): 974.3[M/2+H]+.
    • Example 22: 4-((2S,5S)-5-isopropyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7,1 1-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonaoxa-3,6,12-triazadotetracontyl)benzyl-((S)-1-(((S)-1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
  • Figure US20230357259A1-20231109-C00772
  • Step 1: 4-((2S,SS)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonaoxa-3,6, 12-triazadotetracontyl)benzyl-((S)-1-(((S)1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
  • At room temperature, compound 53-1 (100 mg, 0.09 mmol) was dissolved in N,N-dimethylformamide (3 mL), then 1-hydroxybenzotriazole (13 mg, 0.09 mmol), N,N-diisopropylethylamine (36 mg, 0.28 mmol) and compound 52-1 (67 mg, 0.09 mol) were added. The reaction solution was stirred at room temperature for 16 hours, and then purified by preparative high performance liquid chromatography (method D) to obtain the title compound (120 mg). ESI-MS (m/z): 830.1[M/2+H]+.
  • Step 2: synthesis of 4-((2S,5S)-5-isopropyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,7, 11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonaoxa-3,6, 12-triazadotetracontyl)benzyl-((S)-1-(((S)-1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
  • At room temperature, compound 52-2 (22 mg, 0.07 mmol) was dissolved in a mixed solution of dimethyl sulfoxide and water (3 mL/0.3 mL), then cuprous bromide (18 mg, 0.13 mmol) was added and stirred for 1 h. The reaction solution was filtered. The filtrate was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (92 mg). ESI-MS (m/z): 982.8[M/2+H]+.
    • Example 23: Synthesis of (S)-2-((2R,3R)-3-((2S)-1-((3R,4S,SS)-4-((S)-N,3-dimethyl-2-((S)-3-methyl2-(methyl(((4-((S)-2-((S)-3-methyl-2-(32-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-carbamoyl)methyl)-1H-1,2,3-triazol-1-yl)-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azatriacontamino)butyrylamino)-5-ureidovalerylamino)benzyl)oxy)carbonyl)amino)butyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionyl)-L-phenylalanine
  • Figure US20230357259A1-20231109-C00773
  • Step 1: synthesis of 4-((2S,5S)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-nonoxy-\3,6,12-triazaoctatriacontamino)benzyl-(4-nitrophenyl)-carbonate
  • \\At 25° C., compound 29-1 (500 mg, 0.55 mmol) was dissolved in N,N-dimethylformamide (10 mL), and added with N,N-diisopropylethylamine (141 mg, 1.09 mmol), then followed by a dropwise addition of a solution of di(p-nitrobenzol)carbonate (332 mg, 1.09 mmol) in dichloromethane (1 mL). After the addition, the mixture was reacted at 25° C. for 3 hours under stirring. The reaction solution was purified by reverse column (C18) chromatography (acetonitrile/water=1:2) to obtain the title compound (400 mg). ESI-MS (m/z):1081.9[M+H]+.
  • \\\Step 2: synthesis of (S)-2-((2R\,3R)-3-((2S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-((((4-((S)-2-((S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azatriacontamido)-3-methylbutyrylamino)-5-ureidopentanoylamino)benzyl)oxy)carbonyl)(methyl)amino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionyl)-L-phenylalanine
  • At 25° C., compound 53-1 (60 mg, 0.06 mmol) and ((2R)-3-((2S)-1-((3R, 5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butyrylamino)butyrylamino)-3-methoxy-5-methylheptyl)pyrrolidine-2-yl)-3-methoxy-2-methypropionyl)-L-phenylalanine (41 mg, 0.06 mmol) were dissolved in N,N-dimethylformamide (2 mL). After complete dissolution, 1-hydroxybenzotriazole (8 mg, 0.06 mmol) was added. After the addition, the mixture was stirred at 25° C. for 16 hours. The reaction solution was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (38 mg). ESI-MS (m/z): 837.2[M/2+H]+.
  • Step 3: synthesis of (S)-2-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl2-(methyl(((4-((S)-2-((S)-3-methyl-2-(32-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-carbamoyl)methyl)-1H-1,2,3-triazol-1-yl)-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azatriacontamino)butyrylamino)-5-ureidovalerylamino)benzyl)oxy)carbonyl)amino)butyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionyl)-L-phenylalanine
  • At 25° C., 2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)-oxazol-4-formamide (9 mg, 0.03 mmol) and compound 53-2 (50 mg, 0.03 mmol) were dissolved in a mixed solvent of dimethyl sulfoxide and water (1 mL/0.25 mL). After complete dissolution, cuprous bromide (11 mg, 0.08 mmol) was added. After the addition, the mixture was stirred for 1 h under N2 protection. Filtration was then conducted, and the filtrate was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (25 mg). ESI-MS (m/z): 989.9[M/2+H]+.
    • Example 24: 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl-((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
  • Figure US20230357259A1-20231109-C00774
  • Step 1: synthesis of (S)-4-(35-azido-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyryl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl-(4-nitrophenyl)-carbonate
  • At room temperature, compound 54-1 1 g, 0.95 mmol) was dissolved in dichloromethane (20 ml), then added with N,N-diisopropylethylamine (488 mg, 3.77 mmol), followed by a dropwise addition of a solution of di-(p-nitrophenyl)-carbonate (860 mg, 2.83 mmol) in dichloromethane (10 mL). The resulting reaction solution was stirred at room temperature for 6 hours and purified by silica gel column chromatography (dichloromethane/methanol=40/1) to obtain the title compound (900 mg). ESI-MS (m/z): 953.0[M+H-273]+.
  • Step 2: synthesis of 4-((S)-35-azide-2-(4-(((4-methoxyphenyl) benzhydryl)amino)butyryl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl((S)-1-(((S)-1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
  • At room temperature, to compound 54-2 (2 ml) were added 1-hydroxybenzotriazole (33 mg, 0.25 mmol), N, N-diisopropylethylamine (48 mg, 0.37 mmol), and then compound 52-1 (88 mg, 0.12 mmol). The obtained reaction solution was stirred at room temperature for 16 hours and then purified by preparative high performance liquid chromatography (method B) to obtain the title compound (150 mg). ESI-MS (m/z): 1803.6[M+H]+.
  • Step 3: synthesis of 4-((S)-2-(4-(((4-methoxyphenyl)benzhydryl)amino)butyryl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl((S)-1-(((S)-1-(((3R,4S,SS)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
  • At room temperature, compound 54-3 (100 mg, 0.06 mmol) and 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)-5-hexynamide (26 mg, 0.08 mmol) were dissolved in dimethyl sulfoxide (2 mL) and water (0.5 mL), then cuprous bromide (16 mg, 0.11 mmol) was added and stirred for 2 hours. Filtration was then performed, and the filtrate was purified by preparative high performance liquid chromatography (method B) to obtain the title compound (70 mg). ESI-MS (m/z): 1936.6[M+H-273]+.
  • Step 4: synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamino)benzyl-((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxypropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxyheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
  • At room temperature, compound 54-4 (70 mg, 0.04 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.2 mL) was added dropwise. The obtained reaction solution was stirred at room temperature for 20 min, then concentrated, and the residue was purified by preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (55 mg). ESI-MS (m/z): 918.8[M/2+H]+.
    • Example 25: Synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((4-(2-(methylsulfonyl)pyrimidin-5-yl)benzamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3\′\,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • Figure US20230357259A1-20231109-C00775
  • Step 1: synthesis of methyl 4-(2-(methylthio)pyrimidin-5-yl)benzoate
  • At 25° C., compound 49-1 (252 mg, 1.0 mmol), water (3 mL), Pd(dppf)Cl2 (40 mg, 0.05 mmol) and potassium carbonate (277 mg, 2.0 mmol) were added successively to a solution of methyl p-bromobenzoate (215 mg, 1.0 mmol) in 1,4-dioxane (5 mL) and stirred at 80° C. for 4 hours. The reaction solution was extracted with ethyl acetate (30 mL×3). The organic phases were combined and dried, then the insoluble substances were removed by filtration, and the residue was purified by silica gel column chromatography to obtain the title compound (220 mg). ESI-MS (m/z):261.0[M+H]+.
  • Step 2: synthesis of 4-(2-(methylthio)pyrimidin-5-yl)benzoic acid
  • At 25° C., lithium hydroxide monohydrate (322 mg, 7.68 mmol) and water (3 ml) were respectively added to a solution of compound 55-1 (500 mg, 1.92 mmol) in tetrahydrofuran (3 ml) and stirred for 4 hours. The reaction solution was adjusted with 1N hydrochloric acid to pH=3-4, and extracted with ethyl acetate (20 mL×3). The organic phases were combined and dried. The insoluble substances were removed by filtration, and the residue was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (430 mg). ESI-MS (m/z):246.9[M+H]+.
  • Step 3: synthesis of 4-(2-(methylsulfonyl)pyrimidin-5-yl)benzoic acid
  • At 25° C., m-chloroperoxybenzoic acid (420 mg, 2.44 mmol) was added to a solution of compound 55-2 (200 mg, 0.81 mmol) in dichloromethane (5 ml), and stirred for 5 hours, and then purified by silica gel column chromatography to obtain the title compound (180 mg). ESI-MS (m/z):279.0[M+H]+.
  • Step 4: synthesis of 4-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)benzamide
  • At 25° C., benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate (100 mg, 0.26 mmol) was added to a solution of compound 55-3 (50 mg, 0.18 mmol) in dichloromethane (10 mL), and stirred for 30 min, then propynylamine (10 mg, 0.2 mmol) and N,N-diisopropylethylamine (70 mg, 0.5 mmol) were added to the reaction solution and reacted for 2.5 h under stirring. The reaction solution was purified by silica gel column chromatography to obtain the title compound (20 mg). ESI-MS (m/z):316.0[M+H]+.
  • Step 5: synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((4-(2-(methylsulfonyl)pyrimidin-5-yl)benzamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl)carbonate
  • At 25° C. and under N2 protection, cuprous iodide (10 mg, 0.05 mmol) and water (2 mL) were successively added to dimethyl sulfoxide solution (2 mL) of compound 55-4 (16 mg, 0.05 mmol) and compound 33-1 (80 mg, 0.05 mmol) and reacted for 1 h under stirring. Purificaiton (method B) was performed to obtain the title compound (79 mg). ESI-MS (m/z): 1641.5[M-273+H]+.
  • Step 6: synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((4-(2-(methylsulfonyl)pyrimidin-5-yl)benzamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonoxy-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-\3,14-dioxo-\3,4,12,14-tetrahydro-1H-pyrano[3\′\,4′:6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
  • At 25° C., compound 55-5 (55 mg, 0.029 mmol) was added to trifluoroacetic acid (0.5 mL) in a mixed solvent of water/acetonitrile (0.1 mL/0.5 mL), and reacted for 15 min under stirring. The reaction solution was purified by preparative high performance liquid chromatography (method C) to obtain the trifluoroacetate of the title compound (42 mg). ESI-MS (m/z):821.0[M/2+H]+.
    • Example 26: N-((1-((6S,9S)-1-amino-6-((4-((S)-3-azido-2-((2R,3R)-3-((S)-1-((3R,4S,SS)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetraoxo-13,19,22,25,28,31,34,37,40-nonoxy-2,7,10,16-tetraazadotetracont-42-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide
  • Figure US20230357259A1-20231109-C00776
  • Step 1: synthesis of 32-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azadotriacontanoic acid
  • At 20° C., compound 56-1 (750 mg, 1.28 mmol) and 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)hex-5-ynylamide (496 mg, 1.54 mmol) were dissolved in dimethyl sulfoxide (10 mL), and cuprous bromide (465 mg, 3.21 mmol) was added in one batch. After the addition, the mixture was reacted for 12 hours under stirring. The reaction solution was filtered, and the filtrate was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (500 mg). ESI-MS (m/z): 860.4[M+H]+.
  • Step 2: synthesis of (9H-fluoren-9-yl)methyl((S)-1-(((S)-1-((4-((S)-3-azido-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)amino)-1-oxo-5-ureidopentanoylamino-2-yl)amino)-3-methyl-1 -oxobutan-2-yl)carbamate
  • At 25° C., (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((S)-1-(4-aminophenyl)-3-azidopropyl-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptyl-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamine(185 mg, 0.24 mmol) was dissolved in N,N-dimethylformamide (5 mL), then HATU (137 mg, 0.36 mmol) was added and stirred for 5 min, followed by an addition of (S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutyrylamino)-5-ureidopentanoic acid (131 mg, 0.26 mmol). The mixture was stirred at room temperature for 30 min. The reaction solution was directly used in further reaction. ESI-MS (m/z): 626.0[M/2+H]+.
  • Step 3: synthesis of (S)-2-((S)-2-amino-3-methylbutyrylamino)-N-(4-((S)-3-azido-2-((2R,3R)-3-((S)-l-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)-5-ureidovaleramide
  • At 25° C., diethylamine (0.5 mL) was added to the reaction solution obtained in step 2, and stirred for reaction for 30 min after the addition. The reaction solution was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (70 mg). ESI-MS (m/z): 515.0[M/2+H]+.
  • Step 4: synthesis of N-((1-((6S,9S)-1-amino-6-((4-((S)-3-azido-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetraoxo-13,19,22,25,28,31,34,37,40-nonoxy-2,7,10,16-tetraazadotetracont-42-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide
  • At 25° C., (S)-2-((S)-2-amino-3-methylbutyrylamino)-N-(4-((S)-3-azido-2-((2R,3R)-3-((S)- 1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)-5-ureidovaleramide (95 mg, 0.092 mmol) and 32-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl)-5-oxo-3,9,12,15,18,21,24,27,30-nonoxy-6-azadotriacontanic acid (79 mg, 0.092 mmol) were dissolved in N,N-dimethylformamide (4 mL), and HATU (70 mg, 0.184 mmol) was added in one batch. The mixture was stirred at room temperature for 1 h. The reaction solution was purified by preparative high performance liquid chromatography (method D) to obtain the title compound (30 mg). ESI-MS (m/z): 935.8[M/2+H]+.
    • III. Coupling of the Compound Containing the Bioactive Molecule and the Linker With an Antibody Example 27: Preparation of BT001002
  • 0.3 mL of antibody Sacituzumab (anti-Trop-2, 33.5 mg/mL) was diluted with 0.25 ml of a solution (pH 7.6) containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, to which 0.45 ml of a solution (pH 7.6) containing 20 mM PB and 150 mM NaCl was added and evenly mixed. The mixture was adjusted with 1 M K2HPO4 solution to pH=7.4, and then 10 mM TCEP (tris(2-carboxyethyl)phosphine) solution was added and evenly mixed, which was allowed to stand at room temperature for 30 min. To the solution system, TL003 dissolved in dimethyl sulfoxide was added in an amount of 15 equiv. and evenly mixed, which was allowed to stand at room temperature for 2 hours. After the addition, 6.1 µl of 100 mM cysteine was added to terminate the reaction. At last, the buffer was replaced with a 20 mM PB buffer solution of pH 6.44 by G-25 gel column to obtain the coupling product of TL003 with Sacituzumab, which was named as BT001002.
    Figure US20230357259A1-20231109-C00777
    • Example 28: Preparation of BT001004
  • 0.285 mL of Sacituzumab (anti-Trop-2, 17.6 mg/mL) was diluted with 0.095 mL of a diluent (a solution containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, pH 7.6). Then the diluted solution was adjusted with 1 M Na2HPO4 solution to pH 7.4, and 10 mM TCEP solution was added and evenly mixed, which was allowed to stand at room temperature for 30 min. To the solution system, TL019 dissolved in dimethyl sulfoxide was added in an amount of 9 equiv. and evenly mixed, which was allowed to stand at room temperature for 2 h. At last, the buffer was replaced with a PBS buffer solution of pH 6.5 by G-25 gel column to obtain the coupling product of TL019 with Sacituzumab, which was named as BT001004.
    Figure US20230357259A1-20231109-C00778
    • Example 29: Preparation of BT001012
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL024 with Sacituzumab, which was named as BT001012, except that TL003 was replaced by trifluoroacetate of TL024.
    Figure US20230357259A1-20231109-C00779
    • Example 30: Preparation of BT001013
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL048 with Sacituzumab, which was named as BT001013, except that TL003 was replaced by trifluoroacetate of TL048.
    Figure US20230357259A1-20231109-C00780
    • Example 31: Preparation of BT001018
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL030 with Sacituzumab, which was named as BT001018, except that TL003 was replaced by TL030.
    Figure US20230357259A1-20231109-C00781
    • Example 32: Preparation of BT001021
  • 0.3 mL of Sacituzumab (anti-Trop-2, 33.5 mg/mL) was diluted with 0.25 ml of a solution (pH 7.6) containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, then 0.45 mL of a solution (pH 7.6) containing 20 mM PB and 150 mM NaCl was added and evenly mixed. The mixture was adjusted with 1 M Na2HPO4 solution to pH=7.4, then 10 mM TCEP (tris(2-carboxyethyl)phosphine) solution was added and evenly mixed, which was allowed to stand at room temperature for 30 min. To the solution system, trifluoroacetate of TL033 dissolved in dimethyl sulfoxide was added in an amount of 10 equiv. and evenly mixed, which was allowed to stand at room temperature for 2 hours. Then 6.1µl of 100 mM cysteine was added to terminate the reaction. At last, the buffer was replaced by a PBS buffer solution of pH 6.5 by G-25 gel column to obtain the coupling product of TL033 with Sacituzumab, which was named as BT001021.
    Figure US20230357259A1-20231109-C00782
    • Example 33: Preparation of BT001022
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL034 with Sacituzumab, which was named as BT001022, except that TL003 was replaced by trifluoroacetate of TL034.
    Figure US20230357259A1-20231109-C00783
    • Example 34: Preparation of BT001023
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL035 with Sacituzumab, which was named as BT001023, except that TL003 was replaced by trifluoroacetate of TL035.
    Figure US20230357259A1-20231109-C00784
    • Example 35: Preparation of BT001032
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL045 with Sacituzumab, which was named as BT001032, except that TL003 was replaced by trifluoroacetate of TL045.
    Figure US20230357259A1-20231109-C00785
    • Example 36: Preparation of BT001033
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL033 with antibody M1, which was named as BT001033, except that TL003 was replaced by trifluoroacetate of TL033 and Sacituzumab was replaced by antibody M1.
    Figure US20230357259A1-20231109-C00786
    • Example 37: Preparation of BT001034
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL033 with antibody M2, which was named as BT001034, except that TL003 was replaced by trifluoroacetate of TL033 andSacituzumab was replaced by antibody M2.
    Figure US20230357259A1-20231109-C00787
    • Example 38: Preparation of BT001035
  • 0.3 mL of antibody M3 (anti-Trop-2, 33.5 mg/mL) was diluted with 0.25 ml of a solution (pH 7.6) containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, then 0.45 mL of a solution (pH 7.6) containing 20 mM PB and 150 mM NaCl was added and evenly mixed. The mixture was adjusted with 1 M Na2HPO4 solution to pH=7.4, then 10 mM TCEP (tris(2-carboxyethyl)phosphine) solution was added and evenly mixed, which was allowed to stand at room temperature for 30 min. To the solution system, trifluoroacetate of TL033 dissolved in dimethyl sulfoxide was added in an amount of 10 equiv. and evenly mixed. The resulting mixture was allowed to stand at room temperature for 2 hours. Then 6.1 µl of 100 mM cysteine was added to terminate the reaction. At last, the buffer was replaced with a PBS buffer solution of pH 6.5 by G-25 gel column to obtain a coupling product of TL033 with antibody M3, which was named as BT001035.
    Figure US20230357259A1-20231109-C00788
    • Example 39: Preparation of BT001036
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL033 with Trastuzumab, which was named as BT001036, except that TL003 was replaced by trifluoroacetate of TL033 and Sacituzumab was replaced by Trastuzumab.
    Figure US20230357259A1-20231109-C00789
    • Example 40: Preparation of BT001040
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL049 with Sacituzumab, which was named as BT001040, except that TL003 was replaced by trifluoroacetate of TL049.
    Figure US20230357259A1-20231109-C00790
    • Example 41: Preparation of BT001041
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL050 with Sacituzumab, which was named as BT001041, except that TL003 was replaced by trifluoroacetate of TL050.
    Figure US20230357259A1-20231109-C00791
    • Example 42: Preparation of BT001042
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL051 with Sacituzumab, which was named as BT001042, except that TL003 was replaced by TL051.
    Figure US20230357259A1-20231109-C00792
    • Example 43: Preparation of BT001043
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL052 with Sacituzumab, which was named as BT001043, except that TL003 was replaced by TL052.
    Figure US20230357259A1-20231109-C00793
    • Example 44: Preparation of BT001044
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL053 with Sacituzumab, which was named as BT001044, except that TL003 was replaced by TL053.
    Figure US20230357259A1-20231109-C00794
    • Example 45: Preparation of BT001045
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL054 with Sacituzumab, which was named as BT001045, except that TL003 was replaced by trifluoroacetate of TL054.
    Figure US20230357259A1-20231109-C00795
    • Example 46: Preparation of BT001046
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL055 with Sacituzumab, which was named as BT001046, except that TL003 was replaced by trifluoroacetate of TL055.
    Figure US20230357259A1-20231109-C00796
    • Example 47: Preparation of BT001047
  • A method similar to that described in example 27 was adopted to obtain the coupling product of TL056 with Sacituzumab, which was named as BT001047, except that TL003 was replaced by TL056.
    Figure US20230357259A1-20231109-C00797
    • Example 48: Determination of Molecular Weight of BT001002 by LC-MS
  • The molecular weight of BT001002 obtained by coupling was analyzed by LC-MS. LC conditions:
    • Liquid chromatographic column: ACQUITU UPLC® Protein BEH C4 1.7 µm, 2.1mm x 100 mm;
    • Mobile phase A: 0.1%FA/98%H2O/2%ACN; Mobile phase B: 0.1%FA/2%H2O/98%ACN;
    • Flow rate: 0.25 mL/min; Sample room temperature: 8° C.; Column temperature: 60° C.; Sample size: 1 µg;
  • Time (min.) 1 7 8 9 13
    Mobile phase A (%volume) 90 20 20 90 90
    Mobile phase B (%volume) 10 80 80 10 10
  • MS conditions:
    • Mass spectrometer model: Triple TOF 5600+;
    • GS160; GS2 60; CUR30; TEM600; ISVF5000; DP300; CE10 m/z600-5000;
  • Results were shown in FIGS. 1-3 .
  • Theoretical molecular weight and measured molecular weight of BT001002
    Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.0 24610.7 25887.3 27163.9 28440.5
    Measured value Not detected 24611.1 Not detected Not detected Not detected
    HC Theoretical value 50734.0 52010.6 53287.2 54563.8 55840.4
    Measured value Not detected Not detected Not detected 54563.1 Not detected
  • In the table, mAb stands for a monoclonal antibody; LC stands for the light chain of an antibody; HC stands for the heavy chain of an antibody; DAR1 stands for a conjugate containing a light chain/heavy chain of an antibody and a bioactive molecule; DAR2 stands for a conjugate containing a light chain/heavy chain of an antibody and two bioactive molecules; DAR3 stands for a conjugate containing a light chain/heavy chain of an antibody and three bioactive molecules; DAR4 stands for a conjugate containing a light chain/heavy chain of an antibody and four bioactive molecules; glycoform stands for the structure of glycan of the two heavy chains: G0F stands for fucosylation and free of galactosylation. The mAb, LC, HC, DAR1, DAR2, DAR3, DAR4, and G0F hereinafter are as described above.
  • As can be seen from FIGS. 1-3 , both the molecular weights of the light chain and the heavy chain of the antibody are changed after being coupled with TL003, wherein the light chain was coupled with 1 bioactive molecule and the heavy chain was coupled with 3 bioactive molecules. Therefore, it could be inferred that the DAR of the antibody to the bioactive molecule was 8.
    • Example 49: Determination of Molecular Weight of BT001004 by LC-MS
  • The molecular weight of BT001004 obtained from coupling was analyzed by LC-MS.
  • LC conditions:
    • Liquid chromatographic column: ACQUITU UPLC® Protein BEH C18 1.7 µm, 2.1 mm × 100 mm;
    • Mobile phase A: 0.1%FA/98%H2O/2% ACN; Mobile phase B: 0.1%FA/2%H2O/98% ACN;
    • Flow rate: 0.25 mL/min; Sample room temperature: 8° C.; Column temperature: 60° C.; Sample size: 1 µg;
  • Time (min.) 2 20 22 25 26 30
    Mobile phase A (%volume) 80 60 10 10 80 80
    Mobile phase B (%volume) 20 40 90 90 20 20
  • MS conditions:
    • Mass spectrometer model: Triple TOF 5600+;
    • GS160; GS2 60; CUR30; TEM 350; ISVF5500; DP300; CE10; m/z 600-5000;
  • Results were shown in FIGS. 4-6 .
  • Theoretical molecular weight and measured molecular weight of BT001004
    Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24832.7 26331.4 27830.0 29328.7
    Measured value 23334.9 24833.7 Not detected Not detected Not detected
    HC Theoretical value 50734.0 52232.6 53731.3 55230.0 56728.6
    Measured value Not detected 52232.1 53730.8 55229.3 Not detected
  • LC stands for the light chain of an antibody; and HC stands for the heavy chain of an antibody.
  • As can be seen from FIGS. 4-6 , in BT001004, the light chain of the antibody was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 14% and 86%, respectively), and the heavy chain was coupled with 1-3 bioactive molecules (DAR1, DAR2 and DAR3 accounted for 13%, 19% and 68%, respectively). Therefore, it could be calculated that the DAR of the antibody to the bioactive molecule was 7.0.
    • Example 50: Determination of Molecular Weight of BT001012 by LC-MS
  • A method similar to that as described in example 48 was adopted, and results were shown in FIGS. 10 and 11 .
  • The theoretical molecular weight and measured molecular weight of the light chain and heavy chain of BT001012 obtained by coupling TL024 and the antibody (calculated from main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24803.7 26273.4 27743.0 29212.7
    Measured value 23334.8 24804.6 Not detected Not detected Not detected
    HC Theoretical value 50734.0 52203.6 53673.3 55143.0 56612.6
    Measured value Not detected 52203.0 53672.2 55141.8 Not detected
  • As can be seen from FIGS. 10 and 11 , in BT001012, the light chain of the antibody was coupled with 0-1 toxin (LC and DAR1 accounted for 12.9% and 87.1%, respectively), and the heavy chain was coupled with 1-3 toxins (DAR1, DAR2 and DAR3 accounted for 13.4%, 10.8% and 75.8%, respectively). Therefore, it could be calculated that the DAR of the antibody to toxins was 7.0.
    • Example 51: Determination of Molecular Weight of BT001013 by LC-MS
  • A method similar to that as described in example 48 was adopted, and results were shown in FIGS. 12 and 13 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001013 obtained from coupling TL048 and the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24767.7 26201.3 27634.9 29068.5
    Measured value 23334.6 24768.6 Not detected Not detected Not detected
    HC Theoretical value 50734.0 52167.6 53601.2 55034.8 56468.4
    Measured value Not detected 52166.9 53600.8 55034.3 56468.2
  • As can be seen from FIGS. 12 and 13 , in BT001013, the light chain of the antibody was coupled with 0-1 toxin (LC and DAR1 accounted for 6.8% and 93.2%, respectively), and the heavy chain was coupled with 1-4 toxins (DAR1, DAR2, DAR3 and DAR4 accounted for 12.8%, 12.8%, 64.9% and 9.5%, respectively). Therefore, it could be calculated that the DAR of the antibody to toxins was 7.3.
    • Example 52: Determination of Molecular Weight of BT001018 by LC-MS
  • A method similar to that as described in example 48 was adopted, and results were shown in FIGS. 14 and 15 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001018 obtained from coupling TL030 and the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24926.8 26519.6 28112.3 29705.1
    Measured value 23335.6 24928.2 Not detected Not detected Not detected
    HC Theoretical value 50734.0 52326.7 53919.5 55512.3 57105.0
    Measured value 50736.3 52328.0 53920.7 55513.3 Not detected
  • As can be seen from FIGS. 14 and 15 , in BT001018, the light chain of the antibody was coupled with 0-1 toxin (LC and DAR1 accounted for 55.3% and 44.7%, respectively), and the heavy chain was coupled with 1-3 toxins (DAR1, DAR2 and DAR3 accounted for 19.6%, 23.3% and 49.6%, respectively). Therefore, it could be calculated that the DAR of the antibody to toxins was 5.2.
    • Example 53: Determination of Molecular Weight of BT001021 by LC-MS
  • The molecular weight of the coupled BT001021 was analyzed by LC-MS.
  • LC conditions:
    • Liquid chromatographic column: ACQUITU UPLC® Protein BEH C4 1.7 µm, 2.1 mm × 100 mm;
    • Mobile phase A: 0.1%FA/98%H2O/2%ACN; Mobile phase B: 0.1%FA/2%H2O/98%ACN;
    • Flow rate: 0.25 mL/min; Sample room temperature: 8° C.; Column temperature: 60° C.; Sample size: 1 µg;
  • Time (min.) 1 7 8 9 13
    Mobile phase A (%volume) 90 20 20 90 90
    Mobile phase B (%volume) 10 80 80 10 10
  • MS conditions:
    • Mass spectrometer model: Triple TOF 5600+;
    • GS160; GS2 60; CUR30; TEM600; ISVF5000; DP300; CE10 m/z600-5000;
  • Results were shown in FIGS. 16 and 17 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001021 obtained from coupling TL033 and the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24884.8 26435.5 27986.3 29537.0
    Measured value 23334.6 24885.9 Not detected Not detected Not detected
    HC Theoretical value 50734.0 52284.7 53835.5 55386.2 56937.0
    Measured Not 52284.3 53834.5 55385.4 Not
    value detected detected
  • As can be seen from FIGS. 16 and 17 , in BT001021, the light chain of the antibody was coupled with 0-1 toxin (LC and DAR1 accounted for 4.5% and 95.5%, respectively), and the heavy chain wascoupled with 1-3 toxins (DAR1, DAR2 and DAR3 accounted for 15.3%, 17.6% and 67.1%, respectively). Therefore, it could be calculated that the DAR of the antibody to toxins was 6.9.
    • Example 54: Determination of Molecular Weight of BT001023 by LC-MS
  • A method similar to that as described in example 48 was adopted, and results were shown in FIGS. 18 and 19 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001023 obtained by coupling TL035 and the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24848.7 26363.4 27878.1 29392.7
    Measured value 23335.4 24850.2 Not detected Not detected Not detected
    HC Theoretical value 50733.98 52248.7 53763.3 55278.0 56792.7
    Measured value 50735.2 52249.1 53764.1 55278.6 Not detected
  • As can be seen from FIGS. 18 and 19 , in BT001023, the light chain of the antibody was coupled with 0-1 toxin (LC and DAR1 accounted for 15% and 85%, respectively), and the heavy chain was coupled with 0-3 toxins (HC, DAR1, DAR2 and DAR3 accounted for 6.7%, 16.7%, 12.7% and 63.9%, respectively). Therefore, it could be calculated that the DAR of the antibody to toxins was 6.4.
    • Example 55: Determination of Molecular Weight of BT001040 by LC-MS
  • The molecular weight of BT001040 obtained by coupling was analyzed by LC-MS.
    • Liquid chromatographic column: Thermo MabPacTM RP 4 µm, 3.0 mm* 100 mm
    • Mobile phase A: 0.1%FA/98%H2O/2% ACN; Mobile phase B: 0.1%FA/2%H2O/98% ACN
    • Flow rate: 0.25 mL/min; Sample room temperature: 8° C.; Column temperature: 60° C.; Sample size: 1 µg
  • Time (min.) 2 20 22 25 26 30
    Mobile phase A (%volume) 80 60 10 10 80 80
    Mobile phase B (%volume) 20 40 90 90 20 20
  • MS conditions:
    • Mass spectrometer model: Triple TOF 5600+
    • GS135; GS2 35; CUR30; TEM 350; ISVF5000; DP250; m/z 600-5000
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001040 obtained by coupling TL049 with the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24901.8 26469.5 28037.3 29605.0
    Measured value 23334.2 24902.8 Not detected Not detected Not detected
    HC Theoretical value 50733.98 52301.7 53869.5 55437.2 57005.0
    Measured value Not detected 52301.6 53869.2 55437.4 57005.3
  • As can be seen from FIGS. 20 and 21 , in BT001040, the light chain of the antibody was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 4.9% and 95.1%, respectively), and the heavy chain was coupled with 1-4 bioactive molecules (DAR1, DAR2, DAR3 and DAR4 accounted for 16.5%, 14.3%, 52.6% and 16.6%, respectively). Therefore, it could be calculated that the DAR of the antibody to bioactive molecules was 7.3.
    • Example 56: Determination of Molecular Weight of BT001041 by LC-MS
  • A method similar to that as described in example 55 was adopted, and results were shown in FIGS. 22 and 23 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001041 obtained by coupling TL050 with the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24885.7 26437.4 27989.1 29540.8
    Measured value 23334.5 24886.9 Not detected Not detected Not detected
    HC Theoretical value 50733.98 52285.7 53837.3 55389.0 56940.7
    Measured value Not detected 52285.2 53836.9 55389.1 56940.9
  • As can be seen from FIGS. 22 and 23 , the light chain of the antibody in BT001041 was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 10.5% and 89.5%, respectively), and the heavy chain was coupled with 1-4 bioactive molecules (DAR1, DAR2, DAR3 and DAR4 accounted for 21.3%, 14.8%, 57.9% and 6.0%, respectively). Therefore, it could be calculated that the DAR of the antibody to bioactive molecules was 6.8.
    • Example 57: Determination of Molecular Weight of BT001042 by LC-MS
  • A method similar to that as described in example 55 was adopted, and results were shown in FIGS. 24 and 25 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001042 obtained by coupling TL051 with the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 25202.3 27070.6 28938.9 30807.2
    Measured value 23335.2 25203.8 Not detected Not detected Not detected
    HC Theoretical value 50733.98 52602.3 54470.6 56338.9 58207.2
    Measured value Not detected 52602.8 54471.0 56339.8 Not detected
  • As can be seen from FIGS. 24 and 25 , the light chain of the antibody in BT001042 was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 14.9% and 85.1%, respectively), and the heavy chain was coupled with 1-3 bioactive molecules (DAR1, DAR2 and DAR3 accounted for 19.7%, 9.4% and 70.9%, respectively). Therefore, it could be calculated that the DAR of the antibody to bioactive molecules was 6.7.
    • Example 58: Determination of Molecular Weight of BT001043 by LC-MS
  • A method similar to that as described in example 55 was adopted, and results were shown in FIGS. 26 and 27 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001043 obtained by couplingTL052 with the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 25202.3 27100.6 28983.9 30867.2
    Measured value 23335.5 25221.1 Not detected Not detected Not detected
    HC Theoretical value 50733.98 52617.3 54500.6 56383.9 58267.2
    Measured value Not detected 52620.4 54505.8 56391.5 Not detected
  • As can be seen from FIGS. 26 and 27 , the light chain of the antibody in BT001043 was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 9.1% and 90.9%, respectively), and the heavy chain was coupled with 1-3 bioactive molecules (DAR1, DAR2 and DAR3 accounted for 20.1%, 11.4% and 68.4%, respectively). Therefore, it could be calculated that the DAR of the antibody to bioactive molecules was 6.8.
    • Example 59: Determination of Molecular Weight of BT001044 by LC-MS
  • A method similar to that as described in example 55 was adopted, and results were shown in FIGS. 28 and 29 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001044 obtained by coupling TL053 with the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 25233.3 27132.5 29031.8 30931.1
    Measured value 23335.5 25234.7 Not detected Not detected Not detected
    HC Theoretical value 50733.98 52633.2 54532.5 56431.7 58331.0
    Measured value Not detected 52634.1 54532.9 56432.1 Not detected
  • As can be seen from FIGS. 28 and 29 , in BT001044, the light chain of the antibody was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 23.0% and 77.0%, respectively), and the heavy chain was coupled with 1-3 bioactive molecules (DAR1, DAR2 and DAR3 accounted for 19.4%, 11.4% and 69.3%, respectively). Therefore, it could be calculated that the DAR of the antibody to bioactive molecules was 6.5.
    • Example 60: Determination of Molecular Weight of BT001046 by LC-MS
  • A method similar to that as described in example 55 was adopted, and results were shown in FIGS. 30 and 31 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001046 obtained by coupling TL055 with the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 24894.8 26455.5 28016.2 29577.0
    Measured value 23335.5 24896.7 Not detected Not detected Not detected
    HC Theoretical value 50733.98 52294.7 53855.4 55416.2 56976.9
    Measured value 50735.4 52296.1 53856.9 55418.0 Not detected
  • As can be seen from FIGS. 30 and 31 , in BT001046, the light chain of the antibody was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 33.8% and 66.2%, respectively), and the heavy chain was coupled with 0-3 bioactive molecules (DAR0, DAR1, DAR2 and DAR3 accounted for 21.9%, 6.1%, 9.6% and 62.3%, respectively). Therefore, it could be calculated that the DAR of the antibody to bioactive molecules was 5.6.
    • Example 61: Determination of Molecular Weight of BT001047 by LC-MS
  • A method similar to that as described in example 55 was adopted, and results were shown in FIGS. 32 and 33 .
  • The theoretical molecular weight and measured molecular weight of the light chain and the heavy chain of BT001047 obtained by coupling TL056 with the antibody (calculated based on main glycoform G0F) were shown in the table below:
  • Peptide chain mAb DAR1 DAR2 DAR3 DAR4
    LC Theoretical value 23334.04 25124.2 26914.4 28704.6 30494.8
    Measured value 23335.5 25126.3 Not detected Not detected Not detected
    HC Theoretical value 50733.98 52524.2 54314.3 56104.5 57894.7
    Measured value 50735.4 52524.6 54314.1 56106.5 Not detected
  • As can be seen from FIGS. 32 and 33 , in BT001047, the light chain of the antibody was coupled with 0-1 bioactive molecule (LC and DAR1 accounted for 13.7% and 86.3%, respectively), and the heavy chain was coupled with 1-3 bioactive molecules (DAR1, DAR2 and DAR3 accounted for 22.2%, 13.5% and 64.3%, respectively). Therefore, it could be calculated that the DAR of the antibody to bioactive molecules was 6.6.
    • Example 62: Size Exclusion Chromatography Analysis
  • The coupling reaction was monitored by SEC-HPLC, and the conjugates were tested by SEC.
  • Chromatographic conditions:
    • Liquid chromatographic column: TOSOH TSKgel SuperSW mAb, 4 µm, 7.8 mm × 300 mm;
    • Mobile phase: 100 mmol/L Na2HPO4, 100 mmol/L NaCl, 5% isopropanol, pH7.0;
    • Flow rate: 0.5 ml/min; Detection wavelength: 280 nm; Column temperature: room temperature; Sample room temperature: 8° C.;
    • Sample size: 30 µg; Isocratic operation: 30 min.
  • The SEC chromatogram and molecular weight Marker SEC chromatogram of BT001002 obtained by coupling TL003 with the antibody were shown in FIGS. 7 and 8 respectively. According to the molecular weight Marker, it is confirmed that the molecular weight of the main peak of the coupling product is about 150 kD, i.e., for BT001002 obtained by coupling TL003 with the antibody, the light chain and the heavy chain are not dissociated, and the antibody still maintains its integral structure.
  • The SEC chromatogram of BT001004 obtained by coupling TL019 with the antibody is shown in FIG. 9 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001004 obtained by coupling TL019 with the antibody still maintains the integral structure of the antibody.
  • The SEC chromatogram of BT001012 obtained by coupling TL024 with the antibody is shown in FIG. 34 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001012 obtained by coupling TL024 with the antibody still maintains the integral structure of the antibody.
  • The SEC chromatogram of BT001013 obtained by coupling TL048 with the antibody is shown in FIG. 35 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001013 obtained by coupling TL048 with the antibody still maintains an integral structure of the antibody.
  • The SEC chromatogram of BT001018 obtained by coupling TL030 with the antibody is shown in FIG. 36 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001018 obtained by coupling TL030 with the antibody still maintains an integral structure of the antibody.
  • The SEC chromatogram of BT001021 obtained by coupling TL033 with the antibody is shown in FIG. 37 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001021 obtained by coupling TL033 with the antibody still maintains an integral structure of the antibody.
  • The SEC chromatogram of BT001023 obtained by coupling TL035 with the antibody is shown in FIG. 38 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001023 obtained by coupling TL035 with the antibody still maintains an integral structure of the antibody.
  • The SEC chromatogram of BT001042 obtained by coupling TL051 with an antibody is shown in FIG. 39 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001042 obtained by coupling TL051 with the antibody still maintains the integral structure of the antibody.
  • The SEC chromatogram of BT001043 obtained by coupling TL052 with the antibody is shown in FIG. 40 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150kD, i.e., BT001043 obtained by coupling TL052 with the antibody still maintains the integral structure of the antibody.
  • The SEC chromatogram of BT001044 obtained by coupling TL053 with the antibody is shown in FIG. 41 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001044 obtained by coupling TL053 with the antibody still maintains the integral structure of the antibody.
  • The SEC chromatogram of BT001046 obtained by coupling TL055 with the antibody is shown in FIG. 42 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001046 obtained by coupling TL055 with the antibody still maintains the integral structure of the antibody.
  • The SEC chromatogram of BT001047 obtained by coupling TL056 with the antibody is shown in FIG. 43 . According to the retention time and peak area ratio in the SEC, it is confirmed that the molecular weight of the main coupling product is about 150 kD, i.e., BT001047 obtained by coupling TL056 with the antibody still maintains the integral structure of the antibody.
    • Example 63: Test of Inhibitory Effects of Bioactive Molecules and Antibody Drug Conjugates on Activity of Cells in vitro
  • First, tumor cells MDA-MB-468 (Trop-2 positive cell lines) and HCC1806 (Trop-2 positive cell lines) were cultured. The bioactive molecules and ADC molecules disclosed in the disclosure were co-cultured with the tumor cells, then a CCK8 reagent (Dojindo Molecular Technologies, Inc., Cat: CK04, Lot:JJ744) was added . The activity of dehydrogenase in mitochondria was tested through readings (detection wave length was 450 nm) from a microplate reader (manufacturer: Molecular Devices, model: SpectraMax M2) so as to evaluate the inhibitory effect of ADC on cell proliferation. Sources of the tumor cells were shown in table 1.
  • TABLE 1
    Cell name Tumor type Source
    MDA-MB-468 Breast cancer Concortis
    HCC1806 Breast cancer Cobioer Biosciences Co., Ltd.
  • In-vitro cell activity testing: bioactive molecules or ADCs were diluted (12 concentration gradients) with corresponding test media (containing 2% FBS). The tumor cells were trypsinized with trypsin by a conventional method, collected and counted, and then resuspended with corresponding test media (containing 2% FBS). Diluted bioactive molecules or ADCs were added to a 96-well plate, and then cells were added. 20 µL of the CCK8 reagent was added to each well and reacted for 4 h, and readings (detection wavelength was 450 nm) were taken from a microplate reader. Experimental conditions and test results were shown in Table 2 and Table 3.
  • TABLE 2
    Killing effects of bioactive molecules on cells
    Name Cell name EC50(nM)
    T001 MDA-MB-468 (7500 cells/well, 4 days) 1.126
    T011 0.211
    T012 HCC1806 (7500 cells/well, 3 days) 1.621
    T013 0.414
    T015 7.428
    T-028 6.016
    T-030 6.734
  • The test results indicated that all of the bioactive molecules had killing effects on the tumor cells.
  • TABLE 3
    Killing effects of conjugates (ADCs) on cell lines
    Name Cell name EC50(nM)
    BT001002 MDA-MB-468 (10000 cells/well, 3 days) 0.072
    BT001004 HCC1806 (7500 cells/well, 3 days) 6.139
    BT001012 14.41
    BT001013 48.01
    BT001018 13.42
    BT001021 13.15
    BT001022 23.43
    BT001023 21.65
    BT001040 11.08
    BT001041 10.34
    BT001042 0.0186
    BT001043 0.062
    BT001044 0.0051
    BT001046 0.81
    BT001047 0.23
  • The test results indicated that ADC molecules obtained by a novel coupling way had killing effects on tumor cells, indicating that the ADCs formed by the novel coupling method had killing effects on the tumor cells, and the novel coupling method was workable in the synthesis of ADC molecules.
    • Example 64: Pharmacodynamic Test of Antibody Drug Conjugates and Bioactive Molecules In vivo Drugs Under Test
  • Drug name, source and preparation method:
    • BT001021, liquid aliquots were stored at -20° C. at a concentration of 5.44 mg/ml, and diluted with physiological saline by dosage before use to obtain a test solution;
    • Immu-132 (prepared according to example 2 of WO2015/012904A2, DAR=5.4, also described as IMMU-132), liquid aliquots were stored at -20° C. at a concentration of 13.158 mg/ml, and diluted with physiological saline by dosage before use to obtain a test solution;
    • Solid powder of T-030 was prepared with 100% DMSO (Sigma) into a solution at a concentration of 5.2 mg/mL, and liquid aliquots were stored at -20° C., and diluted with physiological saline to a desired dose before use to obtain a test solution;
    • Solid powder of SN-38 (also described as SN38) was prepared with 100% DMSO (Sigma) into a solution at a concentration of 3.23 mg/ml, liquid aliquots were stored at -20° C., and diluted with physiological saline by dosage before use to obtain a test solution.
  • Note: Toxin was prepared and administered in an equimolar ratio of ADC samples.
  • Structures of T-030, SN-38 and Immu-132 were as follows:
  • Figure US20230357259A1-20231109-C00798
  • Figure US20230357259A1-20231109-C00799
  • Figure US20230357259A1-20231109-C00800
    • Experimental Animals and Cell Lines
  • Balb/c-nu mice (Beijing Vital River Laboratory Animal Technology Co., Ltd., production license No.: SCXK (Beijing) 2016-0011); Gastric cancer cell line NCI-N87 (ATCC), breast cancer cell line HCC1806 (COBIOER Nanjing).
    • Experimental Grouping and Evaluation Method
  • Tumor-bearing mice (6 mice/group) with tumor volume of 100 - 200 mm3 were randomly grouped (the number of groups was determined according to sample number). The administration volume was 10 ml/kg, and the administration route was tail intravenous injection. The mice were administered twice a week, and tumor diameter was measured with a vernier caliper, and tumor volume was calculated based on the following calculation formula: V = 0.5 a × b2, wherein a and b stand for the long diameter and short diameter of a tumor respectively. Animal deaths were observed and recorded every day.
  • The tumor growth inhibition rate TGI (%) was calculated from the following formula to evaluate tumor inhibitory effect of antibody drug conjugates:
  • TGI % = 1 - V Tend -V Tstart / V Cend -V Cstart * 100 %
    • wherein, VTend: average tumor volume at the end of the experiment in the treatment group
    • VTstart: average tumor volume at the begining of administration in the treatment group
    • VCend: average tumor volume at the end of the experiment in the control group
    • VCstart: average tumor volume at the begining of administration in the control group
  • In the following experimental examples 1 and 2, the inhibition of the antibody conjugate BT001021 on tumor proliferation of tumor-bearing mice constructed by subcutaneous xenograft of human tumor cells was evaluated. Specifically, in the experimental examples 1 and 2, tumor-bearing mice models were constructed by subcutaneous xenograft of a human gastric cancer cell line NCI-N87 or a human triple negative breast cancer cell line HCC1806. After the tumor volume was about 100 mm3, the mice were randomly grouped, and intravenously administered with BT001021 twice a week for a total of 6 times. Changes in tumor volume and animal body weight were measured twice a week to evaluate the efficacy (tumor inhibitory effect) of the antibody drug conjugate on tumor-bearing mice.
    • Experimental Example 1. Inhibition of NCI-N87 by Antibody Drug Conjugates and Bioactive Molecules Experimental Methods
  • NCI-N87 cells were cultured in a 1640 culture medium containing 10% fetal bovine serum at 37° C. and 5% CO2. NCI-N87 cells in the exponential growth stage were collected, resuspended in PBS to a suitable concentration, and inoculated subcutaneously into female Balb/c-nu mice to construct gastric cancer models. When the mean tumor volume was about 90 mm3, the mice were randomly grouped into a physiological saline group, a BT001021 (3 mg/kg, IV, BIW×3W) group, a positive drug Immu-132 (3 mg/kg, IV, BIW×3W) group, a T030 group and a SN38 group according to the tumor size, followed by tail intravenous injection of corresponding drugs twice a week for a total of 6 times. After administration, the tumor volume and body weight of the mice were observed and measured regularly. Specific results were shown in Table 4, FIGS. 44 and 45 .
    • Conclusion
  • In the experimental example, a human gastric cancer cell line NCI-N87 was used to construct subcutaneous xenograft models of human gastric cancer, and the efficacy of BT001021 in the NCI-N87 human gastric cancer tumor-bearing mice models was evaluated.
  • Experimental results showed that BT001021 (3 mg/kg, IV, BIW×3W) could significantly inhibit the tumor growth of xenograft model mice of NCI-N87 gastric cancer, and tumor regression occurred at the end of administration, with anti-tumor activity superior to that of positive control Immu-132. Neither animal death nor significant animal weight loss occurred in all treatment groups during the observation period, indicating that BT001021 had no significant toxicity.
  • TABLE 4
    NCI-N87 model of gastric cancer
    Group No. Regimen D21 after administration
    Tumor volume (mm3) (x ±S) Tumor growth inhibition rate (%) P value (vs group 1)
    Group 1 Physiological saline 405.67± 91.81
    Group 2 BT001021 42.78± 21.87 114.61 0.0000
    Group 3 Immu-132 259.04± 42.41 46.46 0.0053
    Group 4 T-030 339.02± 152.80 21.48 0.3813
    Group 5 SN-38 416.11±195.15 -2.75 0.9079
    • Experimental Example 2. Inhibition of HCC1806 by Antibody Drug Conjugates Experimental Methods
  • HCC1806 cells were cultured in a 1640 culture medium containing 10% fetal bovine serum at 37° C. and 5% CO2. HCC1806 cells in the exponential growth stage were collected, resuspended in PBS in a suitable concentration, and inoculated subcutaneously into female Balb/c-nu to construct breast cancer models. When the mean tumor volume was about 130 mm3, the mice were randomly grouped into a physiological saline group, a BT001021 (10 mg/kg, IV, BIW×3W) group and a positive drug Immu-132 (10 mg/kg, IV, BIW×3W) group according to the tumor size, followed by tail intravenous injection of corresponding drugs twice a week for a total of 5 times. After administration, the tumor volume of the mice was observed and measured regularly. Specific results were shown in Table 5 and FIG. 46 .
    • Conclusion
  • In the experimental example, a human breast cancer cell line HCC1806 was used to construct subcutaneous xenograft models of human breast cancer, and the efficacy of BT001021 in the HCC1806 human breast cancer tumor-bearing mice models was evaluated.
  • Experimental results showed that BT001021 (10 mg/kg, IV, BIW×3W) could significantly inhibit the tumor growth of xenograft model mice of HCC1806 breast cancer, with anti-tumor activity superior to that of positive Immu-132.
  • TABLE 5
    HCC1806 model of breast cancer
    D17 after administration
    Group No. Regimen Tumor Volume (mm3) (x̅ ±S) Tumor growth inhibition rate (%) P value (vs group 1)
    Group 1 Physiological saline 2638.22±553.81
    Group 2 BT001021 1260.87± 415.60 54.93 0.0006
    Group 3 Immu-132 2347.05± 317.79 11.62 0.2901
  • According to Table 4, Table 5 and FIGS. 44-46 , the antibody drug BT001021 of the invention could significantly inhibit tumor growth in NCI-N87 mice models. It was significantly superior to Immu-132 at the same dosage, and had neither significant weight loss nor significant drug toxicity. In the HCC1806 mice models, when the dosage increased to 10 mg/kg due to high malignancy of the tumor, Immu-132 did not show significant inhibitory activity, whereas BT001021 could significantly inhibit tumor growth. The results indicated that BT001021 of the invention had good efficacy and excellent safety.
  • In the subcutaneous xenograft models of the experimental examples 1 and 2, the anti-tumor activity of BT001021 was significantly superior to that of Immu-132 at the same dosage, suggesting that BT001021 had the potential to treat solid tumors, and was expected to benefit more patients clinically than Immu-132.
    • Experimental Example 3. Inhibition of HCC827 by Antibody Drug Conjugates
  • The experimental example 3 was used to evaluate the inhibitory effect of BT001021 and BT001035 on proliferation of tumor-bearing mice models constructed by subcutaneous xenograft human tumor cells of HCC827 non-small cell lung cancer. Specifically, in the experiment, tumor-bearing mice models were constructed by subcutaneous xenograft of a human non-small cell lung cancer cell line HCC827. After the tumor volume was about 100 mm3, the mice were randomly grouped, and intravenously administrated with BT001021 and BT001035 twice a week for a total of 6 times. Then changes in tumor volume and animal body weight were measured twice a week to calculate the efficacy (tumor inhibitory effect) of BT001021 and BT001035 on the tumor-bearing mice.
    • Experimental Methods
  • HCC827 cells were cultured in a 1640 culture medium containing 10% fetal bovine serum at 37° C. and 5% CO2. HCC827 cells in the exponential growth stage were collected, resuspended in PBS in a suitable concentration, and inoculated subcutaneously into female Balb/c-nu mice to construct xenograft models of lung cancer. When the mean tumor volume was about 80 mm3, the mice were randomly grouped into a physiological saline group, a positive drug Immu-132 (10 mg/kg, IV, BIW×3W) group, a BT001021 (10 mg/kg, IV, BIW×3W) group and a BT001035 (10 mg/kg, IV, BIW×3W) group according to the tumor size, followed by tail intravenous injection of corresponding drugs twice a week for a total of 6 times. After administration, the tumor volume and body weight of the mice were observed and measured regularly. Results were shown in Table 6, FIG. 47A and FIG. 47B.
    • Conclusion
  • Experimental results showed that BT001021 and BT001035 could significantly inhibit the tumor growth of xenograft model mice of HCC827 non-small cell lung cancer, and tumor regression occurred at the end of administration, with anti-tumor activity superior to that of the positive control Immu-132 group. During the observation period, no animal death and significant animal weight loss occurred in all treatment groups, and no significant drug toxicity was observed. During the treatment period, the mice showed good tolerance to all drugs to be evaluated.
  • TABLE 6
    HCC827 model of lung cancer
    D21 after administration
    Group No. Regimen Tumor Volume (mm3) (x̅ ±S) TGI(%) P value(vs group 1)
    1 Physiological saline 515.25±165.09
    2 Immu-132 145.94±19.72 85.19 0.0003
    3 BT001021 40.26±8.36 108.70 0.0001
    4 BT001035 48.61±9.99 106.95 0.0000
  • According to Table 6, FIG. 47A and FIG. 47B, both BT001021 and BT001035 had significant inhibitory activity on tumor growth during the evaluation period, and they are significantly superior to that of Immu-132 at the same dosage. During treatment, no significant weight loss and drug toxicity were observed in all groups. The results indicated that both BT001021 and BT001035 had excellent anti-tumor activity.
  • In the subcutaneous xenograft models, the anti-tumor activity of both BT001021 and BT001035 was significantly superior to that of Immu-132 at the same dosage, suggesting that both BT001021 and BT001035 had the potential to treat solid tumors, and was expected to benefit more patients clinically than Immu-132.
    • Experimental Example 4. Inhibition of NCI-N87 by Antibody Drug Conjugates
  • The experimental example 4 was used to evaluate the inhibition of the antibody drug conjugate BT001036 on tumor proliferation of tumor-bearing mice constructed by subcutaneous xenograft of human tumor cells. Specifically, in the experiment, tumor-bearing mice models were constructed by subcutaneous xenograft of a human gastric cancer cell line NCI-N87. After the tumor volume was about 140 mm3, the mice were randomly grouped, and intravenously administrated with BT001036 twice a week for a total of 6 times. Changes in tumor volume and animal body weight were measured twice a week to evaluate the efficacy (tumor inhibitory effect) of the antibody drug conjugate on tumor-bearing mice.
    • Experimental Methods
  • NCI-N87 cells were cultured in a 1640 culture medium containing 10% fetal bovine serum at 37° C. and 5% CO2. NCI-N87 cells in the exponential growth stage were collected, resuspended in PBS in a suitable concentration, and inoculated subcutaneously into female Balb/c-nu mice to construct xenograft models of gastric cancer. When the mean tumor volume was about 140 mm3, the mice were randomly grouped into a physiological saline group, a BT001036 (1.5 mg/kg, IV, BIW×3W) group and a BT001036 (3 mg/kg, IV, BIW×3W) group according to the tumor size, followed by tail intravenous injection of corresponding drugs twice a week for a total of 6 times. After administration, the tumor volume and body weight of the mice were observed and measured regularly. Specific results were shown in Table 7, FIG. 48A and FIG. 48B.
  • TABLE 7
    NCI-N87 model of gastric cancer
    D21 after administration
    Group No. Regimen Tumor Volume (mm3) x̅ (±S) TGI(%) P value (vs group 1)
    Group 1 Physiological saline 601.29±198.92
    Group 2 BT001036 (1.5 mg/kg) 150.87±112.84 97.78 0.0017
    Group 3 BT001036 (3 mg/kg) 2.74± 0.64 129.95 0.0000
    • Conclusion:
  • In the experimental example, subcutaneous xenograft models of human gastric cancer were constructed by subcutaneous xenograft of a human gastric cancer cell line NCI-N87, and the efficacy of BT001036 in the NCI-N87 human gastric cancer tumor-bearing mice models was evaluated.
  • Experimental results showed that both the high and low dosags of BT001036 (1.5 mg/kg, 3 mg/kg) could significantly inhibit the tumor growth of xenograft model mice of NCI-N87 gastric cancer, and tumor regression occurred at the end of administration, with excellent anti-tumor activity. During the observation period, no animal death and significant animal weight loss occurred in all treatment groups, and no significant drug toxicity was observed. During the treatment period, the mice showed good tolerance to all drugs to be evaluated.
    • Experimental Example 5. Inhibition of MDA-MB-231 by Antibody Drug Conjugates
  • The experimental example 5 was used to evaluate the inhibitory effect of BT001021 on the proliferation of tumor-bearing mice models constructed by subcutaneous xenograft human tumor cells of MDA-MB-231 breast cancer. Specifically, in the experiment, tumor-bearing mice models were constructed by subcutaneous xenograft of a human breast cancer cell line MDA-MB-231. After the tumor volume was about 130 mm3, the mice were randomly grouped, and intravenously administreatd with BT001021 twice a week for a total of 6 times. Then changes in tumor volume and animal body weight were measured to calculate the efficacy (tumor inhibitory effect) of BT001021 on the tumor-bearing mice.
    • Experimental Methods
  • NCI-MDA-MB-231 cells were cultured in a RPMI1640 culture medium containing 10% fetal bovine serum at 37° C. and 5% CO2. MDA-MB-231 cells in the exponential growth stage were collected, resuspended in PBS in a suitable concentration, and inoculated subcutaneously into female Balb/c-nu mice to construct xenograft models of lung cancer. When the mean tumor volume was about 130 mm3, the mice were randomly grouped into a physiological saline group and a BT001021 (3 mg/kg) group according to the tumor size, followed by tail intravenous injection of corresponding drugs twice a week for a total of 6 times. After administration, the tumor volume and body weight of the mice were observed and measured regularly. Results were shown in Table 8, FIG. 49A and FIG. 49B.
    • Conclusion
  • Results showed that BT001021 could significantly inhibit the tumor growth of xenograft model mice of MDA-MB-231 breast cancer, and tumor regression occurred at the end of administration. During the observation period, neither animal death nor significant animal weight loss occurred in all treatment groups, no significant drug toxicity was observed, either. During the treatment period, the mice showed good tolerance to all drugs to be evaluated.
  • TABLE 8
    MDA-MB-231 model of breast cancer
    D33 after administration
    Group No. Regimen Tumor Volume (mm3) x̅ (±S) TGI (%) P value (vs group 1)
    1 Physiological saline 744.53±306.66
    2 BT001021 43.96±7.72 114.18 0.0119
  • In the subcutaneous xenograft models, BT001021 had significant anti-tumor activity. During the observation period, neither animal death nor significant animal weight loss occurred in all treatment groups, no significant drug toxicity was observed, either. During the treatment period, the mice showed good tolerance to all drugs to be evaluated.
    • Example 65: Test of Pharmacokinetics of Antibody Drug Conjugates and Bioactive Molecules in vivo
  • Experimental example 6 was used to evaluate pharmacokinetics of antibody drug conjugates and bioactive molecules in vivo. Specifically, in the experiment, a tumor-bearing mice model was constructed by subcutaneous xenograft of a human gastric cancer cell line NCI-N87 to Balb/c-nu mice. After the tumor volume was 100-200 mm3, the mice were randomly grouped, and intravenously administrated with a single dose of BT001021 and T-030. The concentration of the T-030 in tumor tissues and serum was determined to evaluate the pharmacokinetics in vivo of the antibody conjugate BT001021 and the bioactive molecule T-030 in the tumor-bearing mice.
    • Drugs Under Test
  • Drug names and preparation methods:
    • BT001021, liquid aliquots were stored at -20° C. at a concentration of 20 mg/ml, and diluted with physiological saline to the desired doses before use to obtain a test solution;
    • T-030, which was prepared into 1 mg/ml with dimethyl sulfoxide and diluted with physiological saline to a desired dose to obtain a test solution.
    Experimental Animals and Cell Lines
  • Balb/c-nu mice (Beijing Vital River Laboratory Animal Technology Co., Ltd., production license No.: SCXK (Beijing) 2016-0011); Gastric cancer cell line NCI-N87 (ATCC).
    • Experimental Groups and Evaluation Method
  • Tumor-bearing mice (4 mice/group) with tumor volume of 100 - 200 mm3 were randomly grouped (the number of groups was determined according to sample number), and the administration route was single tail intravenous injection.
    • Experimental Example 6. Test of Pharmacokinetics of BT001021 and T-030 in Tumor-Bearing Mice in vivo Experimental Method
  • NCI-N87 cells were cultured in a 1640 culture medium containing 10% heat-inactivated fetal bovine serum at 37° C. and 5% CO2. NCI- N87 cells in the exponential growth stage were collected, resuspended in PBS to a suitable concentration, and inoculated subcutaneously into Balb/c-nu mice to construct xenograft models of lung cancer. When the mean tumor volume was about 100-200 mm3, the mice were randomly grouped into a physiological saline group, a T-030 (0.23 mg/kg, IV, single dose) group and a BT001021 (10 mg/kg, IV, single dose) group according to the tumor size, followed by tail intravenous injection of corresponding drugs. For the T-030 group, serum and tumor tissues were collected 1 h, 2 h, 4 h, 8 h, 24 h and 72 h after administration (T-030 was not detected in the serum and tumor tissues 72 h after administration, therefore, serum and tumor tissues were not collected 168 h after administration). For BT001021 group, serum and tumor tissues were collected 1 h, 2 h, 4 h, 8 h, 24 h, 72 h and 168 h after administration to test the concentration of the T-030 in the serum and the tumors by LC-MS/MS. Specific results were shown in Table 9. The administration dose of the T-030 (0.23 mg/kg) was converted to isomolar dose (10 mg/kg) of BT001021.
  • TABLE 9
    Pharmacokinetic parameters of T-030 in tumors and serum of tumor-bearing mice after intravenous administration of T-030 and BT001021
    Regimen T-030 (0.23 mg/kg) administration group BT001021 administration (10 mg/kg) group
    Tumor Serum Tumor Serum
    AUClast(h*ng/ml) 3.85 5.58 850.1 174.97
    Cmax(ng/ml) 1.20 1.81 7.82 11.7
    MRTINF(h) 1.52 1.11 64.24 42.9
    Tmax(h) 1.00 1.00 8.00 1.00
    T½(h) 2.55 1.76 93.14 44.35
    • Conclusion:
  • AUClast of the drug in the tumors and serum of BT001021 (10 mg/kg) administration group was 850.1 h*ng/ml and 174.97 h*ng/ml, respectively, whereas the AUClast of the drug in the tumors and serum of the T-030 administration group was 3.85 h*ng/ml and 5.58 h*ng/ml, respectively. The comparison indicated that the exposure doses of T-030 of BT001021 administration group was significantly increased compared with those of the T-030 administration group. In addition, the exposure doses of the bioactive molecule T-030 in the tumors of BT001021 administration group was significantly higher than those in the serum, whereas, the exposure doses of the active biomolecule in the serum and tumors of the T-030 administration group was basically the same, indicating that the antibody drug conjugate (BT001021) had high tumor tissue targetability.
  • Cmax of the bioactive molecule T-030 in the tumors and serum of BT001021 (10 mg/kg) administration group was 7.82 ng/ml and 11.7 ng/ml, respectively, whereas the Cmax of the bioactive molecule T-030 in the tumors and serum of the T-030 administration group was 1.20 ng/ml and 1.81 ng/ml, respectively, indicating that the antibody drug conjugate (BT001021) had higher concentration of the bioactive molecule (T-030) in tumor tissues and serum.
  • T½ of the bioactive molecule T-030 in the tumors of BT001021 (10 mg/kg) administration group was 93.14 h, whereas the T½ of the bioactive molecule T-030 in the tumors of the T-030 administration group was 2.55 h, indicating that the antibody drug conjugate (BT001021) had a longer half life in the tumor tissues.
  • In conclusion, BT001021 had significant tumor tissue targetability and good pharmacokinetic properties compared with the corresponding bioactive molecule (T-030).
    • Experimental Example 7. Test of Pharmacokinetics of Antibody Drug Conjugates BT001021 and Immu-132 in vivo
  • In the experiment, tumor-bearing mice models were constructed by subcutaneous xenograft of a human gastric cancer cell line NCI-N87 to Balb/c-nu mice. After the tumor volume was 100-200 mm3, the mice were randomly grouped, and intravenously given a single dose of BT001021 and Immu-132. The concentration of the bioactive molecule T-030 and the SN-38 corresponding to BT001021 and Immu-132 in tumor tissues and serum was respectively measured to evaluate the pharmacokinetics of the antibody conjugates BT001021 and Immu-132 in tumor-bearing mice in vivo.
    • Drugs Under Test
  • Drug names and preparation methods:
    • BT001021, liquid aliquots were stored at -20° C. at a concentration of 20 mg/ml, and diluted with physiological saline to the desired doses before use to obtain the test solution;
    • Immu-132 was diluted with physiological saline to the desired dose to obtain the test solution.
    Experimental Animals and Cell Lines
  • Balb/c-nu mice (Beijing Vital River Laboratory Animal Technology Co., Ltd., production license No.: SCXK (Beijing) 2016-0011); Gastric cancer cell line NCI-N87 (ATCC).
    • Experimental Groups and Evaluation Method
  • Tumor-bearing mice (4 mice/group) with tumor volume of 100 - 200 mm3 were randomly grouped (the number of groups was determined according to sample number), and the administration route was single tail intravenous injection.
    • Experimental Methods
  • NCI-N87 cells were cultured in a 1640 culture medium containing 10% heat-inactivated fetal bovine serum at 37° C. and 5% CO2. NCI- N87 cells in the exponential growth stage were collected, resuspended in PBS to a suitable concentration, and inoculated subcutaneously into Balb/c-nu mice to construct an xenograft model of lung cancer. When the mean tumor volume was about 100-200 mm3, the mice were randomly grouped into a BT001021 (5 mg/kg, IV, single dose) group and an Immu-132 (5 mg/kg, IV, single dose) group according to the tumor size, followed by tail intravenous injection of corresponding drugs. Serum and tumor tissues were collected at 2 h, 24 h, 48 h and 72 h after administration respectively to test the concentration of the T-030 or SN-38 in the serum and tumors by LC-MS/MS.
  • TABLE 10
    Pharmacokinetic parameters of T-030 and SN-38 in tumors and serum of tumor-bearing mice after intravenous administration of BT001021 and Immu-132
    Regimen Immu-132 (5 mg/kg) administration group BT001021 (5 mg/kg) administration group
    Tumor Serum Tumor Serum
    AUClast (h*ng/ml) 116.8 422.7 427.2 115.3
    Cmax (ng/ml) 2.8 19.58 6.8 5.08
    MRTlast (h) 21.5 15.66 31.9 17.6
    • Conclusion
  • AUClast of small toxin molecules in the tumors and serum of BT001021 administration group was 427.2 h*ng/ml and 115.3 h*ng/ml respectively, whereas the AUClast of small toxin molecules in the tumors and serum of Immu-132 administration group was 116.8 h*ng/ml and 422.7 h*ng/ml respectively. Cmax of small toxin molecules in the tumors of BT001021 administration group was 6.8 ng/ml, whereas the Cmax of small toxin molecules in the tumors of Immu-132 administration group was 2.8 ng/ml. The results showed that BT001021 had better tumor tissue targetability, better pharmacokinetic properties and better therapeutic window, compared with Immu-132.
  • Even though specific modes for carrying out the invention have been described in detail, it should be understood by a person skilled in the art that various modifications and alternatives can be made to the details according to all published teachings, and such changes are within the protection scope of the invention. The full scope of the invention is given by the attached claims and any equivalent thereof.

Claims (41)

1-91. (canceled)
92. A compound of formula (I) or a pharmaceutically acceptable salt thereof,
Figure US20230357259A1-20231109-C00801
wherein, T is a fragment of a bioactive molecule,
L1 is selected from
Figure US20230357259A1-20231109-C00802
an amino acid, a peptide composed of 2-10 amino acids, an oligosaccharide, -(CH
2)t1-, -(CH2CH2O)t1-(CH2)t2-,
Figure US20230357259A1-20231109-C00803
Figure US20230357259A1-20231109-C00804
Figure US20230357259A1-20231109-C00805
Figure US20230357259A1-20231109-C00806
Figure US20230357259A1-20231109-C00807
Figure US20230357259A1-20231109-C00808
Figure US20230357259A1-20231109-C00809
Figure US20230357259A1-20231109-C00810
Figure US20230357259A1-20231109-C00811
Figure US20230357259A1-20231109-C00812
Figure US20230357259A1-20231109-C00813
Figure US20230357259A1-20231109-C00814
Figure US20230357259A1-20231109-C00815
Figure US20230357259A1-20231109-C00816
Figure US20230357259A1-20231109-C00817
Figure US20230357259A1-20231109-C00818
Figure US20230357259A1-20231109-C00819
Figure US20230357259A1-20231109-C00820
Figure US20230357259A1-20231109-C00821
Figure US20230357259A1-20231109-C00822
wherein each of R, R′, R1 and R2 is independently hydrogen, deuterium, halogen, a carboxylic acid group, a sulfonic acid group, cyano, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano, C1-6 alkoxy, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, 6-10 membered aryl or 5-12 membered heteroaryl, each Z1 is independently an amino acid or a peptide composed of 2-10 amino acids, each of t1 and t2 is independently 0, 1, 2, 3, 4, 5 or 6, each of x1 and x2 is independently 0, 1, 2, 3, 4, 5 or 6, each x3 is independently 0, 1, 2, 3 or 4, and L1 is bonded to T at the position 1 of L1;
L2 is selected from
Figure US20230357259A1-20231109-C00823
Figure US20230357259A1-20231109-C00824
Figure US20230357259A1-20231109-C00825
an amino acid, a peptide composed of 2-10 amino acids, an oligosaccharide, -(CH
2)t1-, -(CH2CH2O)t1-(CH2)t2-,
Figure US20230357259A1-20231109-C00826
Figure US20230357259A1-20231109-C00827
Figure US20230357259A1-20231109-C00828
Figure US20230357259A1-20231109-C00829
Figure US20230357259A1-20231109-C00830
Figure US20230357259A1-20231109-C00831
wherein each of R3, R4, R5 and R6 is independently selected from hydrogen, deuterium, halogen, a carboxylic acid group, a sulfonic acid group, CN, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano, C1-6 alkoxy, C2-10 alkenyl, C2-10 alkynyl or C3-6 cycloalkyl or R3 and R4, R5 and R6 or R3 and R5 together with the carbon atoms attached thereto form a 3-8 membered ring, each of t1 and t2 is independently 0, 1, 2, 3, 4, 5 or 6, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and L2 is bonded to L1 at the position 1 of L2;
L3 is selected from the following groups optionally substituted with one or more R7: 5-12 membered heteroarylene, amino, 3-8 membered cycloalkylene, 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene, 6-12 membered fused heterocyclylene, 6-10 membered arylene or 3-8 membered cycloalkylene-W-; wherein W is oxygen or NR8, R7 is independently selected from hydrogen, deuterium, halogen, =O, CN, carboxyl, sulfonic acid group, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano, C1-6 alkoxy, C2-10 alkenyl or C2-10 alkynyl, R8 is independently selected from hydrogen, deuterium, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy or cyano C1-2 alkyl;
L4 is selected from
Figure US20230357259A1-20231109-C00832
wherein Z
5 is selected from C2-6 alkynyl, C2-6 alkenyl, amido group, sulfuryl, sulfinyl, 6-10 membered arylene or 5-6 membered heteroarylene; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene, C3-8 cycloalkylene, 6-10 membered arylene or 5-14 membered heteroarylene; R9 is selected from hydrogen or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene, halogenated C1-6 alkylene or C1-6 alkylene substituted with alkoxy; or R9 and Z3 together with nitrogen atom attached thereto form a 4-8 membered heterocyclyl; α is independently 0, 1, 2, 3,4, 5 or 6; and L4 is bonded to E at the position 2 of L4;
E is selected from the following groups optionally substituted with one or more R12: pyrimidylene, quinolylene or pyrrolo[2,3-d]pyrimidylene; wherein R12 is independently selected from hydrogen, deuterium, halogen, CN, nitro, C1-6 alkyl or halogenated C1-6 alkyl;
G is a leaving group for nucleophilic substitutions;
each of m1, m2, and m3 is independently 0, 1, 2, 3, 4,5, 6, 7, 8, 9 or 10.
93. The compound or the pharmaceutically acceptable salt of claim 92, wherein,
L1 is selected from
Figure US20230357259A1-20231109-C00833
Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide composed of 2-5 amino acids,
Figure US20230357259A1-20231109-C00834
Figure US20230357259A1-20231109-C00835
Figure US20230357259A1-20231109-C00836
Figure US20230357259A1-20231109-C00837
Figure US20230357259A1-20231109-C00838
Figure US20230357259A1-20231109-C00839
Figure US20230357259A1-20231109-C00840
Figure US20230357259A1-20231109-C00841
Figure US20230357259A1-20231109-C00842
Figure US20230357259A1-20231109-C00843
Figure US20230357259A1-20231109-C00844
Figure US20230357259A1-20231109-C00845
wherein each of R, R′, R
1 and R2 is independently hydrogen, deuterium, C1-6 alkyl, C2-10 alkenyl, C2-10 alkynyl or C3-6 cycloalkyl, Z1 is Lys, Val, Cit, Phe, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg or Ala-Ala-Asn, x1 is 0, 1, 2 or 3, and x3 is 0, 1, 2, 3 or 4.
94. The compound or the pharmaceutically acceptable salt of claim 92, wherein,
L2 is selected from
Figure US20230357259A1-20231109-C00846
Figure US20230357259A1-20231109-C00847
Figure US20230357259A1-20231109-C00848
Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide composed of 2-5 amino acids,
Figure US20230357259A1-20231109-C00849
Figure US20230357259A1-20231109-C00850
Figure US20230357259A1-20231109-C00851
Figure US20230357259A1-20231109-C00852
Figure US20230357259A1-20231109-C00853
Figure US20230357259A1-20231109-C00854
wherein each of R
3, R4, R5 and R6 is independently selected from hydrogen, deuterium, halogen, a carboxylic acid group, a sulfonic acid group, CF3, CN, CH2CN, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkyl, each of y1 and y2 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L2 is bonded to L1 at the position 1 of L2;and
m1 is 0, 1, 2 or 3.
95. The compound or the pharmaceutically acceptable salt of claim 92, wherein,
L3 is selected from the following groups optionally substituted with one or more R7: 5-12 membered heteroarylene, amino, 3-8 membered cycloalkylene, 3-8 aliphatic heterocyclylene, 6-12 membered bridged heterocyclylene, 6-12 membered spiroheterocyclylene, 6-12 membered fused heterocyclylene, 6-10 membered arylene or 3-8 membered cycloalkylene-W-; wherein W is oxygen or NR8, R7 is independently selected from hydrogen, deuterium, halogen, =O, CF3, CN, CH2CN, carboxyl, sulfonic acid group, C1- 4 alkyl, C1-4alkoxy, C2-6 alkenyl or C2-6 alkynyl; and
m2 is 0, 1, 2 or 3.
96. The compound or the pharmaceutically acceptable salt of claim 92, wherein L4 is selected from
Figure US20230357259A1-20231109-C00855
Figure US20230357259A1-20231109-C00856
Figure US20230357259A1-20231109-C00857
Figure US20230357259A1-20231109-C00858
Figure US20230357259A1-20231109-C00859
Figure US20230357259A1-20231109-C00860
Figure US20230357259A1-20231109-C00861
wherein Z
4 is 6-10 membered arylene or 5-6 membered heteroarylene; R10 is selected from hydrogen or C1-6 alkyl; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene or C3-8 cycloalkylene; R9 is selected from hydrogen or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene; or R9 and Z3 together with the nitrogen atom attached thereto form a 4-8 membered heterocyclylene; α is independently 0, 1, 2, 3, 4, 5 or 6, and L4 is bonded to E at the position 2 of L4; and
m3 is 0, 1, 2 or 3.
97. The compound or the pharmaceutically acceptable salt of claim 92, wherein, E is selected from pyrimidylene optionally substituted with one or more R12; wherein R12 is independently selected from hydrogen or deuterium.
98. The compound or the pharmaceutically acceptable salt of claim 92, wherein, G is selected from alkyl sulfonyl, halogen, OMs, OTs, OTf, nitro or the following groups optionally substituted with one or more R13: alkylthio, arylthio, heteroarylthio, alkyl sulfinyl, aryl sulfinyl, heteroaryl sulfinyl, aryl sulfonyl or heteroaryl sulfonyl; wherein R13 is independently selected from hydrogen, deuterium, halogen, CN, nitro, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, 6-10 membered aryl or 5-12 membered heteroaryl.
99. The compound or the pharmaceutically acceptable salt of claim 92, wherein, in
Figure US20230357259A1-20231109-C00862
G is methylsulfonyl, E is pyrimidylene, and m
3 is 1.
100. The compound or the pharmaceutically acceptable salt of claim 92, wherein -[L1-(L2)m1-(L3)m2-(L4)m3-E]-G is selected from the following fragments:
Figure US20230357259A1-20231109-C00863
Figure US20230357259A1-20231109-C00864
Figure US20230357259A1-20231109-C00865
Figure US20230357259A1-20231109-C00866
Figure US20230357259A1-20231109-C00867
Figure US20230357259A1-20231109-C00868
Figure US20230357259A1-20231109-C00869
Figure US20230357259A1-20231109-C00870
Figure US20230357259A1-20231109-C00871
Figure US20230357259A1-20231109-C00872
Figure US20230357259A1-20231109-C00873
Figure US20230357259A1-20231109-C00874
Figure US20230357259A1-20231109-C00875
Figure US20230357259A1-20231109-C00876
Figure US20230357259A1-20231109-C00877
Figure US20230357259A1-20231109-C00878
Figure US20230357259A1-20231109-C00879
Figure US20230357259A1-20231109-C00880
Figure US20230357259A1-20231109-C00881
Figure US20230357259A1-20231109-C00882
Figure US20230357259A1-20231109-C00883
Figure US20230357259A1-20231109-C00884
Figure US20230357259A1-20231109-C00885
Figure US20230357259A1-20231109-C00886
Figure US20230357259A1-20231109-C00887
Figure US20230357259A1-20231109-C00888
Figure US20230357259A1-20231109-C00889
Figure US20230357259A1-20231109-C00890
Figure US20230357259A1-20231109-C00891
or
Figure US20230357259A1-20231109-C00892
.
101. The compound or the pharmaceutically acceptable salt of claim 92, wherein, T is a fragment of a bioactive molecule, and the bioactive molecule is selected from a metal complex; a glycopeptide antibiotic; a DNA topoisomerase inhibitor; a drug interfering with DNA synthesis; a drug acting on a structural protein; a tumor cell signaling pathway inhibitor; a proteasome inhibitor; a histone deaceylase inhibitor; a tumor angiogenesis inhibitor; a cyclin inhibitor; a maytansine derivative; a calicheamicin derivative; a auristatin derivative; a pyrrolobenzodiazepine dimers (PBD) derivative; melphalan; mitomycin C; or chlorambucil; or other active substances which inhibit the growth of tumor cells, promote the apoptosis or necrosis of tumor cells.
102. The compound or the pharmaceutically acceptable salt of claim 92, wherein T is selected from
Figure US20230357259A1-20231109-C00893
Figure US20230357259A1-20231109-C00894
Figure US20230357259A1-20231109-C00895
Figure US20230357259A1-20231109-C00896
Figure US20230357259A1-20231109-C00897
Figure US20230357259A1-20231109-C00898
Figure US20230357259A1-20231109-P00002
Figure US20230357259A1-20231109-C00899
Figure US20230357259A1-20231109-C00900
Figure US20230357259A1-20231109-C00901
Figure US20230357259A1-20231109-C00902
Figure US20230357259A1-20231109-C00903
Figure US20230357259A1-20231109-C00904
Figure US20230357259A1-20231109-C00905
Figure US20230357259A1-20231109-C00906
Figure US20230357259A1-20231109-C00907
Figure US20230357259A1-20231109-C00908
Figure US20230357259A1-20231109-C00909
Figure US20230357259A1-20231109-C00910
Figure US20230357259A1-20231109-C00911
Figure US20230357259A1-20231109-C00912
Figure US20230357259A1-20231109-C00913
Figure US20230357259A1-20231109-C00914
Figure US20230357259A1-20231109-C00915
Figure US20230357259A1-20231109-C00916
Figure US20230357259A1-20231109-C00917
Figure US20230357259A1-20231109-C00918
.
103. The compound or the pharmaceutically acceptable salt of claim 92,
wherein, T is a fragment of a bioactive molecule;
L1 is selected from an amino acid, a peptide composed of 2-10 amino acids, -(CH2)t1-,
Figure US20230357259A1-20231109-C00919
Figure US20230357259A1-20231109-C00920
t
1 is 0, 1, 2, 3, 4, 5 or 6;
L2 is selected from
Figure US20230357259A1-20231109-C00921
Figure US20230357259A1-20231109-C00922
an amino acid, a peptide composed of 2-10 amino acids, or
Figure US20230357259A1-20231109-C00923
y
1 and y2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
L3 is selected from 5-12 membered heteroarylene or amino;
L4 is selected from
Figure US20230357259A1-20231109-C00924
wherein Z
2 is C1-6 alkylene; Z3 is absent or C1-6 alkylene; R9 is hydrogen; α is independently 0, 1, 2, 3,4, 5 or 6;
E is pyrimidylene;
G is a leaving group for nucleophilic substitutions; and
each of m1, m2, and m3 is independently 0, 1, 2, 3, 4,5, 6, 7, 8, 9 or 10.
104. The compound or the pharmaceutically acceptable salt of claim 92,
wherein, T is a fragment of a bioactive molecule;
L1 is selected from an amino acid, a peptide composed of 2-10 amino acids, -(CH2)t1-,
Figure US20230357259A1-20231109-C00925
Figure US20230357259A1-20231109-C00926
t
1 is 0, 1, 2, 3, 4, 5 or 6;
L2 is selected from
Figure US20230357259A1-20231109-C00927
Figure US20230357259A1-20231109-C00928
an amino acid, a peptide composed of 2-10 amino acids, or
Figure US20230357259A1-20231109-C00929
y
1 and y2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
L3 is selected from 5-12 membered heteroarylene or amino;
Figure US20230357259A1-20231109-C00930
Figure US20230357259A1-20231109-C00931
Figure US20230357259A1-20231109-C00932
wherein m
4 is an integer from 0 to 6, methylsulfonyl is a substituent on a carbon atom adjacent to a nitrogen atom in the pyrimidine ring; and
each of m1, m2, and m3 is independently 0, 1, 2, 3, 4,5, 6, 7, 8, 9 or 10.
105. The compound or the pharmaceutically acceptable salt of claim 92,
wherein, T is a fragment of a bioactive molecule;
L1 is
Figure US20230357259A1-20231109-C00933
or -(CH
2)t1-,
wherein each of R, R′ and R1 is independently hydrogen, deuterium, halogen, a carboxylic acid group, a sulfonic acid group, cyano, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl substituted with cyano, C1-6 alkoxy, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, 6-10 membered aryl or 5-12 membered heteroaryl, Z1 is independently an amino acid or a peptide composed of 2-10 amino acids, t1 is 0, 1, 2, 3, 4, 5 or 6, each of x1, and x2 is independently 0, 1, 2, 3, 4, 5 or 6, each x3 is independently 0, 1, 2, 3 or 4, and L1 is bonded to T at the position 1 of L1;
L2 is selected from
Figure US20230357259A1-20231109-C00934
an amino acid, a peptide composed of 2-10 amino acids; y
1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and L2 is bonded to L1 at the position 1 of L2;
L3 is 5-12 membered heteroarylene;
L4 is
Figure US20230357259A1-20231109-C00935
wherein Z
5 is selected from C2-6 alkynyl, C2-6 alkenyl, amido group, sulfuryl, sulfinyl, 6-10 membered arylene or 5-6 membered heteroarylene; Z2 is selected from C1-6 alkylene, C2-10 alkenylene, C2-10 alkynylene, C3-8 cycloalkylene, 6-10 membered arylene or 5-14 membered heteroarylene; R9 is selected from hydrogen or C1-6 alkyl; Z3 is absent or selected from C1-6 alkylene, halogenated C1-6 alkylene or C1-6 alkylene substituted with alkoxy; or R9 and Z3 together with nitrogen atom attached thereto form a 4-8 membered heterocyclyl; α is independently 0, 1, 2, 3,4, 5 or 6; and L4 is bonded to E at the position 2 of L4;
E is pyrimidylene optionally substituted with one or more R12; wherein R12 is independently selected from hydrogen, deuterium, halogen, CN, nitro, C1-6 alkyl or halogenated C1-6 alkyl;
G is a leaving group for nucleophilic substitutions; and
each of m1, m2, and m3 is independently 0, 1, 2, 3, 4,5, 6, 7, 8, 9 or 10.
106. The compound or the pharmaceutically acceptable salt of claim 92,
wherein T is
Figure US20230357259A1-20231109-C00936
L1 is
Figure US20230357259A1-20231109-C00937
and L
1 is bonded to T at the position 1 of L1;
L2 is
Figure US20230357259A1-20231109-C00938
y
1 is 0, 1, 2, 3, 4, 5, 6, 7 or 8, and L2 is bonded to L1 at the position 1 of L2; m1 is 1;
L3 is triazolylene; m2 is 0 or 1;
L4 is
Figure US20230357259A1-20231109-C00939
Figure US20230357259A1-20231109-C00940
m
3 is 1; and L4 is bonded to E at the position 2 of L4;
E is pyrimidylene; and
G is methylsulfonyl.
107. The compound or the pharmaceutically acceptable salt of claim 92, wherein -[L1-(L2)m1-(L3)m2-(L4)m3-E]-G is the following fragments:
Figure US20230357259A1-20231109-C00941
.
108. The compound or the pharmaceutically acceptable salt of claim 92, wherein the compound is selected from
Figure US20230357259A1-20231109-C00942
Figure US20230357259A1-20231109-P00999
Figure US20230357259A1-20231109-P00999
Figure US20230357259A1-20231109-P00999
Figure US20230357259A1-20231109-P00999
Figure US20230357259A1-20231109-P00999
Figure US20230357259A1-20231109-C00943
Figure US20230357259A1-20231109-C00944
Figure US20230357259A1-20231109-C00945
Figure US20230357259A1-20231109-C00946
Figure US20230357259A1-20231109-C00947
Figure US20230357259A1-20231109-C00948
Figure US20230357259A1-20231109-C00949
Figure US20230357259A1-20231109-C00950
Figure US20230357259A1-20231109-C00951
Figure US20230357259A1-20231109-C00952
Figure US20230357259A1-20231109-C00953
Figure US20230357259A1-20231109-C00954
Figure US20230357259A1-20231109-C00955
Figure US20230357259A1-20231109-C00956
Figure US20230357259A1-20231109-C00957
Figure US20230357259A1-20231109-C00958
Figure US20230357259A1-20231109-C00959
Figure US20230357259A1-20231109-C00960
Figure US20230357259A1-20231109-C00961
Figure US20230357259A1-20231109-C00962
Figure US20230357259A1-20231109-C00963
Figure US20230357259A1-20231109-C00964
Figure US20230357259A1-20231109-C00965
Figure US20230357259A1-20231109-C00966
Figure US20230357259A1-20231109-C00967
Figure US20230357259A1-20231109-C00968
Figure US20230357259A1-20231109-C00969
Figure US20230357259A1-20231109-C00970
Figure US20230357259A1-20231109-C00971
Figure US20230357259A1-20231109-C00972
Figure US20230357259A1-20231109-C00973
Figure US20230357259A1-20231109-C00974
Figure US20230357259A1-20231109-C00975
Figure US20230357259A1-20231109-C00976
Figure US20230357259A1-20231109-C00977
Figure US20230357259A1-20231109-C00978
Figure US20230357259A1-20231109-C00979
Figure US20230357259A1-20231109-C00980
Figure US20230357259A1-20231109-C00981
Figure US20230357259A1-20231109-C00982
Figure US20230357259A1-20231109-C00983
.
109. The compound or the pharmaceutically acceptable salt of claim 92, wherein the compound is
Figure US20230357259A1-20231109-C00984
.
110. A pharmaceutical composition comprising the compound of claim 92, and one or more pharmaceutical excipients.
111. A method of treating a disease associated with an abnormal cell activity, comprising administering an effective amount of the compound of claim 92 to an individual in need thereof.
112. A compound or the pharmaceutically acceptable salt thereof, wherein the compound is
Figure US20230357259A1-20231109-C00985
Figure US20230357259A1-20231109-C00986
Figure US20230357259A1-20231109-C00987
Figure US20230357259A1-20231109-C00988
Figure US20230357259A1-20231109-C00989
wherein R14 is selected from acyl or sulfonyl, which is substituted with R15, and R15 is selected from C1-6 alkyl, halogenated C1-6 alkyl, 6-10 membered aryl or 5-12 membered heteroaryl; R16 is selected from hydrogen, deuterium, C1-6 alkyl or C1-6 alkyl substituted with R17, and R17 is selected from aryl or heteroaryl, including but not limited to phenyl and pyridyl, and m11 is 0, 1 or 2.
113. A pharmaceutical composition comprising the compound of claim 112, and one or more pharmaceutical excipients.
114. A method of treating a disease associated with an abnormal cell activity, comprising administering an effective amount of the compound of claim 112 to an individual in need thereof.
115. A compound, which is:
Figure US20230357259A1-20231109-C00990
Figure US20230357259A1-20231109-C00991
Figure US20230357259A1-20231109-C00992
Figure US20230357259A1-20231109-C00993
Figure US20230357259A1-20231109-C00994
Figure US20230357259A1-20231109-C00995
Figure US20230357259A1-20231109-C00996
Figure US20230357259A1-20231109-C00997
Figure US20230357259A1-20231109-C00998
Figure US20230357259A1-20231109-C00999
Figure US20230357259A1-20231109-C01000
Figure US20230357259A1-20231109-C01001
Figure US20230357259A1-20231109-C01002
Figure US20230357259A1-20231109-C01003
Figure US20230357259A1-20231109-C01004
Figure US20230357259A1-20231109-C01005
Figure US20230357259A1-20231109-C01006
Figure US20230357259A1-20231109-C01007
Figure US20230357259A1-20231109-C01008
Figure US20230357259A1-20231109-C01009
Figure US20230357259A1-20231109-C01010
Figure US20230357259A1-20231109-C01011
Figure US20230357259A1-20231109-C01012
Figure US20230357259A1-20231109-C01013
Figure US20230357259A1-20231109-C01014
Figure US20230357259A1-20231109-C01015
Figure US20230357259A1-20231109-C01016
Figure US20230357259A1-20231109-C01017
Figure US20230357259A1-20231109-C01018
6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynoic acid, 6-(2-(methylthio)pyrimidin-5-yl)-5-hexynoic acid, or methyl 6-(2-(methylthio)pyrimidin-5-yl)-5-hexynoate.
116. A process of preparing compound T030:
Figure US20230357259A1-20231109-C01019
comprising reacting belotecan hydrochloride with methanesulfonyl chloride.
117. A process for preparing a compound, comprising deprotecting a protective form of the compound, wherein the compound is:
Figure US20230357259A1-20231109-C01020
Figure US20230357259A1-20231109-C01021
Figure US20230357259A1-20231109-C01022
Figure US20230357259A1-20231109-C01023
and the protective form of the compound is
Figure US20230357259A1-20231109-C01024
Figure US20230357259A1-20231109-C01025
Figure US20230357259A1-20231109-C01026
Figure US20230357259A1-20231109-C01027
.
118. A process for preparing the protective form of the compound according to claim 117, comprising reacting an azide compound with an alkynyl compound, wherein the azide compound is
Figure US20230357259A1-20231109-C01028
and the alkynyl compound is:
Figure US20230357259A1-20231109-C01029
Figure US20230357259A1-20231109-C01030
Figure US20230357259A1-20231109-C01031
Figure US20230357259A1-20231109-C01032
.
119. A process for preparing the azide compound according to claim 118, comprising reacting compound T030:
Figure US20230357259A1-20231109-C01033
with (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azatriacetamido)-N-(4-(hydroxymethyl)phenyl)-6(((4-methoxyphenyl)benzhydryl)amino)acetamide.
120. A process for preparing the alkynyl compound according to claim 118, comprising reacting an carboxylic acid with propargylamine, wherein the carboxylic acid is:
Figure US20230357259A1-20231109-C01034
Figure US20230357259A1-20231109-C01035
Figure US20230357259A1-20231109-C01036
Figure US20230357259A1-20231109-C01037
.
121. A process for preparing the carboxylic acid according to claim 120, comprising reacting a 2-methylthiopyrimidine compound with m-chloroperoxybenzoic acid, wherein the 2-methylthiopyrimidine compound is
Figure US20230357259A1-20231109-C01038
Figure US20230357259A1-20231109-C01039
Figure US20230357259A1-20231109-C01040
Figure US20230357259A1-20231109-C01041
.
122. A process for preparing the 2-methylthiopyrimidine compound according to claim 121, wherein the 2-methylthiopyrimidine compound is 6-(2-(methylthio)pyrimidin-5-yl)-5-hexynoic acid, comprising hydrolyzing methyl 6-(2-(methylthio)pyrimidin-5-yl)-5-hexynoate.
123. A process for preparing methyl 6-(2-(methylthio)pyrimidin-5-yl)-5-hexynoate according to claim 122, comprising reacting methyl 5-hexynoate with 5-bromo-2-methylthiopyrimidine.
124. A process for preparing an amide compound, comprising reacting an carboxylic acid with an amine, wherein the carboxylic acid is:
Figure US20230357259A1-20231109-C01042
Figure US20230357259A1-20231109-C01043
Figure US20230357259A1-20231109-C01044
Figure US20230357259A1-20231109-C01045
.
125. A conjugate comprising a fragment of a bioactive molecule, a linker, and a targeting moiety, wherein the targeting moiety is linked to the linker via an active group to form a conjugate; wherein the conjugate has a structure shown in formula (II):
Figure US20230357259A1-20231109-C01046
wherein, A is a targeting moiety; γ is an integer or a decimal from 1 to 10; and
the rest groups are as defined in claim 92.
126. A pharmaceutical composition comprising the conjugate of claim 125, and one or more pharmaceutical excipients.
127. A method of treating a disease associated with an abnormal cell activity, comprising administering an effective amount of the conjugate of claim 125 to an individual in need thereof.
128. A method for preparing the conjugate of claim 125 comprising a step of coupling the linker of the compound of formula (I) with an active group of the targeting moiety.
129. A conjugate comprising a fragment of a bioactive molecule, a linker, and a targeting moiety, wherein the targeting moiety is linked to the linker via an active group to form a conjugate; wherein the targeting moiety is an anti-Trop-2 monoclonal antibody of antibody M1, M2 or M3;
wherein the antibody comprises:
the heavy chain variable region of the antibody M1 which has the amino acid sequence of SEQ ID No.: 11; and the light chain variable region of the antibody M1 which has the amino acid sequence of SEQ ID No.: 12;
the heavy chain variable region of the antibody M2 which has the amino acid sequence of SEQ ID No.: 13; and the light chain variable region of the antibody M2 wchih has the amino acid sequence of SEQ ID No. : 14; or
the heavy chain variable region of the antibody M3 which has the amino acid sequence of SEQ ID No. : 15; and the light chain variable region of the antibody M3 which has the amino acid sequence of SEQ ID No.: 16.
130. A pharmaceutical composition comprising the conjugate of claim 129, and one or more pharmaceutical excipients.
131. A method of treating a disease associated with an abnormal cell activity, comprising administering an effective amount of the conjugate of claim 129 to an individual in need thereof.
US18/155,650 2017-12-15 2023-01-17 Bioactive conjugate, preparation method therefor and use thereof Pending US20230357259A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/155,650 US20230357259A1 (en) 2017-12-15 2023-01-17 Bioactive conjugate, preparation method therefor and use thereof

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201711347535.6 2017-12-15
CN201711347535 2017-12-15
CN201810230346.9 2018-03-20
CN201810230346 2018-03-20
CN201811071947 2018-09-14
CN201811071947.6 2018-09-14
PCT/CN2018/120125 WO2019114666A1 (en) 2017-12-15 2018-12-10 Bioactive conjugate, preparation method therefor and use thereof
US202016758980A 2020-04-24 2020-04-24
US18/155,650 US20230357259A1 (en) 2017-12-15 2023-01-17 Bioactive conjugate, preparation method therefor and use thereof

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2018/120125 Division WO2019114666A1 (en) 2017-12-15 2018-12-10 Bioactive conjugate, preparation method therefor and use thereof
US16/758,980 Division US11970506B2 (en) 2017-12-15 2018-12-10 Bioactive molecule conjugate, preparation method and use thereof

Publications (1)

Publication Number Publication Date
US20230357259A1 true US20230357259A1 (en) 2023-11-09

Family

ID=66819957

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/758,980 Active 2040-07-31 US11970506B2 (en) 2017-12-15 2018-12-10 Bioactive molecule conjugate, preparation method and use thereof
US18/155,650 Pending US20230357259A1 (en) 2017-12-15 2023-01-17 Bioactive conjugate, preparation method therefor and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/758,980 Active 2040-07-31 US11970506B2 (en) 2017-12-15 2018-12-10 Bioactive molecule conjugate, preparation method and use thereof

Country Status (7)

Country Link
US (2) US11970506B2 (en)
EP (1) EP3725798A4 (en)
JP (2) JP7446993B2 (en)
KR (1) KR20200099123A (en)
CN (5) CN113683622A (en)
CA (1) CA3080236A1 (en)
WO (1) WO2019114666A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3617221A4 (en) * 2017-04-19 2021-04-14 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Cytotoxin and conjugate, uses of same, and preparation method therefor
CN113683622A (en) * 2017-12-15 2021-11-23 四川科伦博泰生物医药股份有限公司 Bioactive substance conjugate and preparation method and application thereof
CN113286796B (en) * 2019-01-30 2024-07-05 四川科伦博泰生物医药股份有限公司 Camptothecin derivative, water-soluble prodrug thereof, pharmaceutical composition containing camptothecin derivative, preparation method and application of camptothecin derivative
WO2021027851A1 (en) * 2019-08-12 2021-02-18 凯惠科技发展(上海)有限公司 Trop2 antibody, preparation method therefor, and conjugate and use thereof
EP4095148A4 (en) * 2020-01-22 2023-07-26 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
CA3168654A1 (en) * 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
JP7407973B2 (en) * 2020-05-15 2024-01-04 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド Antibody-drug conjugates, methods of their preparation, and uses thereof
MX2023002805A (en) 2020-09-16 2023-03-16 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anti-nectin-4 antibody, conjugate including same, and application thereof.
JP2023545382A (en) * 2020-09-30 2023-10-30 江蘇恒瑞医薬股▲ふん▼有限公司 Pharmaceutical compositions containing antibody-drug conjugates and uses thereof
JP2024506819A (en) * 2021-02-05 2024-02-15 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド Camptothecin compounds, their preparation methods and their applications
CN115279417A (en) * 2021-02-09 2022-11-01 苏州宜联生物医药有限公司 Bioactive substance conjugate and preparation method and application thereof
CN117440832A (en) * 2021-03-03 2024-01-23 索伦托药业有限公司 Antibody-drug conjugates comprising anti-BCMA antibodies
US20240209080A1 (en) 2021-04-10 2024-06-27 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CN117203238A (en) 2021-04-23 2023-12-08 普方生物制药美国公司 CD70 binding agents, conjugates thereof, and methods of use thereof
CN114106088A (en) * 2021-04-28 2022-03-01 联宁（苏州）生物制药有限公司 Bromomethylpyrazine-based drug conjugates and ADCs
BR112023022540A2 (en) * 2021-04-30 2024-01-02 Sichuan Kelun Biotech Biopharmaceutical Co Ltd USE OF MEDICINE IN THE TREATMENT OF TUMOR DISEASE
CN113181373B (en) * 2021-05-10 2024-03-01 深圳安特生物医药科技有限公司 Antibody drug coupling preparation and preparation method and application thereof
JP2024521629A (en) * 2021-06-02 2024-06-04 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド Antibody drug conjugates, and methods for preparing same and uses thereof
TW202320857A (en) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 Linkers, drug linkers and conjugates thereof and methods of using the same
WO2023016488A1 (en) * 2021-08-13 2023-02-16 昆山新蕴达生物科技有限公司 Microtubule inhibitor-based antibody-drug conjugate
CA3229934A1 (en) * 2021-09-01 2023-03-09 Ruibin HU Method for improving product quality of antibody-drug conjugate
CN115991784A (en) 2021-10-19 2023-04-21 宝船生物医药科技(上海)有限公司 anti-CD 47-CLDN18.2 bispecific antibody and uses thereof
CA3239379A1 (en) 2021-12-02 2023-06-08 Weibiao HAN Method for preparing drug-linker conjugate
AU2022422015A1 (en) * 2021-12-23 2024-07-04 Adcentrx Therapeutics Inc. Novel auristatin analogs and immunoconjugates thereof
WO2023134706A1 (en) * 2022-01-13 2023-07-20 四川科伦博泰生物医药股份有限公司 Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents
WO2023143208A1 (en) * 2022-01-26 2023-08-03 苏州宜联生物医药有限公司 Preparation method for drug linker conjugate
WO2023143154A1 (en) * 2022-01-28 2023-08-03 四川科伦博泰生物医药股份有限公司 Pharmaceutical composition, method for preparing same, and use thereof
WO2023155808A1 (en) * 2022-02-16 2023-08-24 苏州宜联生物医药有限公司 Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023201268A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating tumor antigen expressing cancers
WO2023221975A1 (en) * 2022-05-18 2023-11-23 苏州宜联生物医药有限公司 Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
CN117143177A (en) * 2022-05-30 2023-12-01 苏州宜联生物医药有限公司 Preparation method of drug connector conjugate and intermediate thereof
WO2024002042A1 (en) * 2022-06-27 2024-01-04 百奥泰生物制药股份有限公司 Method for treating solid tumor
WO2024012523A1 (en) * 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 Antibody-drug conjugate, and preparation method therefor and use thereof
CN118251241A (en) * 2022-07-15 2024-06-25 启德医药科技（苏州）有限公司 Antibodies, linkers, supports, conjugates and uses thereof
TW202415409A (en) * 2022-08-02 2024-04-16 中國商諾納生物（蘇州）有限公司 MSLN antibody-drug conjugate
WO2024078586A1 (en) 2022-10-14 2024-04-18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug conjugate binding to human ptk7 and method for preparation and use thereof
WO2024097812A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Therapy for treating bladder cancer
WO2024109928A1 (en) * 2022-11-25 2024-05-30 成都微芯新域生物技术有限公司 Linker, linker-containing antibody drug conjugate, and preparation method therefor and use thereof
WO2024114318A1 (en) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 Drug linker compound, preparation method therefor, and use thereof
WO2024114528A1 (en) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 Compound usable in conjugation reaction and conjugate thereof
WO2024123914A1 (en) * 2022-12-07 2024-06-13 Merck Sharp & Dohme Llc Process for making antibody-drug conjugates

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
AU2003209447B8 (en) 2002-03-01 2008-10-23 Immunomedics, Inc. RS7 antibodies
SI1725249T1 (en) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
JP2008507520A (en) 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド HER2 antibody composition
US8609105B2 (en) 2008-03-18 2013-12-17 Seattle Genetics, Inc. Auristatin drug linker conjugates
TWI504410B (en) 2010-02-08 2015-10-21 Agensys Inc Antibody drug conjugates (adc) that bind to 161p2f10b proteins
US20110250642A1 (en) 2010-04-12 2011-10-13 Sorrento Therapeutics Method for Displaying Antibodies
JPWO2011155579A1 (en) 2010-06-10 2013-08-15 北海道公立大学法人 札幌医科大学 Anti-Trop-2 antibody
BR112014012609A2 (en) 2011-11-17 2020-10-20 Pfizer Inc cytotoxic and conjugated antibody drug peptides thereof
EP2849790B1 (en) 2012-05-15 2019-04-10 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
PL2900277T3 (en) 2012-12-13 2022-05-16 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2014144878A2 (en) * 2013-03-15 2014-09-18 The Scripps Research Institute Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof
CN103319599B (en) 2013-05-27 2015-02-18 上海交联药物研发有限公司 Anti-human ErbB2 antibody-ansamitocin conjugate and applications thereof
JP6427789B2 (en) * 2013-07-23 2018-11-28 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Antibody-SN-38 immune complex with CL2A linker
KR20170086121A (en) * 2014-12-03 2017-07-25 제넨테크, 인크. Quaternary amine compounds and antibody-drug conjugates thereof
LT3268047T (en) 2015-03-09 2023-11-10 Heidelberg Pharma Research Gmbh Amatoxin-antibody conjugates
EP3954394A1 (en) 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
JP6714687B2 (en) * 2015-08-14 2020-06-24 アールシー バイオテクノロジーズ，インコーポレイテッド Covalent Linker in Antibody Drug Conjugate, and Method for Producing and Using the Same
CN106729743B (en) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 anti-ErbB 2 antibody-drug conjugate, and composition, preparation method and application thereof
CN107029244B (en) 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 anti-HER 2 antibody-drug conjugate and application thereof
EP3493853A1 (en) * 2016-08-03 2019-06-12 Pfizer Inc Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
EP3600283A4 (en) 2017-03-27 2020-12-16 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
CA3065919A1 (en) * 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody construct conjugates
CN113683622A (en) * 2017-12-15 2021-11-23 四川科伦博泰生物医药股份有限公司 Bioactive substance conjugate and preparation method and application thereof
CN110903395A (en) * 2018-09-14 2020-03-24 四川科伦博泰生物医药股份有限公司 Antibody, conjugate, preparation method and application thereof

Also Published As

Publication number Publication date
US20210101906A2 (en) 2021-04-08
CN113683622A (en) 2021-11-23
CN111295389A (en) 2020-06-16
US11970506B2 (en) 2024-04-30
EP3725798A4 (en) 2021-11-10
US20200347075A1 (en) 2020-11-05
EP3725798A1 (en) 2020-10-21
CN111295389B (en) 2021-10-22
CA3080236A1 (en) 2019-06-20
CN113651831A (en) 2021-11-16
CN113603703A (en) 2021-11-05
JP2024038168A (en) 2024-03-19
JP2021506743A (en) 2021-02-22
KR20200099123A (en) 2020-08-21
JP7446993B2 (en) 2024-03-11
WO2019114666A1 (en) 2019-06-20
CN113698414A (en) 2021-11-26

Similar Documents

Publication Publication Date Title
US20230357259A1 (en) Bioactive conjugate, preparation method therefor and use thereof
US20210113710A1 (en) Hydrophilic self-immolative linkers and conjugates thereof
US20160051695A1 (en) Her2 antibody-drug conjugates
US9950077B2 (en) Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
CN111447939B (en) Method for preparing conjugate
US20160015831A1 (en) Anti-cd22 antibody-drug conjugates and methods of using thereof
CN116209679A (en) Antibody-drug conjugates containing anti-mesothelin antibodies and uses thereof
US11207420B2 (en) Cytotoxin and conjugate, uses of same and preparation method therefor
CN111542324B (en) Cytotoxic agent and conjugate thereof, preparation method and application thereof
US20230330258A1 (en) Conjugates comprising a phosphorus (v) and a drug moiety

Legal Events

Date Code Title Description
AS Assignment

Owner name: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAI, JIAQIANG;SONG, SHUAI;XUE, TONGTONG;AND OTHERS;REEL/FRAME:062565/0919

Effective date: 20200220

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION